



BEST AVAILABLE COPY

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1991-1-50, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	11/154,805
Filing Date	October 17, 2001
First Named Inventor	Oron JACOBY-ZEEVI
Art Unit	1636
Examiner Name	unknown
Attorney Docket Number	29714

Sheet 1 of 19

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-6,177,545	01-13-2001	Pecker et al.	
	2	US-6,348,344	02-19-2002	Ayal-HersHKovitz et al.	
	3	US-4,946,778	08-8-1990	Ladner et al.	
	4	US-5,997,863	07-7-1999	Zimmermann et al.	
	5	US-6,242,238	05-5-2001	Freeman et al.	
	6	US-5,688,679	11-18-1997	Powell	
	7	US-6,387,643	05-14-2002	Heinrikson et al.	
	8	US-6,423,312	07-23-2002	Yacoby-Zeevi	
	9	US-6,531,129	03-11-2003	Pecker et al.	
	10	US-4,453,296	06-19-1984	Hansen et al.	
	11	US-5,571,506	05-5-1996	Regan et al.	
	12	US-5,917,830	06-29-1999	Chen et al.	
	13	US-5,859,660	01-12-1999	Perkins et al.	
	14	US-5,600,366	04-4-1997	Schulman	
	15	US-6,020,931	01-1-2000	Bilbrey et al.	
	16	US-5,968,822	10-19-1999	Pecker et al.	
	17	US-6,153,187	11-28-2000	Yacoby-Zeevi	
	18	US-6,664,105	12-16-2003	Pecker et al.	
	19	US-5,145,679	08-8-1992	Hinson	
	20	US-5,736,137	07-7-1998	Anderson et al.	
	21	US-5,194,596	03-16-1993	Tischer et al.	
	22	US-5,350,836	09-27-1994	Kopchick et al.	
	23	US-6,562,950	05-13-2003	Peretz et al.	
	24	US-6,699,672	02-2-2004	Pecker et al.	
	25	US-5,580,862	03-3-1996	Rosen et al.	
	26	US-5,474,983	12-12-1995	Kuna et al.	
	27	US-2002/0102560	01-1-2002	Pecker et al.	
	28	US-6,790,658	09-14-2004	Pecker et al.	
	29	US-6,798,658	09-28-2004	Takedomi et al.	
	30	US-5,618,709	08-8-1997	Gewirtz et al.	
	31	US-5,656,595	08-12-1997	Schweighoffer et al.	
	32	US-4,687,195	07-28-1987	Mullis et al.	
	33	US-5,602,095	02-11-1997	Pastan et al.	
	34	US-2004/0142427	07-22-2004	Pecker et al.	
	35	US-4,117,841	03-3-1978	Perrotta et al.	
	36	US-2003/0161823	08-28-2003	Ilan et al.	
	37	US-5,962,321	05-5-1999	Gough et al.	
	38	US-5,830,759	03-3-1998	Chang et al.	
	39	US-4,859,581	08-22-1989	Nicholson et al.	
	40	US-4,882,318	11-21-1989	Vlodavsky et al.	
	41	US-5,129,877	07-14-1992	Gallo et al.	
	42	US-5,206,223	04-27-1993	Vlodavsky et al.	
	43	US-5,332,812	07-26-1994	Nicolson et al.	
	44	US-5,362,641	08-8-1994	Fuks et al.	

45	US-5,399,351	03-21-1995	Leshchiner et al	
46	US-5,550,116	08-27-1996	Lormeau et al.	
47	US-5,667,501	09-16-1997	Fowler et al.	
48	US-5,739,115	04-14-1998	Fugedi et al	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Documents		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ²	Number ³ Kind Code ⁴ (if known)				
	49*	PCT	WO 99/57244	11-11-1999	Ben-Artzi et al.		
	50*	PCT	WO 99/57153	11-11-1999	Pecker et al.		
	51*	PCT	WO 99/11798	03-11-1999	Pecker et al.		
	52*	PCT	WO 88/01280	02-25-1988	Nicolson et al.		
	53*	PCT	WO 95/04158	09-9-1995	Hoogewerf et al.		
	54*	PCT	WO 99/21975	06-6-1999	Freeman et al.		
	55*	PCT	WO 91/19197	12-12-1991	Nicolson et al.		
	56*	PCT	WO 95/04518	02-18-1995	Midha et al.		
	57*	PCT	WO 03/006645 A2	01-23-2003	Bohlen et al.		
	58*	PCT	WO 97/11684	03-3-1997	Bennett et al.		
	59*	PCT	WO 91/02977	07-7-1991	Fuks et al.		
	60*	PCT	WO 97/27327	07-31-1997	Van Ness et al.		
	61*	PCT	WO 00/52149	08-8-2000	Yacoby-Zeevi		
	62*	PCT	WO 00/52178	08-8-2000	Pecker et al.		
	63*	PCT	WO 00/52178	08-8-2000	Pecker et al.		
	64*	PCT	WO 99/40207	08-12-1999	Nakjima et al.		
	65*	PCT	WO 98/46258	10-22-1998	Bhaskar et al.		
	66*	EP	0254067	01-27-1988	Cohen et al.		
	67*	PCT	WO 98/03638	01-29-1998	Freeman et al.		
	68*	PCT	WO 01/00643	04-4-2001	Pecker et al.		
	69*	DE	2819129	11-15-1979	Köhler et al.		
	70*	PCT	WO 99/48478	09-30-1999	Yacoby-Zeevi		
Examiner Signature					Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 10 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	11/154,805
(use as many sheets as necessary)		Filing Date	October 17, 2000
		First Named Inventor	Oron JACOBY- ZEEVI
		Group Art Unit	1636
		Examiner Name	unknown
		Attorney Docket Number	29716
Sheet	3	Of	19
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Che No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
	71	Wight et al. "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation", Curr. Opin. Cell. Biology, 4: 793-801, 1992.	
	72	Jackson et al. "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Review, 71(2): 481-529, 1991.	
	73	Schoepe et al. "Neutralization of Hemolytic and Mouse Lethal Activities of C. Perfringens Alpha-Toxin Need Simultaneous Blockage of Two Epitopes by Monoclonal Antibodies", Microbiol. Pathogenesis, 23: 1-10, 1997.	
	74	Chiba et al. "Generation of Neutralizing Antibody to the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 by Immunizing of Mice With An Infectious Vaccinia Virus Recombinant", J. Immunological Methods, 207:53-60, 1997.	
	75	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number", Genetic Engineering News, P.23-49, 1998.	
	76	Sherman-Gold "Monoclonal Antibodies: The Evolution From '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", Genetic Engineering News, P.4, 35, 1997.	
	77	Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, Yet FDA Still Has Bulk Manufacture Concerns", Genetic Engineering News, P.1, 6, 33, 38, 1997.	
	78	Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci. USA, 95: 8910-8915, 1998.	
	79	Mateo et al. "Humanization of A Mouse Monoclonal Antibody That Blocks the Epidermal Growth Factor Receptor: Recovery Antagonistic Activity", Immunotechnology, 3: 71-81, 1997.	
	80	Nakajima et al. "Heparanases and Tumor Metastasis", Journal of Cellular Biochemistry, 36(2): 157-167, 1988.	
	81	Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser, Boston, P.433, 492-495, 1994.	
	82	Colman "Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions", Research in Immunology, 145(1): 33-36, 1994.	
	83	Abaza et al. "Effects of Amino Acid Substitutions Outside An Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration With Region 94-100 (Antigenic Site 3) of Myoglobin", Journal of Protein Chemistry, 11(5): 433-444, 1992.	
	84	Vederman et al. "A Single Amino Acid Substitution in A Common African Allele of the CD4 Molecule Abolishes Binding of the Monoclonal Antibody, OKT4", Molecular Immunology, 28: 1171-1181, 1991.	
	85	Li et al. "β-Endorphin Omission Analogs: Dissociation of Immunoreactivity From Other Biological Activities", PNAS, 77: 3211-3214, 1980.	
	86	Marchetti et al. "Neurotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", Cancer Research, 56: 2856-2863, 1996. Also in: Advances in Enzyme Regulation, 37: 111-134, 1997.	
	87	Kosir et al. "Human Prostate Carcinoma Cells Produce Extracellular Heparanase", Journal of Surgical Research, 67: 98-105, 1997.	
	88	Köhler et al. "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", Nature, 256: 495-497, 1975.	

89	Hulett et al. "Cloning of Mammalian Heparanase, An Important Enzyme in Tumor Invasion and Metastasis", <i>Nature Medicine</i> , 5(7): 803-809, 1999.
90	Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression", <i>J. Biolog. Chemistry</i> , 274(34): 24153-24160, 1999.
91	Kussie et al. "Cloning and Functional Expression of A Human Heparanase Gene", <i>Biochemical and Biophysical Research Communication</i> , 261(1): 183-187, 1999.
92	Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neurotrophin Receptor With Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", <i>Int. J. Cancer</i> , 82: 112-120, 1999.
93	Freeman et al. "Evidence That Platelet and Tumour Heparanases Are Similar Enzymes", <i>Biochem J.</i> , 342: 361-368, 1999.
94	Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", <i>Crit. Rev. in Biochemistry and Molecular Biology</i> , 30(5): 387-444, 1995.
95	Zhou et al. "A 182 Bp Fragment of the Mouse Pro α 1(11) Collagen Gene Is Sufficient to Direct Chondrocyte Expression in Transgenic Mice", <i>J. Cell Science</i> , 108: 3677-3684, 1995.
96	Hormuzzi et al. "A Gene-Targeting Approach Identifies A Function for the First Intron in Expression of the α 1 (I) Collagen Gene.", <i>Mol Cell Biol</i> , 18(6): 3368-3375, 1998. Abstract.
97	Chow et al. "Development of An Epithelium-Specific Expression Cassette With Human DNA Regulatory Elements for Transgene Expression in Lung Airways", <i>Proc. Natl. Acad. Sci. USA</i> , 94: 14695-14700, 1997.
98	Ye et al. "Targeted Gene Correction: A New Strategy for Molecular Medicine", <i>Molecular Medicine Today</i> , P.431-437, 1998.
99	Lai et al. "Homologous Recombination Based Gene Therapy", <i>Exp. Nephrol</i> , 7(1):11-14, 1999. Abstract.
100	Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", <i>Biochimica et Biophysica Acta</i> , 1172: 37-42, 1993.
101	Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", <i>Proc. Natl. Acad. Sci. USA</i> , 94: 5332-5337, 1997.
102	Gewirtz et al. "Nucleic Acid Therapeutics: State of the Art and Future Prospects", <i>Blood</i> , 92(3): 712-736, 1998.
103	Shastri "Gene Disruption in Mice: Models of Development and Disease", <i>Molecular and Cellular Biochemistry</i> , 181: 163-179, 1998.
104	Carpentier et al. "DNA Vaccination With HuD Inhibits Growth of A Neuroblastoma in Mice", <i>Clinical Cancer Research</i> , 4: 2819-2824, 1998.
105	Lai et al. "DNA Vaccines", <i>Critical Reviews in Immunology</i> , 18: 449-484, 1998.
106	Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", <i>Journal of Biological Chemistry</i> , 270(10): 5276-5281, 1995.
107	Shekhar et al. "Correlation of Differences in Modulation of Ras Expression With Metastatic Competence of Mouse Mammary Tumour Subpopulations", <i>Invasion Metastasis</i> , 14: 27-37, 1994/5.
108	Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced From Hydrophobic Cluster Analysis", <i>Glycobiology</i> , 7(2): 277-284, 1997.
109	Korb et al. "Stimulation of Gene Expression by Introns: Conversion of An Inhibitory Intron to A Stimulatory Intron by Alteration of the Splice Donor Sequence", <i>Nucleic Acids Research</i> , 21(25): 5901-5908, 1993.
110	Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme Is A Heterodimer", <i>Journal of Biol. Chem.</i> , 274(42): 29587-29590, 1999.
111	Linhardt et al. "Polysaccharide Lyases", <i>Applied Biochemistry and Biotechnology</i> , 12: 135-176, 1986.
112	Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", <i>TIBS</i> , 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.
113	Niwa et al. "Efficient Selection for High-Expression Transfectants With A Novel Eukaryotic Vector", <i>Gene</i> , 108(2): 193-199, 1991.
114	Clark "The Mammary Gland as A Bioreactor: Expression, Processing, and Production of Recombinant Proteins", <i>J. Mammary Gland Biol. and Neoplasia</i> , 3(3): 337-350, 1998.

115	Mirault et al. "Transgenic Glutathione Peroxidase Mouse Models for Neuroprotection Studies", <i>Ann. NY Acad. Sci.</i> , 738: 104-115, 1994.
116	Lampard et al. "Secretion of Foreign Proteins Mediated by Chicken Lysozyme Gene Regulatory Sequences", <i>Biochem. Cell Biol.</i> , 80(6): 777-788, 2002.
117	Harvey et al. "Expression of Exogenous Protein in the Egg White of Transgenic Chickens", <i>Nature Biotechnology</i> , 19: 396-399, 2002.
118	Morrison et al. "Sequences in Antibody Molecules Important for Receptor-Mediated Transport Into the Chicken Egg Yolk", <i>Mol. Immunol.</i> , 38(8): 619-625, 2002.
119	Clark et al. "Pharmaceuticals From Transgenic Livestock", <i>TIBTECH</i> , 5: 20-24, 1987.
120	Richards et al. "Construction and Preliminary Characterization of the Rat Casein and Alpha-Lactalbumin cDNA Clones", <i>J. Biol. Chem.</i> , 256(1): 526-32, 1981.
121	Campbell et al. "Comparison of the Whey Acidic Protein Genes of the Rat and Mouse", <i>Nucleic Acids Res.</i> , 12(22): 8685-8697, 1984.
122	Gordetsky et al. "Isolation and Characterization of the Bos Taurus β -Casein Gene", <i>Gene</i> , 66: 87-96, 1988.
123	Alexander et al. "Complete Sequence of the Bovine β -Lactoglobulin cDNA", <i>Nucleic Acids Research</i> , 17(16): 6739-6744, 1989.
124	Benezra et al. "Thrombin Enhances the Degradation of Heparan Sulfate in the Extracellular Matrix by Tumor Cell Heparanase", <i>Exptl. Cell. Res.</i> , 201: 208-215, 1992.
125	Harlow et al. "Antibodies - A Laboratory Manual", Cold Spring Harbor Press, P. 471-510, 1988.
126	Murray et al. "The Extracellular Matrix", <i>Harper's Biochemistry</i> , McGraw-Hill Professional, 24th Ed., Chap. 57, P.667-685, 1998.
127	Selvan et al. "Heparan Sulfate in Immune Responses", <i>Ann. NY Acad. Sci.</i> , 797: 127-139, 1996.
128	Prockop "Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues", <i>Science</i> , 276: 71-74, 1997.
129	Krivit et al. "Microglia: The Effector Cell for Reconstitution of the Central Nervous System Following Bone Marrow Transplantation for Lysosomal and Peroxisomal Storage Diseases", <i>Cell Transplant</i> , 4(4): 385-392, 1995. Abstract.
130	Robey et al. "Biochemical Characterization of Marrow Stromal Fibroblasts", 6th Internatl. Conf. on Molec. Biol. and Pathology of Matrix, Session IV.
131	Lazarus et al. "Ex Vivo Expansion and Subsequent Infusion of Human Bone Marrow-Derived Stromal Progenitor Cells (Mesenchymal Progenitor Cells): Implications for Therapeutic Use", <i>Bone Marrow Transplantation</i> , 16: 557-564, 1995.
132	Pomahac et al. "Tissue Engineering of Skin", <i>Crit. Rev. Oral Biol. Med.</i> , 9(3): 333-344, 1998. Abstract.
133	Benathan et al. "Living Epidermal and Dermal Substitutes for Treatment of Severely Burned Patients", <i>Rev. Med. Suisse Romande</i> , 118(2): 149-153, 1998. Abstract-Art. in French.
134	Wang et al. "Basic Fibroblast Growth Factor Enhances Bone-Graft Incorporation: Dose and Time Dependence in Rats", <i>J. Orthop. Res.</i> , 14(2): 316-323, 1996. Abstract.
135	Duffy et al. "Maximizing Flap Survival in A Prefabrication Model Using Exogenous and Endogenous bFGF: A New Approach", <i>Microsurgery</i> , 17(4): 176-179, 1996. Abstract.
136	Gartner "Epidermal Regulation of Dermal Fibroblast Activity", <i>Plast. Reconstr. Surg.</i> , 102(1):135-139, 1998. Abstract.
137	Raghunath et al. "Cultured Epithelial Autografts: Diving From Surgery Into Matrix Biology", <i>Pediatr. Surg. Int.</i> , 12(7): 478-483, 1997. Abstract.
138	Myers et al. "Transplantation of Keratinocytes in the Treatment of Wounds", <i>American J. Surg.</i> , 170(1): 75-83, 1995. Abstract.
139	Kawaja et al. "Employment of Fibroblasts for Gene Transfer: Applications for Grafting Into the Central Nervous System", <i>Genet. Eng. NY</i> , 13: 205-220, 1991. Abstract.
140	Maillard et al. "Pre-Treatment With Elastase Improves the Efficiency of Percutaneous Adenovirus-Mediated Gene Transfer to the Arterial Media", <i>Gene Therapy</i> , 5: 1023-1030, 1998.
141	Wang "Basic Fibroblast Growth Factor for Stimulation of Bone Formation in Osteoinductive or Conductive Implants", <i>Acta Orthop. Scand. Suppl.</i> , 269: 1-33, 1996. Abstract.

142	Wang "Basic Fibroblast Growth Factor Infused at Different Times During Bone Graft Incorporation. Titanium Chamber Study in Rats", <i>Acta Orthop. Scand.</i> , 67(3): 229-236, 1996. Abstract.
143	Inui et al. "Local Application of Basic Fibroblast Growth Factor Minipellet Induces the Healing of Segmental Bony Defects in Rabbits".
144	Tabata et al. "Bone Regeneration by Basic Fibroblast Growth Factor Complexed With Biodegradable Hydrogels", <i>Biomaterials</i> , 19(7-9): 807-815, 1998. Abstract.
145	Aspenberg et al. "Stimulates Bone Formation. Bone Induction Studied in Rats", <i>Acta Orthop. Scand.</i> , 60(4): 473-476, 1989. Abstract.
146	Aspenberg et al. "Dose-Dependent Stimulation of Bone Induction by Basic Fibroblast Growth Factor in Rats", <i>Acta Orthop. Scand.</i> , 62(5): 481-484, 1991. Abstract.
147	Matoba et al. "Evaluation of Omental Implantation for Perforated Gastric Ulcer Therapy: Findings in A Rat Model", <i>J. Gastroenterol.</i> , 31(6): 777-784, 1996. Abstract.
148	Chleboun et al. "The Development and Enhancement of the Collateral Circulation in An Animal Model of Lower Limb Ischaemia", <i>Aust. NZ Surg.</i> , 64(7): 202-207, 1994. Abstract.
149	Aplin "Adhesion Molecules in Implantation", <i>Reviews of Reproduction</i> , 2(2): 84-93, 1997.
150	Lessey et al. "Paracrine Signaling in the Endometrium: Integrins and the Establishment of Uterine Receptivity", <i>J. Reprod. Immunol.</i> , 39(1-2): 105-116, 1998. Abstract.
151	Burrows et al. "Trophoblast Migration During Human Placental Implantation", <i>Hum. Reprod. Update</i> , 2(4): 307-321, 1996.
152	Bischof et al. "The Regulation of Endometrial and Trophoblastic Metalloproteinases During Blastocyst Implantation", <i>Contracept Fertil Sex</i> , 22(1): 48-51, 1994. Abstract. Article in French.
153	Smith et al. "Expression of Heparan Sulfate Protoglycan (Perlecan) in the Mouse Blastocyst Is Regulated During Normal and Delayed Implantation", <i>Dev. Biol.</i> , 184(1): 38-47, 1997. Abstract.
154	Abrahamsohn et al. "Implantation and Recidualization in Rodents", <i>J. Exp. Zool.</i> , 266(6): 603-628, 1993. Abstract.
155	Goshen et al. "Purification and Characterization of Placental Heparanase and Its Expression by Cultured Cytotrophoblasts", <i>Molecular Human Reproduction</i> , 2(9): 679-684, 1996.
156	Yoshida "Effects of Basic Fibroblast Growth Factor on the Development of Mouse Preimplantation Embryos", <i>Nippon Sanka Fujinka Gakkai Zasshi</i> , 48(3): 170-176, 1996. Abstract.
157	Watson et al. "A Growth Factor Phenotype Map for Ovine Preimplantation Development", <i>Biol. Reprod.</i> , 50(4): 725-733, 1994. Abstract.
158	Carlone et al. "Embryonic Modulation of Basic Fibroblast Growth Factor in the Rat Uterus", <i>Biology of Reproduction</i> , 49(4): 653-665, 1993.
159	Wordinger et al. "The Immunolocalization of Basic Fibroblast Growth Factor in the Mouse Uterus During the Initial Stages of Embryo Implantation", <i>Growth Factors</i> , 11(3): 175-186, 1994. Abstract.
160	Schultz et al. "Growth Factors in Preimplantation Mammalian Embryos", <i>Oxford Review of Reproduction in Biology</i> , 15: 43-81, 1993. Abstract.
161	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", <i>Biochem. J.</i> , 330: 1341-1350, 1998.
162	Esko et al. "Tumor Formation Dependnt on Proceglycans Biosynthesis", <i>Science</i> , 241(4869): 1092-1096, 1988. Abstract.
163	Richardson et al. "Regulation of Basic Fibroblast Growth Factor Binding and Avtivity by Cell Density and Heparan Sufate", <i>J. Biological Chemistry</i> , 274(19): 13534-13540, 1990.
164	Hayward et al. "Cellular Mechanisms of Heparinase III Protection in Rat Traumatic Shock", <i>American Journal of Physiology</i> , 275: H23-H30, 1998.
165	Sasisekharan et al. "Heparinase Inhibits Neovascularization", <i>Proc. Natl. Acad.Sci. USA</i> , 91: 1524-1528, 1994.
166	Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases", <i>Journal of Biological Chemistry</i> , 271(17): 10079-10086,

		1996.	
	167	Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells Releases Active Fibroblast Growth Factor From Extracellular Matrix", <i>Cell Regulation</i> , 1: 833-842, 1990.	
	168	Godder et al. "Heparanase Activity in Cultured Endothelial Cells", <i>Journal of Cellular Physiology</i> , 148: 274-280, 1991.	
	169	Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain From An Inhibitor to A Potent Activator of FGF-2", <i>Nature Medicine</i> , 4(6): 691-697, 1998.	
	170	Jin et al. "Immunohistochemical Localization of Heparanase in Mouse and Human Melanomas", <i>Int. J. Cancer</i> , 45: 1088-1095, 1990.	
	171	Hoogwerf et al. "CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 Are Heparin/Heparan Sulfate-Degrading Enzymes", <i>J. Biol. Chem.</i> , 270(7): 3268-3277, 1995.	
	172	Oldburg et al. "Characterization of A Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides", <i>Biochemistry</i> , 19: 5755-5762, 1980.	
	173	Okamoto et al. "Highly Specific and Sensitive Detection of Malignancy in Urine Samples From Patients With Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", <i>Int. J. Cancer</i> , 79(6): 560-564, 1998. Abstract.	
	174	Kang et al. "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine β -Casein Gene", <i>Mol. Cells</i> , 8(3): 259-265, 1998. Abstract.	
	175	Gotschalk et al. "Somatic Gene Therapy: Present Situation and Future Perspective", <i>Arzneimittelforschung</i> , 48(11): 1111-1120, 1998. Abstract.	
	176	Guriec et al. "CD44 Isoforms With Exon V6 and Metastasis of Primary N0M0 Breast Carcinomas", <i>Breast Cancer Res. Treat.</i> , 44(3): 261-268, 1997. Abstract.	
	177	Hida et al. "Antisense E1A Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities" <i>Am. J. Pathol.</i> , 50(6): 2125-2132, 1997. Abstract.	
	178	Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", <i>Nature Medicine</i> , 5(7): 793-802, 1999.	
	179	Faber-Elman et al. "Involvement of Wound-Associated Factors in Rat Brain Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", <i>J. Clin. Invest.</i> , 97(1): 162-171, 1996.	
	180	Zheng et al. "Increment of hFLX Expression With Endogenous Intron 1 In Vitro", <i>Cell Res.</i> , 7(1): 21-29, 1997 Abstract.	
	181	Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target RNA Levels", <i>Curr. Opin. Biotechnol.</i> , 9(5): 486-496, 1998. Abstract.	
	182	Gewirtz et al. "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on Its Promise", <i>Proc. Natl. Acad. Sci. USA</i> , 93: 3161-3163, 1996.	
	183	Green et al. "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease", <i>Journal of American Cell Surgery</i> , 191(1): 93-105, 2000.	
	184	Agrawal "Antisense Oligonucleotides: Towards Clinical Trials", <i>TIBTech</i> , 14: 376-387, 1996.	
	185	Rajur et al. "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules", <i>Bioconjugate Chem.</i> , 8: 935-940, 1997.	
	186	Luft "Making Sense Out of Antisense Oligodeoxynucleotide Delivery: Getting There Is Half the Fun". <i>J. Mol. Med.</i> , P.75-76. 1998.	
	187	Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset", <i>Blood</i> , 91(3): 852-862, 1998.	
	188	Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense Oligodeoxynucleotides", <i>Molecular and Cellular Biochemistry</i> , 172: 213-225, 1997.	
	189	Motokuni et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides Into the Myocardium Using HVJ-Liposome Method", <i>Biochemical and Biophysical Research Communications</i> , 231: 540-545, 1997.	
	190	Jayaraman et al. "Rational Selection and Quantitative Evaluation of Antisense Oligonucleotides", <i>Biochimica et Biophysica Acta</i> , 1520: 105-114, 2001.	
	191	Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to A Structured RNA Target", <i>Biotechnology and Bioengineering</i> , 65(1): 1-9, 1999.	

192	Uno et al. "Antisense-Mediated Suppression of Human Heparanase Gene Expression Inhibits Pleural Dissemination of Human Cancer Cells", <i>Cancer Research</i> , 61(21): 7855-7860, 2001.
193	Clancy "Handbook of Microbiology", 1: 239-242, 1974.
194	Silver et al. "Pseudomonas: Biotransformations, Pathogenesis, and Evolving Biotechnology", American Society for Microbiology, Chap.2-3, 1990.
195	Wang et al. "Isolation and Characterization of Pseudomonas Aeruginosa Genes Inducible by Respiratory Mucus Derived From Cystic Fibrosis Patients", <i>Mol. Microbiol.</i> , 22(5): 1005-1012, 1996. Abstract.
196	Moss et al. "Reduced IL-10 Secretion by CD4+ T Lymphocytes Expressing Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)", <i>Clin. Exp. Immunol.</i> , 106(2): 374-399, 1996. Abstract.
197	Davies et al. "Regulation of the Alginate Biosynthesis Gene AlgC in Pseudomonas Aeruginosa During Biofilm Development in Continuous Culture", <i>Appl. Environ. Microbiol.</i> , 61(3): 860-867, 1995. Abstract.
198	Azghani et al. "A Beta-Linked Mannan Inhibits Adherence of Pseudomonas Aeruginosa to Human Lung Epithelial Cells", <i>Glycobiology</i> , 5(1): 39-44, 1995. Abstract.
199	Ofek et al. "Bacterial Adhesion to Cells and Tissues", Chapman & Hall, NY, P.114-118, 148-153, 418-423, 420-423, 1994.
200	Davies et al. "The Involvement of Cell-to-Cell Signals in the Development of A Bacterial Biofilm", <i>Science</i> , 280: 295-298, 1998.
201	Ghani et al. "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill Biofilms of Mucoid Pseudomonas Aeruginosa", <i>Can. J. Microbiol.</i> , 43(11): 999-1004, 1997. Abstract.
202	Stickler et al. "An Assessment of the Ability of A Silver-Releasing Device to Prevent Bacterial Contamination of Urethral Catheter Drainage Systems", <i>British J. Urology</i> , 78: 579-588, 1996.
203	Potera "Bacteria in Biofilms Exchange Developmental Signals", <i>ASM News</i> , 64(6): 321-322.
204	Gabriel et al. "In Vitro Adherence of Pseudomonas Aeruginosa to Four Intraocular Lenses", <i>J. Cataract Refract. Surg.</i> , 24: 124-129, 1998.
205	Pier "Rationale for Development of Immunotherapies That Target Mucoid Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients", <i>Behring Inst. Mitt.</i> , 98: 350-360, 1997. Abstract.
206	Goldberg et al. "Biologic Activities of Antibodies to the Neutral-Polysaccharide Component of the Pseudomonas Aeruginosa Lipopolysaccharide Are Blocked by O Side Chains and Mucoid Exopolysaccharide (Alginate)", <i>Infect. Immun.</i> , 63(1): 21-26. Abstract.
207	Mehuleni et al. "Mucoid Pseudomonas Aeruginosa Growing in A Biofilm In Vitro Are Killed by Opsonic Antibodies to the Mucoid Exopolysaccharide Capsule But Not by Antibodies Produced During Chronic Lung Infection in Cystic Fibrosis Patients", <i>J. Immun.</i> , 156(4): 2029-2038, 1995. Abstract.
208	Philippon et al. "Virulence Factors (Aerobactin and Mucoid Phenotype) in Klebsiella Pneumoniae and Escherichia Coli Blood Culture Isolates", <i>FEMS Microbiol. Lett.</i> , 130(1): 51-57, 1995. Abstract.
209	Pier et al. "How Mutant CFTR May Contribute to Pseudomonas Aeruginosa Infection in Cystic Fibrosis", <i>Am. J. Respir. Crit. Care Med.</i> , 154(4): S175-S182, 1996. Abstract.
210	Pier et al. "Cystic Fibrosis Transmembrane Conductance Regulator Is An Epithelial Cell Receptor for Clearance of Pseudomonas Aeruginosa From the Lung", <i>Proc. Natl. Acad. Sci. USA</i> , 94(22): 12088-12093, 1997.
211	Boucher et al. "Mucoid Pseudomonas Aeruginosa in Cystic Fibrosis: Characterization of Muc Mutations in Clinical Isolates and Analysis of Clearance in A Mouse Model of Respiratory Infection", <i>Infect. Immun.</i> , 65(9): 3838-3846, 1997. Abstract.
212	Boucher et al. "Two Distinct Loci Affecting Conversion to Mucoid Pseudomonas Aeruginosa in Cystic Fibrosis Encode Homologs of the Serine Protease HtrA", <i>J. Bacteriol.</i> , 178(2): 511-523, 1996. Abstract.
213	Yu et al. "Microbial Pathogens in Cystic Fibrosis: Pulmonary Clearance of Mucoid Pseudomonas Aeruginosa and Inflammation in A Mouse Model of Repeated Respiratory Challenge", <i>Infection and Immunity</i> , 66(1): 280-288, 1998.

214	Van Heeckeren et al. "Excessive Inflammatory Response of Cystic Fibrosis Mice to Bronchopulmonary Infection With <i>Pseudomonas Aeruginosa</i> ", <i>J. Clin. Invest.</i> , 100(11): 2810-2815, 1997.
215	Mrsny et al. "Addition of A Bacterial Alginate Lyase to Purulent CF Sputum In Vitro Can Result in the Disruption of Alginate and Modification of Sputum Viscoelasticity", <i>Pul. Pharmacol.</i> , 7(6): 357-366, 1994. Abstract.
216	Wills et al. "Short-Term Recombinant Human DNase in Bronchiectasis. Effect on Clinical State and In Vitro Sputum Transportability". Abstract.
217	Cai et al. "Comparison of Sputum Processing Techniques in Cystic Fibrosis", <i>Pediatr. Pulmonol.</i> , 22(6): 402-407, 1996. Abstract.
218	Randall et al. "Distribution of DNA and Alginate in Purulent Cystic Fibrosis Sputum: Implications to Pulmonary Targeting Strategies", <i>J. Drug. Therapy</i> , 4(4): 233-243, 1996.
219	Hatch et al. "Alginate Lyase Promotes Diffusion of Aminoglycosides Through the Extracellular Polysaccharide of Mucoid <i>Pseudomonas Aeruginosa</i> ", <i>Antimicrob. Agents. Chemother.</i> , 42(4): 974-977, 1998. Abstract.
220	Speert et al. "Modulation of Macrophage Function for Defense of the Lung Against <i>Pseudomonas Aeruginosa</i> ", <i>Behring Inst. Mitt.</i> , 98: 274-282, 1997. Abstract.
221	Ying et al. "Alginate, the Slime Exopolysaccharide of <i>Pseudomonas Aeruginosa</i> , Binds Human Leukocyte Elastase, Retards Inhibition by Alpha 1-Proteinase Inhibitor, and Accelerates Inhibition by Secretory Leukoprotease Inhibitor", <i>Am. J. Cell. Moll. Biol.</i> , 15(2): 283-291, 1996. Abstract.
222	Johansen et al. "Chronic <i>Pseudomonas Aeruginosa</i> Pneumonia: A New Prophylactic Principle", <i>Behring Inst. Mitt.</i> , 90: 269-273, 1997. Abstract.
223	Pina et al. "The Role of Fluoroquinolones in the Promotion of Alginate Synthesis and Antibiotic Resistance in <i>Pseudomonas Aeruginosa</i> ", <i>Curr. Microbiol.</i> , 35(2): 103-108, 1997. Abstract.
224	Spencer "Invasive Streptococci", <i>Eur. J. Clin. Microbiol. Infect. Dis.</i> , 14(Suppl.1): S26-S32, 1995. Abstract.
225	Mengistu et al. "Continuous Culture Studies on the Synthesis of Capsular Polysaccharide by <i>Klebsiella Pneumoniae</i> K1", <i>J. Appl. Bacteriol.</i> , 76(5): 424-430, 1994. Abstract.
226	Hsueh et al. "Invasive Streptococci Pneumoniae Infection Associated With Rapidly Fatal Outcome in Taiwan", <i>J. Formos Med. Assoc.</i> , 95(5): 364-371, 1996. Abstract.
227	Moses et al. "Relative Contributions of Hyaluronic Capsule and M Protein to Virulence in A Mucoid Strain of the Group A Streptococcus", <i>Infect. Immun.</i> , 65(1): 64-71, 1997. Abstract.
228	Scott et al. "Visualization of An Extracellular Mucoid Layer of <i>Treponema Denticola</i> ATCC 35405 and Surface Sugar Lectin Analysis of Some <i>Treponema</i> Species", <i>Oral Microbiol. Immunol.</i> , 12(2): 121-125, 1997. Abstract.
229	Nilsson et al. "The Role of Staphylococcal Polysaccharide Microcapsule Expression in Septicemia and Septic Arthritis", <i>Infect. Immun.</i> , 65(10): 4216-21, 1997. Abstract.
230	Wessels et al. "Effects on Virulence of Mutations in A Locus Essential for Hyaluronic Acid Capsule Expression in Group A Streptococci", <i>Infect. Immun.</i> , 62(2): 433-441, 1994. Abstract.
231	Fardale et al. "A Direct Spectrophotometric Microassay for Sulfated Glycosaminoglycans in Cartilage Cultures", <i>Connective Tissue Research</i> , 9: 247-248, 1982.
232	Pasquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in Inhibition of Murine Macrophage Response to <i>Pseudomonas Aeruginosa</i> ", <i>FEMS Microbiol. Lett.</i> , 147(2): 195-202, 1997. Abstract.
233	Marty et al. "Influence of Nutrient Media on the Chemical Composition of the Exopolysaccharide From Mucoid and Non-Mucoid <i>Pseudomonas Aeruginosa</i> ", <i>FEMS Microbiol. Letters</i> , 77(1-3): 35-44, 1992. Abstract.
234	Jorba et al. "Variations in the P. <i>Aeruginosa</i> Polysaccharide Synthesis Conditioned by Aminosugars", <i>Rev. Esp. Fisiol.</i> , 36(2): 155-161, 1980. Abstract.
235	Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis in <i>Lactococcus Lactis</i> ", <i>Appl. Environ. Microbiol.</i> , 67(1): 33-41, 2001. Abstract.
236	Bhaskar et al. "Dysregulation of Proteoglycan Production by Intrahepatic Biliary Epithelial Cells Bearing Defective (Delta-f508) Cystic Fibrosis Transmembrane Conductance Regulator", <i>Hepatology</i> , 27(1): 7-14, 1998. Abstract.

237	Vogel et al. "Production of Proteoglycans by Human Lung Fibroblasts (IMR-90) Maintained in A Low Concentration of Serum", <i>Biochem. J.</i> , 207(3): 369-379. Abstract.
238	Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Mouse Model of Cystic Fibrosis", <i>Biochem. Mol. Med.</i> , 62(1): 113-122, 1997. Abstract.
239	Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts", <i>Pediatr. Research</i> , 9(9): 698-702, 1975.
240	Rahmoune et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", <i>Am. J. Resp. Cell & Mol. Biol.</i> , 5(4): 315-320, 1991. Abstract.
241	Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Tissue", <i>Eur. J. Clin. Microbiol.</i> , 6(5): 591-593, 1987. Abstract.
242	Anison et al. "Polysaccharide Production in <i>Pseudomonas Cepacia</i> ", <i>J. Basic. Microbiol.</i> , 34(1): 3-10, 1994. Abstract.
243	Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients With Cystic Fibrosis", <i>J. Clin. Microbiol.</i> , 26(12): 2505-2509, 1988. Abstract.
244	Maccone et al. "Mucoid <i>Escherichia Coli</i> in Cystic Fibrosis", <i>The New England Journal of Medicine</i> , 304(24): 1445-1449, 1981. Abstract.
245	Tatnell et al. "Characterisation of Alginates From Mucoid Strains of <i>Pseudomonas Aeruginosa</i> ", <i>Biochemical Society Transactions</i> , 24: 404S, 1996.
246	Tatnell et al. "Chemical Analysis of Alginates From Mucoid Strains of <i>Pseudomonas Aeruginosa</i> ", <i>Biochemical Society Transactions</i> , 22: 370S, 1994.
247	Tatnell et al. "Colonisation of Cystic Fibrosis Patients by Non-Mucoid <i>Pseudomonas Aeruginosa</i> - Characterisation of the Alginate From Mucoid Variants", <i>Biochemical Society Transactions</i> , 24: 406S, 1996.
248	Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide From A Virulent Strain of <i>Pseudomonas Solanacearum</i> and From Three Avirulent Mutants", <i>Journal of Bacteriology</i> , 162(2): 504-509, 1985. Abstract.
249	Sutherland "Structure-Function Relationships In Microbial Exopolysaccharides", <i>Biotech. Adv.</i> , 12: 393-448, 1994.
250	Anatolii "Hyaluronic Capsule as One of the Factors of Hemolytic <i>Streptococcus Pathogenicity</i> ", <i>Chem. Abstracts</i> 96(17): 339, 1977. Abstr.118714 in <i>Zh. Mikrobiol. Epidemiol. Immunobiol.</i> , 2: 22-27, 1977.
251	Campbell "Monoclonal Antibody Technology", <i>Laboratory Techniques in Biochem. & Molecular Biol.</i> , 13: 1-37, 1984.
252	Campbell "Monoclonal Antibody Technology". Elsevier Science Publishers B.V., P.1-33, 1984.
253	Gospodarowicz et al. "Permissive Effect of the ExtraCellular Matrix on Cell Proliferation In Vitro", <i>Proc. Natl. Acad. Sci. USA.</i> , 77(7): 4094-4098, 1980.
254	Li et al. "Immunohistochemical Localization of Heparanase in Mouse and Human Melanomas", <i>Int. J. Cancer</i> , 45: 1088-1095, 1990.
255	Graham et al. "Comparison of the Heparanase Enzymes From Mouse Melanoma Cells, Mouse Microphages, and Human Platelets", <i>Biochem. and Mol. Biol. Int.</i> , 39(3): 563-571, 1996.
256	Kosir et al. Abstract 3378, <i>Cancer Res.</i> , 37: 495, 1996.
257	Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine", <i>Annu. Rev. Biochem.</i> , 50: 657-680, 1981.
258	Friedman et al. "Regulated Expression of Homeobox Genes <i>MSX-1</i> and <i>MSX-2</i> in Mouse Mammary Gland Development Suggests A Role in Hormone Action and Epithelial-Stromal Interactions", <i>Devel. Biol.</i> , 177: 347-355, 1996.
259	Soule et al. "Isolation and Characterization of A Spontaneously Immortalized Human Breast Epithelial Cell Line, <i>MCF-10</i> ", <i>Cancer Res.</i> , 50: 6075-6086, 1990. Abstract.
260	Miller et al. "Xenograft Model of Progressive Human Proliferative Breast Disease", <i>J. Nat. Cancer Inst.</i> , 85: 1725-1732, 1993.
261	Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metastatic Properties of Mouse B16 Melanoma Sublines", <i>Science</i> , 220: 611-613, 1983.
262	Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase", <i>Molecular Biology/Biochemistry, Proceedings of the American Association for Cancer Research</i> , 37: 495, 1996.

263	Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine - B-Lymphocytes", <i>International Journal of Cancer</i> , 47(1): 92-98, 1991.
264	Cordon-Cardo et al. "Expression of Basic Fibroblast Growth Factor in Normal Human Tissue", <i>Laboratory Investigation</i> , 63(6): 832-840, 1990.
265	Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996.
266	Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996.
267	??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991.
268	Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", <i>Pediatric Pulmonology</i> , 24: 137-142, 1997.
269	Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and RhDNase", <i>Pediatric Pulmonology</i> , 22: 161-166, 1996.
270	Crystal "Gene Therapy Strategies for Pulmonary Disease", <i>Am. J. Medicine</i> , 92 (Suppl.6A): 6A-44S - 6A-52S, 1992.
271	Lieberman "The Appropriate Use of Mucolytic Agents", <i>Am. J. Medicine</i> , 49(1): 1-4, 1970.
272	Boat et al. "Biochemistry of Airway Mucus Secretions", <i>Fed. Proc.</i> , 39(13): 3067-3074, 1980. Abstract.
273	Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulfate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", <i>Pediatr. Res.</i> , 38(1): 42-48, 1995. Abstract.
274	Cheng et al. "Increased Sulfation of Glycoconjugates NY Cultured Nasal Epithelial Cells From Patients With Cystic Fibrosis", <i>J. Clin. Invest.</i> , 84(1): 68-72, 1989. Abstract.
275	Boat et al. "Epithelial Cell Dysfunction in Cystic Fibrosis: Implications for Airways Disease", <i>Acta Paediatr. Scand. Suppl.</i> , 363: 25-29, 1989.
276	Schwartz et al. "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower Respiratory Tract", <i>J. Clin. Invest.</i> , 103(1): 68-73, 1997. Abstract.
277	Chase et al. "Respiratory Mucous Secretions in Patients With Cystic Fibrosis: Relationship Between Levels of Highly Sulfated Mucin Component and Severity of the Disease", <i>Clinica Chimica Acta</i> , 132: 143-155, 1983.
278	Allen "Opportunities for the Use Aerosolized α_1 - Antitrypsin for the Treatment of Cystic Fibrosis", <i>Chest</i> , 110/256S-260S, 1996.
279	Schwab et al. "Increased Adherence of Staphylococcus Aureus From Cystic Fibrosis Lungs to Airway Epithelial Cells", <i>Am. Rev. Respir.</i> , 148(2): 365-369, 1993. Abstract.
280	Barghouthi et al. "Nonopsonic Phagocytosis of Pseudomonas Aeruginosa Requires Facilitated Transport of D-Glucose by Macrophages", <i>J. Immunol.</i> , 154(7): 3420-3428, 1995. Abstract.
281	Moser et al. "Chronic Pseudomonas Aeruginosa Lung Infection Is More Severe in Th2 Responding BALB/c Mice Compared to Th1 Responding C3H/HeN Mice", <i>APMIS</i> , 105(11): 838-842, 1997. Abstract.
282	Cowley et al. "Mucociliary Clearance in Cystic Fibrosis Knockout Mice Infected With Pseudomonas Aeruginosa", <i>Eur. Respir.</i> , 10(10): 2312-2318, 1997. Abstract.
283	Zahn et al. "Early Alterations in Airway Mucociliary Clearance and Inflammation of the Lamina Propria in CF Mice", <i>Am. J. Physiol.</i> , 272(3 Pt 1): C853-C859, 1997. Abstract.
284	Thompson et al. "Identification of Chondroitin Sulfate B in Human Lung Mast Cells", <i>J. Immunol.</i> , 140(8): 2708-2713, 1988. Abstract.
285	Giuffre et al. "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-Selectin and Heparan Sulfate Proteoglycans", <i>J. Cell Biol.</i> , 136(4): 945-956, 1997. Abstract.
286	Shimada et al. "Involvement of Cell Surface Heparin Sulfate in the Binding of Lipoprotein Lipase to Cultured Bovine Endothelial Cells", <i>J. Clinical Invest.</i> , 68(4): 995-1002, 1981. Abstract.
287	Hayward et al. "Heparinase III Exerts Endothelial and Cardioprotective Effects in Feline Myocardial Ischemia-Reperfusion Injury", <i>J. Pharm. Exp. Ther.</i> , 283(3): 1032-1038, 1997. Abstract.

288	Yamaguchi et al. "Neutrophil Elastase Inhibitor Reduces Neutrophil Chemoattractant Production After Ischemia-Reperfusion in Rat Liver", <i>Gastroenterology</i> , 112(2): 551-560, 1997. Abstract.
289	Matgolis et al. "Identification of A Major Heparin-Precipitable Protein in Human Serum and Its Relationship to Cystic Fibrosis", <i>Pediatr. Res.</i> , 16(3): 181-186, 1982. Abstract.
290	Leong et al. "Different Classes of Proteoglycans Contribute to the Attachment of <i>Borrelia burgdorferi</i> to Cultured Endothelial and Brain Cells", <i>Infect. Immun.</i> , 66(3): 994-999, 1998. Abstract.
291	Asagoe et al. "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", <i>J. Vet. Med. Sci.</i> , 59(8): 727-728, 1997. Abstract.
292	Krusat et al. "Heparin-Dependent Attachment of Respiratory Syncytial Virus (RSV) to Host Cells", <i>Arch. Virol.</i> , 142(6): 1247-1254, 1997. Abstract.
293	Alvarez-Dominguez et al. "Host Cell Heparan Sulfate Proteoglycans Mediate Attachment and Entry of <i>Listeria monocytogenes</i> , and the Listerial Surface Protein ActA is Involved in Heparan Sulfate Receptor Recognition", <i>Infection & Immun.</i> , 65(1): 78-88, 1997. Abstract.
294	Hagiwara et al. "Inhibitory Effect of Heparin on Red Blood Cell Invasion by <i>Theileria parva</i> Merozoites", <i>Int. J. Parasitol.</i> , 27(5): 535-539, 1997. Abstract.
295	Shakibaei et al. "Dual Interaction of the Malaria Circumsporozoite Protein With the Low Density Lipoprotein Receptor-Related Protein (LRP) and Heparan Sulfate Proteoglycans", <i>J. Exp. Med.</i> , 184(5): 1699-1711, 1996. Abstract.
296	Inaba et al. "Effect of Heparin on Infection of Cells by Porcine Reproductive and Respiratory Syndrome Virus", <i>Am. J. Vet. Res.</i> , 58(5): 488-491, 1997. Abstract.
297	Chen et al. "Dengue Virus Infectivity Depends on Envelope Protein B1 to Target Cell Heparan Sulfate", <i>Nature Medicine</i> , 3(8): 866-871, 1997. Abstract.
298	Gantt et al. "Cell Adhesion to A Motif Shared by the Malaria Circumsporozoite Protein and Thrombospondin is Mediated by Its Glycosaminoglycan-Binding Region and Not by CSVTG", <i>J. Biol. Chem.</i> , 272(31): 19205-19213, 1997. Abstract.
299	Robert et al. "Chondroitin-4-Sulphate (Proteoglycan), A Receptor for <i>Plasmodium falciparum</i> -Infected Erythrocyte Adherence on Brain Microvascular Endothelial Cells", <i>Res. Immunol.</i> , 146(6): 383-393, 1995. Abstract.
300	Herrera et al. "Mediation of <i>Trypanosoma cruzi</i> Invasion by Heparan Sulfate Receptors on Host Cells and Pentrin Counter-Receptors on the Trypanosomes", <i>Mol. & Biochem. Parasit.</i> , 65: 73-83, 1994.
301	Berkow "The Merck Manual", Merck Research Laboratories, P.201, 204, 1308, 177-179, 1016-1017, 194-197, 585, 601, 1997.
302	Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part II. Use of Therapies", <i>Pediatr. Pulmonol.</i> , 28(4): 248-54, 1999. Abstract.
303	Frederiksen et al. "Antibiotic Treatment of Initial Colonization with <i>Pseudomonas aeruginosa</i> Postpones Chronic Infection and Prevents Deterioration of Pulmonary Function in Cystic Fibrosis", <i>Pediatr. Pulmonol.</i> 23(5): 330-335, May 1997.
304	Frederiksen et al. "Changing Epidemiology of <i>Pseudomonas aeruginosa</i> Infection in Danish Cystic Fibrosis Patients (1974-1995)", <i>Pediatr. Pulmonol.</i> 28(3): 159-166, 1999. Abstract.
305	Ramsey et al. "Intermittent Administration of Inhaled Tobramycin in Patients With Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", <i>New England Journal of Medicine</i> , 340(1): 23-30, 1999. Abstract.
306	Teng et al. "Contribution of Specific <i>Pseudomonas aeruginosa</i> Virulence Factors to Pathogenesis of Pneumonia in A Neonatal Mouse Model of Infection", <i>Infect. Immun.</i> , 64(1): 37-43, 1996. Abstract.
307	Bennett et al. "Effect of Uridine 5'-Triphosphate Plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", <i>Am. J. Respir. Crit. Care Med.</i> , 153(6 Pt.1): 1796-1801, 1996. Abstract.
308	Armstrong et al. "Lower Airway Inflammation in Infants and Young Children With Cystic Fibrosis", <i>Am. J. Respir. Crit. Care Med.</i> , 156(4 Pt.1): 1197-1204, 1997. Abstract.
309	Naparstek et al. "Activated T Lymphocytes Produce A Matrix-Degrading Heparan Sulphate Endoglycosidase", <i>Nature</i> , 310(5974): 241-244, 1984. Abstract.
310	Weller "Implications of Early Inflammation and Infection in Cystic Fibrosis: A Review of New and Potential Interventions", <i>Pediatric Pulmonology</i> , 24: 143-146, 1997.

311	Rubin "Emerging Therapies for Cystic Fibrosis Lung Disease", <i>Chest</i> , 115: 1120-1126, 1999.
312	Ducy et al. "The Osteoblast: A Sophisticated Fibroblast Under Central Surveillance", <i>Science</i> , 289: 1501-1504, 2000.
313	Reddi "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and Regeneration", <i>Nature Biotechnology</i> , 16: 247-252, 1998.
314	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", <i>The FASEB Journal</i> , 15: 1661-1663, 2001.
315	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", <i>The FASEB Journal</i> , Published Online, 2001.
316	Finkel "Potential Target Found for Antimetastasis Drugs", <i>Science</i> , 285: 33-34, 1999.
317	Webster et al. "FGFR Activation in Skeletal Disorders: Too Much of A Good Thing", <i>FIG</i> , 13(5): 178-182, 1997.
318	Shimazu et al. "Syndecan-3 and the Control of Chondrocyte Proliferation During Endochondral Ossification", <i>Exp. Cell. Res.</i> , 229(1): 126-136, 1996. Abstract.
319	Blanquaert et al. "CMDBS, Functional Analogs of Sulfate Heparanes, Used as Osseous Cicatrizing Agents", <i>Ann. Endocrinol.</i> , 55(2): 121-123, 1994. Abstract.
320	Blanquaert et al. "Heparan-Like Molecules Induce the Repair of Skull Defects", <i>Bone</i> , 17(6): 499-506, 1995. Abstract.
321	Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone In Vivo", <i>Blood</i> , 88(4): 1314-1320, 1996. Abstract.
322	Hoffman et al. "Human Bone Morphogenic Protein 2 Contains A Heparin-Binding Site Which Modifies Its Biological Activity", <i>Eur. J. Biochem.</i> , 237(1): 295-302, 1996. Abstract.
323	Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", <i>J. Cell. Biol.</i> 143(4): 1113-1128, 1998. [Abstract]
324	Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone Morphogenetic Protein-2 in Equine Cartilage Explant Cultures", <i>Am. J. Vet. Res.</i> , 57(4): 554-559, 1996.
325	Kiberstis et al. "Bone Health in the Balance", <i>Science</i> , 289: 1497, 2000.
326	Service "Tissue Engineers Build New Bone", <i>Science</i> , 289: 1498-1500, 2000.
327	Stracke et al. "Autotaxin, Tumor Motility-Stimulating Exophosphodiesterase", <i>Advan. Enzyme Regul.</i> , 37: 135-144, 1997. Introduction.
328	Bost et al. "Antibodies Against A Peptide Sequence Within the HIV Envelope Protein Crossreacts With Human Interleukin-2", <i>Immunol. Invest.</i> , 17: 577-586, 1988.
329	Bendayan "Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody", <i>J. Histochem. Cytochem.</i> 43: 881-886, 1995.
330	Bar-Ner et al. "Inhibition of Heparanase-Mediated Degradation of Extracellular Matrix Heparan Sulphate by Non-Anticoagulant Heparin Species", <i>Blood</i> , 70(2): 551-557, 1987.
331	Savitsky et al. "Ataxia-Telangiectasia: Structural Diversity of Untranslated Sequences Suggests Complex Post-Transcriptional Regulation of ATM Gene Expression", <i>Nucleic Acids Research</i> , 25(9): 1678-1684, 1997.
332	Ross "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", <i>Nature</i> , 362/801-809, 1993.
333	Pytnak et al. "A Putative Cellular Receptor for Dengue Viruses", <i>Nature Medicine</i> , 3(8): 828-829, 1997.
334	Shieh et al. "Cell Surface Receptors for Herpes Simplex Virus Are Heparan Sulfate Proteoglycan Proteoglycans", <i>J. Cell. Biol.</i> , 116(5): 1273-1281, 1992.
335	Lider et al. "A Disaccharide That Inhibits Tumor Necrosis Factor α Is Formed From the Extracellular Matrix by the Enzyme Heparanase", <i>Proc. Natl. Acad. Sci. USA</i> , 92: 5037-5041, 1995.
336	Spivak-Kroizman et al. "Heparin-Induced Oligomerization of FGF Molecules Is Responsible For FGF Receptor Dimerization, Activation, and Cell Proliferation", <i>Cell</i> , 79: 1015-1024, 1994.
337	Vlodavsky et al. "Endothelial Cell-Derived Basic Fibroblast Growth Factor: Synthesis and Deposition Into Subendothelial Extra-Cellular Matrix", <i>Proc. Natl. Acad. Sci. USA</i> , 84: 2292-2296, 1987.

338	Vlodavsky et al. "Involvement of the ExtraCellular Matrix, Heparin Sulfate Proteoglycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and Metastis", Tumor Angeogenesis, P.125-140, 1997.
339	Bashkin et al. "Basic Fibroblast Growth Factor Binds to Subendothelial ExtraCellular Matrix and Is Released by Heparitanase and Heparin-Like Molecules", Biochemistry, 28: 1737-1743, 1989.
340	Nicolson "Organ Specificity of Tumor Metastis: Role of Preferential Adhesion, Invasion and Growth of Malignant Cells at Specific Secondary Sites", Cancer Met. Rev., 7: 143-188, 1988.
341	Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1996. Claims: 9, 10.
342	Adams et al. "Initial Assesment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547): 13-174, 1995. GenBank Entry AA304653, 1997. Claims: 30.
343	Yagel et al. "Normal Nonmetastatic Human Trophoblast Cells Share In Vitro Invasive Properties of Malignant Cells", J. Cellular Physiology, 136: 455-462, 1988.
344	Kizaki et al. "Cloning and Localization of Heparanase in Bovine Placenta", Placenta, 24: 424-430, 2003.
345	Dempsey et al. "Heparanase Expression in Invasive Trophoblasts and Acute Vascular Damage", Glycobiology, 10(5): 467-475, 2000. Abstract, P.470, Col.1 - P.471, Col.1, P.472, Col.1, § 4 - Col.2, § 2.
346	Haimov-Kochman et al. "Localization of Hepranase in Normal and Pathological Human Placenta", Molecular Human Reproduction, 8(6): 566-573, 2002.
347	Kizaki et al. "Expression of Heparanase mRNA in Bovine Placenta During Gestation", Reproduction, 121: 573-580, 2001.
348	Edwards et al. "Some Properties and Applications of Monoclonal Antibodies", Biochem. Journal, 200: 1-10, 1981.
349	Zhou et al. "HFE Gene Knockout Produces Mouse Model of Hereditary Hemochromatosis", PNAS, 95(5): 2492-2497, 1998.
350	Menezo et al. "Mouse and Bovine Models for Human IVF", Reproductive BioMedicine Online 2002, 4(2): 170-175, 2002. Abstract.
351	Bean et al. "Fertilization In Vitro Increases Non-Disjunction During Early Cleavage Divisions in A Mouse Model System", Human Reproduction, 17(9): 2362-2367, 2002. Abstract.
352	Brinster et al. "Restoration of Fertility by Germ Cell Transplantation Requires Effective Recipient Preparation", Biology of Reproduction 69: 412-420, 2003. Abstract.
353	Liu et al. "Live Offspring by In Vitro Fertilization of Oocytes From Cryopreserved Primordial Mouse Follicles After Sequential In Vivo Transplantation and In Vitro Maturation", Biology of Reproduction, 64: 171-178, 2001. Abstract.
354	Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Piezo-Micromanipulator for In Vitro Fertilization Using Frozen-Thawed Mouse Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell Stage", Biology of Reproduction, 66: 3810385, 2002. Abstract.
355	Pfaff et al. "Cryobiology of Rat Embryos I: Determination of Zygote Membrane Permeability Coefficients for Water and Cryoprotectants, Their Activation Energies, and the Development of Improved Cryopreservation Methods", Biology of Reproduction, 63: 1294-1302, 2000. Abstract.
356	Yesildaglar et al. "The Mouse as A Model to Study Adhesion Formation Following Endoscopic Surgery: A Preliminary Report", Human Reproduction, 14(1): 55-59, 1999. Abstract.
357	Ejima et al. "Induction of Apoptosis in Placentas of Pregnant Mice Exposed to Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System", Biology of Reproduction, 62: 178-185, 2000. Abstract.
358	Prahalada et al. "Diethylstilbestrol-Induced Cervical and Vaginal Adenosis Using the Neonatal Mouse Model", Biology of Reproduction, 38: 935-943, 1988. Abstract.
359	Newbold et al. "Exposure to Diethylstilbestrol During Pregnancy Permanently Alters the Ovary and Oviduct", Biology of Reproduction, 28: 735-744, 1983. Abstract.
360	??? "Mouse Models for Reproductive Biology Research" - www.jax.org/jaxmice : 1-2, Summer 2002.

361	Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA", Proceedings American Association for Cancer Research Annual Meeting, 1992, 33: 57, 1992. Abstract.
362	Thuong et al. "Sequence-Specific Recognition and Modification of Double-Helical DNA by Oligonucleotides", Angew.Chem. Int. Ed. Engl. 32: 666-690, 1993.
363	Cohen "Oligonucleotide Therapeutics", Trends in Biotechnology 10: 87-91, 1992. Abstract.
364	Szczylik et al. "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides", Science, 253: 562-565, 1991. Abstract.
365	Calabretta et al. "Normal and Leukemic Hematopoietic Cell Manifest Differential Sensitivity to Inhibitory Effects of C-myc Antisense Oligodeoxynucleotides: An In Vitro Study Relevant to Bone Marrow Purging", Proc. Natl. Acad. Sci. USA, 88: 2351-2355, 1991.
366	Burch et al. "Oligodeoxynucleotides Antisense to the Interleukin 1 Receptor mRNA Block the Effects of Interleukin 1 in Cultured Murine and Human Fibroblasts and in Mice", J. Clin. Invest., 88: 1190, 1991. Abstract.
367	Agrawal "Antisense Oligonucleotides As Antiviral Agents", Trends Biotechnol., 10(5): 152-158, 1992. Abstract.
368	Ngo et al. "The Protein Folding Problem and Tertiary Structure", Ed Birkhauser, Boston, P.491-495, 1994.
369	Ferber et al. "Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia", Nature Medicine, 6(6): 568-572, 2000.
370	Benjamin et al. "A Plasticity Window for Blood Vessel Remodelling Is Defined by Pericyte Coverage of the Preformed Endothelial Network and Is Regulated by PDGF-B and VEGF", Development, 125: 1591-1598, 1998.
371	Vukicevic et al. "Induction of Nephrogenic Mesenchyme by Osteogenic Protein 1 (Bone Morphogenetic Protein 1)", Proc. Natl. Acad. Sci. USA, 93: 9021-9026, 1996.
372	Massague "The TGF-BETA Family of Growth and Differentiation Factors", Cell, 49: 437-438, 1987.
373	Pilbeam et al. "Comparison of the Effects of Various Lengths of Synthetic Human Parathyroid Hormone-Related Peptide (hPTHrP) of Malignancy on Bone Resorption and Formation in Organ Culture", Bone, 14: 717-720, 1993.
374	Skolnick et al. "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era", Trends in Biotechnology, 18: 34-39, 2000.
375	Bork "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome Research, 10: 398-400, 2000.
376	Doerks et al. "Protein Annotation: Detective Work for Function Prediction", Trends in Genetics, 14(6): 248-250, 1998.
377	Smith et al. "The Challenges of Genome Sequence Annotation or 'The Devil Is in the Details'", Nature Biotechnology, 15: 1222-1223, 1997.
378	Brenner "Errors in Genome Annotation", Trends in Genetics, 15(4): 132-133, 1999.
379	Bork "Go Hunting in Sequence Databases But Watch Out for the Traps", Trends in Genetics, 12(10): 425-427, 1996.
380	Bowie et al. "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", Science, 247: 1306-1310, 1990.
381	?? A Genesq, Accession No. AA17083, 1999.
382	Sendig et al. "Humanization of Rodent Monoclonal Antibodies by CDR Grafting", Methods in Enzymology, 8: 83-93, 1995.
383	Miao et al. "Cloning, Expression and Purification of Mouse Heparanase", Protein Expression and Purification, 26: 425-431, 2002.
384	Coligan et al. "Current Protocols in Immunology", Immunology - Laboratory Manuals, 1991.
385	Sasisekharan et al. "Cloning and Expression of Heparinase I Gene From Flavobacterium Heparinum", Proc. Natl. Acad. Sci. USA, 90: 3660-3664, 1993.
386	Gordon-Cardo et al. "Expression of Basic Fibroblast Growth Factor in Normal Human Tissues", Laboratory Investigation, 63: 832-840, 1990.
387	Harper "Harper's Biochemistry", 24th Ed., P. 660-685.
388	Boat et al. "Increased Sulfation of Glycoconjugates NY Cultured Nasal Epithelia Cells From Patients With Cystic Fibrosis", Journal of Clinical Investmet, 84(1): 68-72, 1989. Abstract.

389	Nossuli et al. "Heparinas III Exerts Endothelial and Cardioprotective Effects in Feline Myocardial Ischemia-Reperfusion Injury", Journal of Pharmaceutical Experimental Therapy, 283(3): 1032-1038, 1997. Abstract.
390	Nakajima et al. "Immunohistochemical Localization of Heparanase in Mouse and Human Melanomas", International Journal of Cancer, 45: 1088-1095, 1990.
391	Wands Federal Circular, 1988,
392	Fisher CCPA, 1970.
393	Carson et al. Mucin and Proteoglycan Functions in Embryo Implantation", BioEssays, 20(7): 577-583, 1998. Abstract, P.580, Col.2, § 2, P.582, Col 1, Fig.1.
394	Clontech Laboratories "RT-PCR Methods and Applications Book 1", Clontech Laboratories, 1st Ed., P.1-15, 26, 40, 1991.
395	Novagen "PET System Manual", Novagen, 6th Ed., P.11, 1995.
396	Eanis et al. "Rapid Cloning of HLA-A,B cDNA by Using the Polymerase Chain Reaction: Frequency and Nature of Errors Produced in Amplification", PNAS USA, 87: 2833-2837, 1990.
397	Gilat et al. "Molecular Behaviour Adapts to Context: Heparanase Functions as An Extracellular Matrix-Degrading Enzyme or as A T-Cell Adhesion Molecule, Depending on the Local PH", Journal of Experimental Medicine, 181: 1929-1934, 1995.
398	Murphy et al. "The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucocytes", Biochem. J., 192: 517-525, 1980.
399	Morel et al. "Human Neutrophil Gelatinase Is A Collagenase Type IV", Biochem. & Biophys. Res. Comm., 191: 269-274, 1993.
400	Kane "High-Level Expression of Foreign Genes in Mammalian Cells", Genetic Eng., 13: 167-182, 1991.
401	Makrides "Strategies for Achieving High-Level Expression of Genes in Escherichia Coli", Microbiolog. Rev., 60: 512-538, 1996.
402	Hrlow et al. "Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.
403	Williams et al. "Cytoplasmic Inclusion Bodies in Escherichia Coli Producing Biosynthetic Human Insulin Proteins", Science, 215: 687-689, 1982.
404	Chubet et al. "Vectors for Expression and Secretion of FLAG Epitope-Tagged Proteins in Mammalian Cells", BioTechniques, 20: 136-141, 1996.
405	Sambrook et al. "Molecular Cloning, A Laboratory Manual", CSH Laboratory Press, 2: 7.37-7.52, 1989.
406	Romanos "Advances in the Use of Pichia Pastoris for High-Level Gene Expression", Curr. Opin. Biotech., 6: 527-533, 1995.
407	Freshney "Animal Cell Culture", P.48-49.
408	Chang et al. "Differential Ability of Heparan Sulfate Proteoglycans to Assemble the Fibroblast Growth Factor Receptor Complex In Situ", FASEB Journal, 14: 137-144, 2000.
409	Hillier et al. "The WashU-Merck EST Project", Database EMBL Accession No. N45367, XP 002198420, 1996. Abstract.
410	Marra et al. "The WashU-HHMI Mouse EST Project", Database EMBL, Accession No. A1122054, XP 002198426, 1998. Abstract.
411	Marra et al. "The WashU-HHMI Mouse Est Project", Database EMBL, Accession No. AA047943, XP002198424, 1996.
412	Evans et al. "Human Chromosome 11 187a8 Cosmid, Complete Sequence", Database EMBL, Accession No. U73640, XP002198427, 1996. Abstract.
413	Maniatis et al. "Extraction, Purification and Analysis of mRNA From Eukaryotic Cells", Molecular Cloning Manual, chapt. 6: 188-246, 1982.
414	Suggs et al. "Use of SyntheticNucleotides as Hybridization Probes: Isolation of Cloned DNA Sequences for Human β 2-Microglobulin", PNAS, 78(11): 6613-6617, 1981. P.13.
415	Alberts et al. "Molecular Biology of the Cell", Garland Publishing, 2nd Ed., P. 195-196, 598, 1989.
416	Sigma Catalog, P. 275, 1992. Collagenase Listing.
417	Ehle et al. "Immunoaffinity Chromatography of Enzymes", Bioseparation, 1(2): 97-110, 1990.
418	Hidde et al. "Construction and Characterization of A Fusion Protein of Single-Chain Anti-Carcinoma Antibody 323/A3 and Human Beta-Glucuronidase", Cancer Immunology Immunotherapy, 45(5): 266-272, 1998.

419	Takayama et al. "Neutrophil-Dependent Goblet Cell Degranulation: Role of Membrane-Bound Elastase and Adhesion Molecules", American Journal of Physiology, 275(2/Part 1): L294-L302, 1998.
420	Lider et al. "Inhibition of T Lymphocyte Heparanase: Purification, Characterization and Catalytic Activity", Biochemical Journal, GB, 330(3): 1341-1350, 1998.
421	Nadav et al. "Activation, Processing and Trafficking of Extracellular Heparanase by Primary Human Fibroblasts", Journal of Cell Science, 115(10): 2179-2187, 2002.
422	Goldshmidt et al. "Cell Surface Expression and Secretion of Heparanase Markedly Promote Tumor Angiogenesis and Metastasis", Proc. Natl. Acad. Sci. USA, 99(15): 10031-10036, 2002.
423	Guo et al. "Protein Tolerance to Random Amino Acid Change", PNAS, 101(25): 9205-9210, 2004.
424	Mirino "RT-PCR Method & Applications", Clontech Laboratories, 1st Ed. 1: 11, 19, 23, 41, 26, 1991.
425	Wight et al. "Cell Biology of Arterial Proteoglycans", Arteriosclerosis, 9(1): 1-20, 1989.
426	Kjellen et al. "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443-475, 1991.
427	Ruoslahti et al. "Proteoglycans as Modulators of Growth Factor Activities", Cell, 64: 867-869, 1991.
428	Vlodavsky et al. "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", in: Basic Membranes: Cellular and Molecular Aspects, Academic Press, Orlando, Fla., P. 327-343, 1993.
429*	Vlodavsky et al. "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extra Vasion", Invasion & Metastasis, 12(2): 112-117, 1992. Abstract.
430*	Vlodavsky et al. "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species of Heparin", Invasion & Metastasis, 14(1-6): 290-302, 1994/95.
431	Liotta et al. "Tumor Invasion and the Extracellular Matrix", Laboratory Investigation, 49(6): 636-647, 1983.
432	Vlodavsky et al. "Lymphoma Cell-Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Research, 43: 2704-2711, 1983.
433	Vlodavsky et al. "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Isr. J. Med. Sci., 24(9-10): 464-470, 1988.
434	Parish et al. "Evidence That Sulfated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor-Cell-Derived Heparanases", Int. J. Cancer, 40: 511-517, 1987.
435	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", Cell, 19: 607-616, 1980.
436	Vlodavsky et al. "Extracellular Sequestration and Release of Fibroblast Growth Factor: A Regulatory Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991.
437	Lider et al. "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals With Low Doses of Heparin", The Journal of Clinical Investigation, 83: 752-756, 1989.
438	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparin", FEBS Letters, 117(1): 203-206, 1980.
439	Suchalter et al. "Importance of Size, Sulfation and Anticoagulant Activity in the Potentiation of Acidic Fibroblast Growth Factor by Heparin", J. Biol. Chem., 254(12): 6892-6897, 1989.
440	Ishai-Michaeli et al. "Importance of Size and Sulfation of Heparin in Release of Basic Fibroblast Growth Factor From the Vascular Endothelium and Extracellular Matrix", Biochemistry, 31(7): 2080-2088, 1992. Abstract.
441	Inoue et al. "Selective N-Desulfation of Heparin With Dimethyl Sulfoxide Containing Water or Methanol", Carbohydrate Research, 46: 67-95, 1976.
442	Nagasawa et al. "Solvolytic Desulfation of Glycosaminoglycuronan Sulfates With Dimethyl Sulfoxide Containing Water or Methanol", Carbohydrate Research, 58: 47-55, 1977.
443	Matia Bar-New et al. Inhibition of Heparanase-Mediated Degradation of Extracellular Matrix Heparin Sulfate by Non-Anticoagulant Heparin Species", Blood, 70(2): 551-557, 1987.

444	Gospodarowicz et al. "Stimulation of Corneal Endothelial Cell Proliferation In Vitro by Fibroblast and Epidermal Growth Factors", <i>Exp. Eye Res.</i> , 25: 75-89, 1977.
445	Haimovits-Friedman et al. "Activation of Platelet Heparitinase by Tumor Cell-Derived Factors", <i>Blood</i> , 78: 789-796, 1991.
446	Vlodavsky et al. "Extracellular Matrix-Resident Growth Factors and Enzymes: Possible Involvement in Tumor Metastasis and Angiogenesis", <i>Cancer and Metastasis Rev.</i> , 9: 203-226, 1990.
447	Regan et al. "Mimicry of Biological Macromolecules by Polyaromatic Anionic Compounds", <i>J. Bioactive and Compatible Polymers</i> , 8: 317-337, 1993.
448	Benezra et al. "Antiproliferative Activity to Vascular Smooth Muscle Cells and Receptor Binding of Heparan-Mimicking Polyaromatic Anionic Compounds", <i>Arteriosclerosis and Thrombosis</i> , 14(12): 1992-1999, 1993.
449	Katz et al. "Antiproliferative Activity to Glomerular Mesangial Cells and Receptor Binding of A Heparan-Mimicking Polyaromatic Anionic Compound", <i>J. Amer. Soc. Nephrology</i> , P.1688-1697, 1997.
450	Miao et al. "Modulation of Fibroblast Growth Factor-2 Receptor Binding Dimerization, Signaling, and Angiogenic Activity by A Synthetic Heparan-Mimicking Polyaromatic Compound", <i>J. Clin. Invest.</i> , 99(7): 1565-1572, 1997.
451	Benezra et al. "Reversal of Fibroblast Growth Factor-Mediated Autocrine Cell Transformation by Aromatic Anionic Compounds", <i>Cancer Research</i> , 52: 5656-5662, 1992.
452	Irimura et al. "Chemically Modified Heparins as Inhibitors of Heparan Sulfate Specific Endo- β -Glucuronidase (Heparanase) of Metastatic Melanoma Cells", <i>Biochemistry</i> , 25: 5322-5328, 1986.
453	Coombe et al. "Analysis of the Inhibition of Tumor Metastasis by Sulphated Polysaccharides", <i>Int. J. Cancer</i> , 39: 82-88, 1987.
454	Ornitz et al. "Heparin Is Required for Cell-Free Binding of Basic Fibroblast Growth Factor to A Soluble Receptor and for Mitogenesis in Whole Cells", <i>Molecular and Cellular Biology</i> , 12: 240-247, 1992.
455	Yayon et al. "Cell Surface, Heparin-Like Molecules Are Required for Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor", <i>Cell</i> , 64: 841-848, 1991.
456	Aviezer et al. "Differential Structural Requirements of Heparin and Heparan Sulfate Proteoglycans That Promote Binding of Basic Fibroblast Growth Factor to Its Receptor", <i>J. Biol. Chem.</i> , 269(1): 114-121, 1994.
457	Bartlett et al. "Comparative Analysis of the Ability of Leucocytes, Endothelial Cells, and Platelets to Degrade the Subendothelial Basement Membrane: Evidence for Cytokine Dependence and Detection of A Novel Sulfatase", <i>Immunology and Cell Biol.</i> , 73: 113-124, 1995.
458	Nakajima et al. "A Solid-Phase Substrate of Heparanase: Its Application to Assay of Human Melanoma for Heparan Sulfate Degradative Activity", <i>Analytical Biochemistry</i> , 157: 162-171, 1986.
459	Oosta et al. "Purification and Properties of Human Platelets Heparitinase", <i>J. Biol. Chem.</i> , 257(19): 11249-11255, 1982.
460	Sewell et al. "Human Mononuclear Cells Contain An Endoglycosidase Specific for Heparan Sulfate Glycosaminoglycan Demonstrable With the Use of A Specific Solid-Phase Metabolically Radiolabelled Substrate", <i>Biochem J.</i> , 264: 777-783, 1989.
461	Freeman et al. "A Rapid Quantitative Assay for the Detection of Mammalian Heparanase Activity", <i>Biochemical Journal</i> , 325: 229-237, 1997.
462	Mullings et al. "New Reducing Sugar Assay for the Study of Cellulases", <i>Enzyme Microb. Technol.</i> , 6: 491-496, 1984.
463	Taylor et al. "A Colorimetric Method for the Quantitation of Uronic Acids and A Specific Assay for Galacturonic Acid", <i>Analytical Biochemistry</i> , 201: 190-196, 1992.
464	Linhart "Capillary Electrophoresis of Oligosaccharides", <i>Methods in Enzymology</i> , 230: 265-280, 1994.
465	Basu et al. "Analysis of Glycosphingolipids by Fluorophore-Assisted Carbohydrate Electrophoresis Using Ceramide Glycanase From <i>Mercenaria Mercenaria</i> ", <i>Analytical Biochemistry</i> , 222: 270-274, 1994.
466	Jackson "The Use of Polyacrylamide-Gel Electrophoresis for the High-Resolution of Separation of Reducing Saccharides Labelled With the Fluorophore 8-Aminonaphthalene-1, 3, 6-Trisulphonic Acid", <i>Biochem J.</i> , 270: 705-713, 1990.

467	Coquet et al. "Applications of A Post-Column Fluorogenic Reaction in Liquid Chromatography for the Determination of Glucose and Fructose in Biological Matrices", <i>Analytica Chimica Acta</i> , 252: 173-179, 1991.	
468	De Vouge et al. "Immunoselection of GRP94/Endoplasmic From A KNRK Cell-Specific λ gt11 Library Using Antibodies Directed Against A Putative Heparanase Amino-Terminal Peptide", <i>Int. J. Cancer</i> , 56: 286-294, 1994.	
469	Zsolnai et al. "Directional Immobilization of Heparin Onto Nonporous Surface of Polystyrene Microplates", <i>Biotechniques</i> , 23(3): 382-385, 1997.	
470	Bellott et al. "Closing the Loop in Combinatorial Chemistry", <i>European Pharmaceutical Contractor</i> , 1997.	
471	Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by Chondrocytes in Culture", <i>Live Tissue Research</i> , 24: 265-275, 1990.	
472	Yan et al. "Potentialities of A New Class of Anticlotting and Antihemorrhagic Polymers", <i>J. Macromol. Sci. Chem.</i> , 4(3): 693-714, in <i>Chem. Abst. AN</i> , 1970 418456 In: <i>Chem. Abst. AN</i> , 1970 418456.	
473	Mes et al. "Use of Triphenyltetrazolium Chloride for the Quantative Analysis of Sugars and Sugar Derivatives Reported in Glycoproteins", <i>J. Chromatogr.</i> , 43(\$): 480-486, 1982.	
474	Mes et al. "Relative Sensitivity of Various Reagents for the Detection and Differentiation of Sugars and Sugar Derivatives in Glycoproteins", <i>J. Chromatogr.</i> , 38(1): 120-125, 1982.	
475	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", <i>Cell</i> , 19: 607-616, 1980.	
476	Burgess et al. "The Heparin-Binding (Fibroblast) Growth Factor of Proteins", <i>Annu. Rev. Biochem.</i> , 58: 575-606, 1989.	
477	Campbell et al. "Heparan Sulfate-Degrading Enzymes Induce Modulation of Smooth Muscle Phenotype", <i>Experimental Cell Research</i> , 20: 156-167, 1992.	
478	Eisenberg et al. "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan Sulfate on Cell Surface and Extracellular Matrix", <i>J. Clin. Invest.</i> , 90: 2013-2021, 1992.	
479	Folkman et al. "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth Factor - Is Stored Within Basement Membrane", <i>Am. J. Pathology</i> , 130(2): 393-400, 1988.	
480	Folkman et al. "Angiogenic Factors", <i>Science</i> , 235: 442-447, 1987.	
481	Gitay-Goren et al. "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-Associated Heparin-Like Molecules", <i>Journal of Biological Chemistry</i> , 267(9): 6093-6098, 1992.	
482	Matzner et al. "Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by A Readily Released Heparanase From Human Neutrophils", <i>Journal of Clinical Investigation</i> , 76(4): 1306-1313, 1985.	
483	Mollinedo et al. "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", <i>Biochem. J.</i> , 327: 917-923, 1997.	
484	Narindrasorasak et al. "High Affinity Interactions Between the Alzheimer's β -Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", <i>J. Biol. Chem.</i> , 266(20): 12878-12883, 1991.	
485	Ornitz et al. "FGF Binding and FGF Receptor Activation by Synthetic Heparin-Derived Di- and Trisaccharides", <i>Science</i> , 268: 432-436, 1995.	
486	Rapraeger et al. "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", <i>Science</i> , 252: 1705-1709, 1991.	
487	Zhong-Sheng et al. "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", <i>J. Biol. Chem.</i> , 268(14): 10160-10167, 1993.	
488	Hudson "Recombinant Antibody Fragment", <i>Curr. Opin. Biotech.</i> , 4:395-402, 1998.	
Signature		Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

PTO/SB/08A (0-96)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE:

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC: 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/785,116
				Filing Date	February 25, 2004
				First Named Inventor	PECKER Iris et al
				Art Unit	1652
				Examiner Name	
				Attorney Docket Number	27674
Sheet				of	
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Document Number Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-5,362,041	08-8-1994	Fuks et al.	
	2	US-5,399,351	03-21-1995	Leshchiner et al	
	3	US-5,550,116	08-27-1996	Lormeau et al.	
	4	US-5,667,501	09-16-1997	Fowler et al.	
	5	US-5,739,115	04-14-1998	Fugedi et al.	
	6	US-6,177,545	01-13-2001	Pecker et al.	
	7	US-6,348,344	02-19-2002	Ayal-Hershkovitz et al.	
	8	US-4,946,778	08-8-1990	Ladner et al.	
	9	US-5,997,863	07-8-1999	Zimmermann et al.	
	10	US-6,242,238	05-5-2001	Freeman et al.	
	11	US-5,688,679	11-18-1997	Powell	
	12	US-6,387,643	05-14-2002	Heinrikson et al.	
	13	US-6,423,312	07-23-2002	Yacoby-Zeevi	
	14	US-6,531,129	01-1-2003	Pecker et al.	
	15	US-4,455,296	06-19-1984	Hansen et al.	
	16	US-5,571,506	05-5-1996	Regan et al.	
	17	US-5,917,830	06-29-1999	Chen et al.	
	18	US-5,859,660	01-12-1999	Perkins et al.	
	19	US-5,600,366	04-4-1997	Schulman	
	20	US-6,020,931	01-1-2000	Bilbrey et al.	
	21	US-5,968,822	10-19-1999	Pecker et al.	
	22	US-6,153,187	11-28-2000	Yacoby-Zeevi	
	23	US-6,664,105	12-16-2003	Pecker et al.	
	24	US-5,145,679	06-8-1992	Hanson	
	25	US-5,736,137	07-7-1998	Anderson et al.	
	26	US-5,194,596	03-16-1993	Tischer et al.	
	27	US-5,350,836	09-27-1994	Kopchick et al.	
	28	US-6,562,950	05-13-2003	Peretz et al.	
	29	US-6,699,672	02-2-2004	Pecker et al.	
	30	US-5,580,862	03-3-1996	Rosen et al.	
	31	US-5,474,683	12-12-1995	Kuna et al.	
	32	US-2002/0102560	01-1-2002	Pecker et al.	
	33	US-6,790,658	09-14-2004	Pecker et al.	
	34	US-6,798,658	09-28-2004	Takedomi et al.	
	35	US-5,618,709	08-8-1997	Gewirtz et al.	
	36	US-5,656,595	08-12-1997	Schweighoffer et al.	
	37	US-4,683,195	07-28-1987	Mullis et al.	
	38	US-5,602,095	02-11-1997	Pastan et al.	
	39	US-4,859,581	08-22-1989	Nicholson et al.	
	40	US-4,882,318	11-21-1989	Vlodavsky et al.	
	41	US-5,129,877	07-14-1992	Gallo et al.	
	42	US-5,206,223	04-27-1993	Vlodavsky et al	
	43	US-5,332,812	07-26-1994	Nicolson et al.	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/785,116
		Filing Date	February 25, 2004
		First Named Inventor	PECKER [et al]
		Group Art Unit	1652
		Examiner Name	
Sheet	Of	Attorney Docket Number 27674	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	44	Hulett et al. "Cloning of Mammalian Heparanase, An Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine, 5(7): 803-809, 1999.	
	45	Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. of Biolog. Chemistry, 274(34): 24153-24160, 1999.	
	46	Kussie et al. "Cloning and Functional Expression of a Human Heparanase Gene", Biochemical and Biophysical Research Communication 261(1): 183-187, 1999.	
	47	Freeman et al. "Evidence that Platelet and Tumour Heparanases are Similar Enzymes", Biochem J. 342: 361-368, 1999.	
	48	Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8): 349-351, 2000. P.350, Col.1, § 1, Col.3, § 1, Claims 1-24.	
	49	Goshen et al. "Purification and Characterization of Placental Heparanase and Its Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction, 2(9): 679-684, 1996.	
	50	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", Biochem. J., 330: 1341-1350, 1998.	
	51	Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7): 793-802, XP 002139970, 1999.	
	52	Uno et al. "Antisense-Mediated Suppression of Human Heparanase Gene Expression Inhibits Pleural Dissemination of Human Cancer Cells", Cancer Research, 61(21): 7855-7860, 2001.	
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

77571 5:16 A

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC :20231.

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE:

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/APTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet	2	OF	2	Attorney Docket Number	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7): 793-802, 1999.			
		Chang et al. "Differential Ability Of Heparan Sulfate Proteoglycans To Assemble The Fibroblast Growth Factor Receptor Complex In situ", FASEB Journal, 14: 37-144, 2000.			
		Ishai-Michaeli et al. "Importance of Size and Sulfation of Heparin in Release of Basic Fibroblast Growth Factor From the Vascular Endothelium and ExtraCellular Matrix", Biochemistry, 31(7): 2080-2088, 1992. Abstract.			
		Gitay-Goren et al. "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-Associated Heparin-Like Molecules", Journal of Biological Chemistry, 267(9): 6093-6098, 1992.			
		Hulett et al. "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis", Nature Medicine, 5(7): 803-809, 1999.			
		Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression", J. of Biolog. Chemistry, 274(34): 24153-24160, 1999			
Examiner Signature		Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC: 20231.



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/781,758
				Filing Date	January 14, 2003
				First Named Inventor	ILAN Netn et al
				Art Unit	
				Examiner Name	
Sheet	1	of	18	Attorney Docket Number	27525
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-6,177,345	01-13-2001	Pecker et al.	
	2	US-6,348,344	02-19-2002	Ayal-Hershkovitz et al	
	3	US-4,946,778	08-8-1990	Ladner et al.	
	4	US-5,997,863	07-7-1999	Zimmermann et al.	
	5	US-6,242,238	05-5-2001	Freeman et al.	
	6	US-5,688,679	11-18-1997	Powell	
	7	US-6,387,643	05-14-2002	Heinrikson et al.	
	8	US-6,423,312	07-23-2002	Yacoby-Zeevi	
	9	US-6,531,129	01-1-2003	Pecker et al.	
	10	US-4,455,296	06-19-1984	Hansen et al.	
	11	US-5,571,506	01-1-1996	Regan et al.	
	12	US-5,917,830	06-29-1999	Chen et al.	
	13	US-5,859,660	01-12-1999	Perkins et al.	
	14	US-5,600,366	04-4-1997	Schulman	
	15	US-6,020,931	01-1-2000	Bilbrey et al.	
	16	US-5,968,822	10-19-1999	Pecker et al.	
	17	US-6,153,187	11-28-2000	Yacoby-Zeevi	
	18	US-6,664,105	12-16-2003	Pecker et al.	
	19	US-5,145,679	08-8-1992	Hinson	
	20	US-5,736,137	07-7-1999	Anderson et al.	
	21	US-5,194,596	03-16-1993	Tischer et al.	
	22	US-5,350,836	09-27-1994	Kopchick et al.	
	23	US-6,562,950	05-13-2003	Peretz et al.	
	24	US-6,699,672	02-2-2004	Pecker et al.	
	25	US-5,580,862	03-3-1996	Rosen et al.	
	26	US-5,474,983	12-12-1995	Kuna et al.	
	27	US-2002/0102560	01-1-2002	Pecker et al.	
	28	US-4,859,581	01-1-1989	Nicholson et al.	
	29	US-4,882,318	01-1-1989	Vlodavsky et al.	
	30	US-5,129,871	01-1-1992	Gallo et al.	
	31	US-5,206,223	04-27-1993	Vlodavsky et al.	
	32	US-5,332,812	07-26-1994	Nicolson et al.	
	33	US-5,262,641	08-8-1994	Fuks et al.	
	34	US-5,399,351	01-1-1995	Leshchiner et al.	
	35	US-5,550,116	01-1-1996	Lormeau et al.	
	36	US-5,667,501	01-1-1997	Fowler et al.	
	37	US-5,739,115	01-1-1998	Fugedi et al.	
FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Foreign Patent Documents Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	38	PCT WO 99/57244	11-11-1999	Ben-Artzi et al.	

40	PCT WO 99/11798	03-11-1999	Pecker et al.	
41	PCT WO 88/01280	01-1-1988	Nicolson et al.	
42	PCT WO 95/04158	09-9-1995	Hoogewerf et al.	
43	PCT WO 99/21975	06-6-1999	Freeman et al.	
44	PCT WO 91/19197	12-12-1991	Nicolson et al.	
45	PCT WO 95/04518	02-16-1995	Midha et al.	
46	PCT WO 03/086645 A2	01-23-2003	Bohlen et al.	
47	PCT WO 97/11684	04-4-1997	Bennett et al.	
48	PCT WO 91/02977	07-7-1991	Fuks et al.	
49	PCT WO 97/27327	07-31-1997	Van Ness et al.	
50	PCT WO 00/52149	08-8-2000	Yacobi-Zeevi	
51	PCT WO 00/52178	08-8-2000	Pecker et al.	
Examiner Signature		Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/781,758
Filing Date	January 14, 2003
First Named Inventor	ILAN Neta et al
Group Art Unit	
Examiner Name	

Sheet	2	Of	18	Attorney Docket Number	27525
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	52	Wight et al. "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation", Curr. Opin. Cell. Biology, 4: 793-801, 1992.			✓
	53	Jackson et al. "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", Physiological Review, 71(2): 481-535, 1991.			✓
	54	Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced from Hydrophobic Cluster Analysis", Glycobiology, 7(2): 277-284, 1997.			✓
	55	Korb et al. "Stimulation of Gene Expression by Introns: Conversion of an Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Donor Sequence", Nucleic Acids Research 21(25): 5901-5908, 1993.			✓
	56	Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", Journal of Biol. Chem., 274,(42): 29587-29590, 1999.			✓
	57	Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology 12: 135-176, 1986.			✓
	58	Dempsey et al. "Heparanase, A Potential Regulator of CellMatrix Interactions", TIBS, 25(8):349-351, 2000. P. 350, Col.1, § 1; P.350, Col.3, § 1; Claims: 1-24.			✓
	59	Niwa et al. "Efficient Selection for High-Expression Transfectants With a Novel Eukaryotic Vector", Gene, 108(2):193-199, 1991.			✓
	60	Clark "The Mammary Gland as a Bioreactor: Expression, Processing, and Production of Recombinant Proteins", J. Mammary Gland Biol. and Neoplasia, 3(3):337-350, 1998.			✓
	61	Mirault et al. "Transgenic Glutathione Peroxidase Mouse Models for Neuroprotection Studies", Ann NY Acad Sci, 738:104-115, 1994.			✓
	62	Lampard et al. " Secretion of Foreign Proteins Mediated by Chicken Lysozyme Gene Regulatory Sequences", Biochem Cell Biol., 80(6):777-788, 2002.			✓
	63	Harvey et al. "Expression of Exogenous Protein in the Egg Whites of Transgenic Chickens", Nature Biotechnology, 19:396-399, 2002.			✓
	64	Morrison et al. "Sequences in Antibody Molecules Important for Receptor-Mediated Transport Into the Chicken Egg Yolk", Mol Immunol., 38(8): 619-625, 2002.			✓
	65	Clark et al. "Pharmaceuticals from Transgenic Livestock", TIBTECH, 5: 20-24, 1987.			✓
	66	Richards et al. "Construction and Preliminary Characterization of the Rat Casein and Alpha-Lactalbumin Cdna Clones", J. Biol. Chem., 256(1): 526-32, 1981.			✓
	67	Campbell et al. "Comparison of the Whey Acidic Protein Genes of the Rat and Mouse", Nucleic Acids Res., 12(22): 8685-8697, 1984.			✓
	68	Gorodetsky et al. "Isolation and Characterization of the Bos Taurus β -Casein Gene", Gene, 66: 87-96, 1988.			✓
	69	Alexander et al. "Complete Sequence of the Bovine β -Lactoglobulin cDNA", Nucleic Acids Research, 17(16): 6739-6744, 1989.			✓
	70	Benezra et al. "Thrombin Enhances the Degradation of Heparan Sulfate in the Extracellular Matrix by Tumor Cell Heparanase." Exptl. Cell. Res. (1992) vol. 201:208-215			✓
	71	Harlow et al. "Antibodies" A Laboratory Manual, eds. Harlow et al.: 471-510.			✓
	72	Murray et al. "The Extracellular Matrix", found in Harper's Biochemistry, 24th Ed., McGraw-Hill Professional, Chap. 57, pp 667-685, 1998.			✓
	73	Selvan et al. "Heparan Sulfate in Immune Responses", An. NY Acad. Sci., 797: 127-			✓

		139, 1996.	
74	Prockop	"Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues", Science 276: 71-74, 1997.	✓
75	Krivit et al.	"Microglia: The Effector cell for reconstitution of the Central Nervous System Following Bone Marrow Transplantation for Lysosomal and Peroxisomal Storage diseases", Cell Transplant, 4(4): 385-392, 1995.(Abstract)	✓
76	Robey et al.	"Biochemical Characterization of Marrow Stromal Fibroblasts", 6th Int'l conf. On Molec. Biol. And Pathology of Matrix, Session IV.	✓
77	Lazarus et al.	"Ex Vivo Expansion and subsequent Infusion of Human Bone Marrow-Derived Stromal Progenitor Cells (Mesenchymal Progenitor cells): Implications for therapeutic Use", Bone Marrow Transplantation, 16:557-564, 1995.	✓
78	Pomahac et al.	"Tissue Engineering of Skin" Crit Rev Oral Biol Med, 9(3):333-344, 1998. (abstract)	✓
79	Benathan et al.	"Living epidermal and Dermal Substitutes for Treatment of Severely burned Patients", Rev Med Suisse Romande, 118(2): 149-153, 1998. (Abstract-art in French)	✓
80	Wang et al.	"Basic Fibroblast Growth Factor Enhances Bone-Graft Incorporation: Dose and Time Dependence in Rats", J. Orthop. Res., 14(2): 316-323, 1996. Abstract.	✓
81	Duffy et al.	"Maximizing Flap Survival in a Prefabrication Model Using Exogenous and Endogenous bFGF: A New Approach", Microsurgery, 17(4): 176-179, 1995. Abstract.	✓
82	Garner	"Epidermal Regulation of Dermal Fibroblast Activity", Plast. Reconstr. Surg., 102(1):135-139, 1998. Abstract.	✓
83	Raghuath et al.	"Cultured Epithelial Autografts: Diving from Surgery into Matrix Biology", Pediatr. Surg. Int., 12(7): 478-483, 1997. Abstract.	✓
84	Myers et al.	"Transplantation of Keratinocytes in the Treatment of Wounds", American J. Surg., 170(1):73-83, 1995. Abstract.	✓
85	Kawaja et al.	"Employment of Fibroblasts for Gene Transfer: Applications for Grafting into the Central Nervous System", Genet Eng (NY), 13: 205-220, 1991. Abstract.	✓
86	Maillard et al.	"Pre-Treatment with Elastase Improves the Efficiency of Percutaneous Adenovirus-Mediated Gene Transfer to the Arterial Media", Gene Therapy, 5: 1023-1030, 1998.	✓
87	Wang	"Basic Fibroblast Growth Factor for Stimulation of Bone Formation in Osteoinductive or Conductive Implants", Acta Orthop Scand Suppl, 269: 1-33, 1996 (abstract)	✓
88	Wang	"Basic Fibroblast Growth Factor Infused at Different Times During Bone Graft Incorporation. Titanium Chamber Study in Rats", Acta Orthop Scand, 67(3): 229-236, 1996. Abstract.	✓
89	Inui et al.	"Local Application of Basic Fibroblast Growth Factor Minipellet Induces the Healing of Segmental Bony Defects in Rabbits".	✓
90	Tabata et al.	"Bone Regeneration by Basic Fibroblast Growth Factor Complexed with Biodegradable Hydrogels", Biomaterials, 19(7-9): 807-815, 1998. Abstract.	✓
91	Aspenberg et al.	"Stimulates Bone Formation. Bone Induction Studied in Rats", Acta Orthop. Scand., 60(4): 473-476, 1989. Abstract.	✓
92	Aspenberg et al.	"Dose-Dependent Stimulation of Bone Induction by Basic Fibroblast Growth Factor in Rats", Acta Orthop. Scand., 62(5): 481-484, 1991. Abstract.	✓
93	Matoba et al.	"Evaluation of Omental Implantation for Perforated Gastric Ulcer Therapy: Findings in a Rat Model", J. Gastroenterol, 31(6): 777-784, 1996. Abstract.	✓
94	Chleboun et al.	"The Development and Enhancement of the Collateral Circulation in an Animal Model of Lower Limb Ischaemia", Aust. NZ Surg., 64(3): 202-207, 1994. Abstract.	✓
95	Aplin	"Adhesion Molecules in Implantation", Rev Reprod, 2(2): 84-93, 1997.	✓
96	Lessey et al.	"Paracrine Signaling in the Endometrium: Integrins and the Establishment of Uterine Receptivity", J. Reprod. Immunol., 39(1-2): 105-116, 1998. Abstract.	✓
97	Burrows et al.	"Trophoblast Migration During Human Placental Implantation", Hum. Reprod. Update, 2(4): 307-321, 1996.	✓
98	Bischof et al.	"The Regulation of Endometrial and Trophoblastic Metalloproteinases During Blastocyst Implantation", Contracept Fertil Sex, (art in French) 22(1): 48-51, 1994. Abstract.	✓

99	Smith et al. "Expression of Heparan Sulfate Protoglycan (perlecan) in the Mouse Blastocyst is Regulated during Normal and Delayed Implantation", <i>Dev. Biol.</i> , 184(1): 38-47, 1997. Abstract.	✓
100	Abrahamsohn et al. "Implantation and Decidualization in Rodents", <i>J. Exp. Zool.</i> , 266(6): 603-628, 1993 Abstract.	✓
101	Goshen et al. "Purification and Characterization of Placental Heparanase and Its Expression by Cultured Cytotrophoblasts", <i>Molecular Human Reproduction</i> , 2(9): 679-684, 1996.	✓
102	Yoshida "Effects of Basic Fibroblast Growth Factor on the Development of Mouse Preimplantation Embryos", <i>Nippon Sanka Fujinka Gakkai Zasshi</i> , 48(3): 170-176, 1996. Abstract.	✓
103	Watson et al. "A Growth Factor Phenotype Map for Ovine Preimplantation Development", <i>Biol. Reprod.</i> , 50(4): 725-733, 1994. Abstract.	✓
104	Carlone et al. "Embryonic Modulation of Basic Fibroblast Growth Factor in the Rat Uterus", <i>Biol. Reprod.</i> 49(4): 653-665, 1993. Abstract.	✓
105	Wordinger et al. "The Immunolocalization of Basic Fibroblast Growth Factor in the Mouse Uterus During the Initial Stages of Embryo Implantation" <i>Growth Factors</i> , 11(3): 175-186, 1994. Abstract.	✓
106	Schultz et al. "Growth Factors in Preimplantation Mammalian Embryos", <i>Oxf. Rev. Reprod. Biol.</i> , 15:43-81, 1993. Abstract.	✓
107	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", <i>Biochem. J.</i> , 330: 1341-1350, 1998. Claims: P,X: 1-47, 51-58 / Y,P: 48-50.	✓
108	Esko et al. "Tumor Formation Dependent on Procoglycans Biosynthesis", <i>Science</i> , 241(4869): 1092-1096, 1988. Abstract.	✓
109	Richardson et al. "Regulation of Basic Fibroblast Growth Factor Binding and Activity by Cell Density and Heparan Sulfate", <i>J. Biological Chemistry</i> , 274(19): 13534-13540, 1990.	✓
110	Hayward et al. "Cellular Mechanisms of Heparinase III Protection in Rat Traumatic Shock", <i>American Journal of Physiology</i> 275:H23-H30, 1998.	✓
111	Sasisekharan et al. "Heparinase Inhibits Neovascularization", <i>Proc. Natl. Acad. Sci.</i> , 91:1524-1528, 1994.	✓
112	Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases", <i>Journal of Biological Chemistry</i> , 271(17):10079-10086, 1996.	✓
113	Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells Releases Active Fibroblast Growth Factor From Extracellular Matrix", <i>Cell Regulation</i> , 1: 833-842, 1990.	✓
114	Godder et al. "Heparanase Activity in Cultured Endothelial Cells", <i>Journal of Cellular Physiology</i> , 148: 274-280, 1991.	✓
115	Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain from an Inhibitor to a Potent Activator of FGF-2", <i>Nature Medicine</i> , 4(6):691-697, 1998.	✓
116	Jin et al. "Immunohistochemical Localization of Heparanase in Mouse and Human Melanomas", <i>Int. J. Cancer</i> . 45: 1088-1095, 1990.	✓
117	Hoogwerf et al. "CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 Are Heparin/Heparan Sulfate-Degrading Enzymes", <i>J. Biol. Chem.</i> , 270(7):3268-3277, 1995.	✓
118	Oldberg et al. "Characterization of a Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides", <i>Biochemistry</i> 19: 5755-5762, 1980.	✓
119	Okamoto et al. "Highly Specific and Sensitive Detection of Malignancy in Urine Samples from Patients with Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", <i>Int. J. Cancer</i> , 79(6): 560-564, 1998. Abstract.	✓
120	Kang et al. "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine β -Casein Gene", <i>Mol Cells</i> , 8(3):259-265, 1998. Abstract.	✓
121	Gottschalk et al. "Somatic Gene Therapy. Present Situation and Future Perspective", <i>Arzneimittelforschung</i> , 48(11):1111-1120, 1998. Abstract.	✓
122	Guriec et al. "CD44 Isoforms with Exon v6 and Metastasis of Primary N0M0 Breast Carcinomas", <i>Breast Cancer Res. Treat.</i> , 44(3):261-268, 1997. Abstract.	✓
123	Hida et al. "Antisense E1AF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities", <i>Am. J. Pathol.</i> , 50(6): 2125-2132,	✓

		1997. Abstract.	
125	Faber-Elman et al. "Involvement of Wound-Associated Factors in Rat Brain Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", <i>J. Clin. Invest.</i> , 97(1):162-171, 1996.	✓	
126	Zheng et al. "Increment of hFIX Expression with Endogenous Intron 1 in vitro", <i>Cell Res.</i> , 7(1):21-29, 1997 (abstract)	✓	
127	Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target RNA Levels", <i>Curr Opin. Biotechnol.</i> , 9(5):486-496, 1998. Abstract.	✓	
128	Gewirtz et al. "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on its Promise", <i>Proc. Natl. Acad. Sci. USA</i> , vol. 93: 3161-3163, April 1996.	✓	
129	Green et al. "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease", <i>Journal of American Cell Surgery</i> , 191(1): 93-105, 2000.	✓	
130	Agrawal "Antisense Oligonucleotides: Towards Clinical Trials", <i>Reviews</i> : 376-387.	✓	
131	Rajar et al. "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules". <i>Bioconjugate Chem.</i> , 8, 935-940, 1997.	✓	
132	Luft "Making sense out of Antisense Oligodeoxynucleotide Delivery: Getting there is Half the Fun". <i>J. Mol. Med.</i> , 75-76. 1998.	✓	
133	Kronenwetter et al. "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset". <i>Blood</i> , 91(3): 852-862, 1998.	✓	
134	Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense Oligodeoxynucleotides". <i>Molecular and Cellular Biochemistry</i> , 172: 213-225, 1997.	✓	
135	Motokuni et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides into the Myocardium Using HVJ-Liposome Method", <i>Biochemical and Biophysical Research Communications</i> 231: 540-545, 1997.	✓	
136	Jayaraman et al. "Rational Selection and Quantitative Evaluation of Antisense Oligonucleotides", <i>Biochimica et Biophysica Acta</i> 1520: 105-114, 2001.	✓	
137	Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to a Structured RNA Target". <i>Biotechnology and Bioengineering</i> , 65(1): 1-9, 1999.	✓	
138	Uno et al. "Antisense-Mediated Suppression of Human Heparanase Gene Expression Inhibits Pleural Dissemination of Human Cancer Cells", <i>Cancer Research</i> 61(21), 7855-7860, 2001.	✓	
139	Clancy "Handbook of Microbiology", Vol. 1: 239-242, 1974.	✓	
140	Silver et al. "Pseudomonas: Biotransformations, Pathogenesis, and Evolving Biotechnology", Chapters 2-7, 1990. American Society for Microbiology.	✓	
141	Wang et al. "Isolation and Characterization of Pseudomonas Aeruginosa Genes Inducible by Respiratory Mucus Derived from Cystic Fibrosis Patients", <i>Mol. Microbiol.</i> 22(5): 1005-1012, 1996. [Abstract]	✓	
142	Moss et al. "Reduced IL-10 Secretion by CD4+ T Lymphocytes Expressing Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)", <i>Clin Exp. Immunol.</i> 106(2): 374-399, 1996. [Abstract]	✓	
143	Davies et al. "Regulation of the Alginate Biosynthesis Gene algC in Pseudomonas Aeruginosa During Biofilm Development in Continuous Culture", <i>Appl. Environ. Microbiol.</i> 61(3): 860-867, 1995. [Abstract]	✓	
144	Azghani et al. "A Beta-linked Mannan Inhibits Adherence of Pseudomonas Aeruginosa to Human Lung Epithelial Cells", <i>Glycobiology</i> 5(1): 39-44, 1995. [Abstract]	✓	
145	Ofek et al. "Bacterial Adhesion to Cells and Tissues", Chapman and Hall, New York, 1994, pp. 114-118, 148-153, 418-423, 420-423.	✓	
146	Davies et al. "The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm", <i>Science</i> 280: 295-298, 1998.	✓	
147	Ghani et al. "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill Biofilms of Mucoid Pseudomonas Aeruginosa", <i>Can. J. Microbiol.</i> 43(11): 999-1004, 1997. [Abstract]	✓	
148	Stickler et al. "An Assessment of the Ability of a Silver-Releasing Device to Prevent Bacterial Contamination of Urethral Catheter Drainage Systems", <i>British J. Urology</i> 78: 579-588, 1996.	✓	
149	Potera "Bacteria in Biofilms Exchange Developmental Signals", <i>ASM News</i> 64(6): 321-322.	✓	
150	Gabriel et al. "In Vitro Adherence of Pseudomonas Aeruginosa to Four Intraocular Lenses", <i>J. Cataract Refract. Surg.</i> 24: 124-129, 1998.	✓	

151	Pier "Rationale for Development of Immunotherapies that Target Mucoïd Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients", Behring Inst. Mitt. 98: 350-360, 1997. [Abstract]	✓
152	Goldberg et al. "Biologic Activities of Antibodies to the Neutral-Polysaccharide Component of the Pseudomonas Aeruginosa Lipopolysaccharide are Blocked by O Side Chains and Mucoïd Exopolysaccharide (Alginate)", Infect. Immun. 63(1): 21-26. [Abstract]	✓
153	Mehuleni et al. "Mucoïd Pseudomonas Aeruginosa Growing in a Biofilm in vitro are Killed by Opsonic Antibodies to the Mucoïd Exopolysaccharide Capsule but not by Antibodies Produced During Chronic Lung Infection in Cystic Fibrosis Patients", J. Immun. 155(4): 2029-2038, 1995. [Abstract]	✓
154	Philippon et al. "Virulence Factors (Acrobactin and Mucoïd Phenotype) in Klebsiella Pneumoniae and Escherichia Coli Blood Culture Isolates", FEMS Microbiol. Lett. 130(1): 51-57, 1995. [Abstract]	✓
155	Pier et al. "How Mutant CFTR May Contribute to Pseudomonas Aeruginosa Infection in Cystic Fibrosis", Am. J. Respir. Crit. Care Med. 154(4): S175-S182, 1996. [Abstract]	✓
156	Pier et al. "Cystic Fibrosis Transmembrane Conductance Regulator Is An Epithelial Cell Receptor for Clearance of Pseudomonas Aeruginosa From the Lung", Proc. Natl. Acad. Sci. USA, 94(22): 12088-12093, 1997.	✓
157	Boucher et al. "Mucoïd Pseudomonas Aeruginosa in Cystic Fibrosis: Characterization of Muc Mutations in Clinical Isolates and Analysis of Clearance in a Mouse Model of Respiratory Infection", Infect. Immun. 65(9): 3838-3846, Sep. 1997. [Abstract]	✓
158	Boucher et al. "Two Distinct Loci Affecting Conversion to Mucoïd Pseudomonas Aeruginosa in Cystic Fibrosis Encode Homologs of the Serine Protease HtrA", J. Bacteriol. 178(2): 511-523, 1996. [Abstract]	✓
159	Yu et al. "Microbial Pathogens in Cystic Fibrosis: Pulmonary Clearance of Mucoïd Pseudomonas Aeruginosa and Inflammation in a Mouse Model of Repeated Respiratory Challenge", Infection and Immunity 66(1): 280-288, 1998.	✓
160	Van Heeckeren et al. "Excessive Inflammatory Response of Cystic Fibrosis Mice to Bronchopulmonary Infection with Pseudomonas Aeruginosa", J. Clin. Invest. 100(11): 2810-2815, 1997.	✓
161	Mrsny et al. "Addition of a Bacterial Alginate Lyase to Purulent CF Sputum in vitro can Result in the Disruption of Alginate and Modification of Sputum Viscosity", Pul. Pharmacol. 7(6): 357-366, 1994. [Abstract]	✓
162	Wills et al. "Short-Term Recombinant Human DNase in Bronchiectasis. Effect on Clinical State and in vitro Sputum Transportability". [Abstract]	✓
163	Cai et al. "Comparison of Sputum Processing Techniques in Cystic Fibrosis", Pediatr. Pulmonol. 22(6): 402-407, 1996. [Abstract]	✓
164	Randall et al. "Distribution of DNA and Alginate in Purulent Cystic Fibrosis Sputum: Implications to Pulmonary Targeting Strategies", J. Drug. Therapy 4(4): 233-243, 1996.	✓
165	Hatch et al. "Alginate Lyase Promotes Diffusion of Aminoglycosides Through the Extracellular Polysaccharide of Mucoïd Pseudomonas Aeruginosa", Antimicrob. Agents. Chemother. 42(4): 974-977, 1998. [Abstract]	✓
166	Speert et al. "Modulation of Macrophage Function for Defense of the Lung against Pseudomonas Aeruginosa", Behring Inst. Mitt. 98: 274-282, 1997. [Abstract]	✓
167	Ying et al. "Alginate, the slime Exopolysaccharide of Pseudomonas Aeruginosa, Binds Human Leukocyte Elastase, Retards Inhibition by Alpha 1-proteinase Inhibitor, and Accelerates Inhibition by Secretory Leukoprotease Inhibitor", Am. J. Cell. Moll. Biol. 15(2): 283-291, 1996. [Abstract]	✓
168	Johansen et al. "Chronic Pseudomonas Aeruginosa Pneumonia: A new Prophylactic Principle", Behring Inst. Mitt. 90: 269-273, 1997. [Abstract]	✓
169	Pina et al. "The Role of Fluoroquinolones in the Promotion of Alginate Synthesis and Antibiotic Resistance in Pseudomonas Aeruginosa", Curr. Microbiol. 35(2): 103-108, 1997. [Abstract]	✓
170	Spencer "Invasive Streptococci", Eur. J. Clin. Microbiol. Infect. Dis., 14 Suppl. 1: S26-S32, 1995. [Abstract]	✓
171	Mengistu et al. "Continuous Culture Studies on the Synthesis of Capsular Polysaccharide by Klebsiella Pneumoniae K1", J. Appl. Bacteriol. 76(5): 424-430, 1994. [Abstract]	✓

172	Hsueh et al. "Invasive Streptococci Pneumonias Infection Associated with Rapidly Fatal Outcome in Taiwan", J. Formos Med. Assoc. 95(5): 364-371, 1996. [Abstract]	✓
173	Moses et al. "Relative Contributions of Hyaluronic Capsule and M Protein to Virulence in a Mucoid Strain of the Group A Streptococcus", Infect. Immun. 65(1): 64-71, 1997. [Abstract]	✓
174	Scott et al. "Visualization of an Extracellular Mucoid Layer of Treponema Denticola ATCC 35405 and Surface Sugar Lectin Analysis of Some Treponema Species", Oral Microbiol. Immunol. 12(2): 121-125, 1997. [Abstract]	✓
175	Nilsson et al. "The Role of Staphylococcal Polysaccharide Microcapsule Expression in Septicemia and Septic Arthritis", Infect. Immun. 65(10): 4216-21, 1997. [Abstract]	✓
176	Wessels et al. "Effects on Virulence of Mutations in a Locus Essential for Hyaluronic Acid Capsule Expression in Group A Streptococci", Infect. Immun. 62(2): 438-441, 1994. [Abstract]	✓
177	Faradale et al. "A Direct Spectrophotometric Microassay for Sulfated Glycosaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 1982.	✓
178	Pasquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Aeruginosa", FEMS Microbiol. Lett. 147(2): 195-202, Feb. 1997. Abstract.	✓
179	Marty et al. "Influence of Nutrient Media on the Chemical Composition of the Exopolysaccharide from Mucoid and non-Mucoid Pseudomonas Aeruginosa", FEMS Microbiol. Letters, 17(1-3): 35-44, Nov. 1992. Abstract.	✓
180	Jorba et al. ["Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars"] (author's translation), Rev. Esp. Fisiol. 36(2): 155-161, 1980. Abstract.	✓
181	Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", Appl. Environ. Microbiol. 67(1): 33-41, 2001. [Abstract]	✓
182	Bhaskar et al. "Dysregulation of Proteoglycan Production by Intrahepatic Biliary Epithelial Cells Bearing Defective (delta-508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatology, 27(1): 7-14, Jan. 1998. [Abstract]	✓
183	Vogel et al. "Production of Proteoglycans by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Serum", Biochem J. 207(3): 369-379. Abstract.	✓
184	Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in A Mouse Model of Cystic Fibrosis", Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.	✓
185	Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts", Pediatr. Research, 9(9): 698-702, 1975.	✓
186	Rahmoune et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991. Abstract.	✓
187	Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Tissue", Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.	✓
188	Allison et al. "Polysaccharide Production in Pseudomonas Cepacia", J. Basic. Microbiol. 34(1): 3-10, 1994. Abstract.	✓
189	Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1988. Abstract.	✓
190	Maccone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.	✓
191	Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 24: 404S, 1996.	✓
192	Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa", Biochemical Society Transactions 22: 310S, 1994.	✓
193	Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants", Biochemical Society Transactions 24: 406S, 1996.	✓
194	Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants", Journal of Bacteriology 162(2): 504-509, 1985. Abstract.	✓
195	Sutherland "Structure-Function Relationships in Microbial Exopolysaccharides",	✓

		Biotech. Adv. 12: 393-448, 1994.	
196	Anatolii "Hyaluronic Capsule as one of the Factors of Hemolytic Streptococcus Pathogenicity", Chem. Abstracts 86(17): 339, Abstr. 118714 citing Zh. Mikrobiol. Epidemiol. Immunobiol. 2: 22-27, 1977.		
197	Campbell "Monoclonal Antibody Technology", Laboratory Techniques in Biochem. & Molecular Biol., 13: 1-32, 1984.		
198	Campbell "Monoclonal Antibody Technology". Elsevier Science Publishers B.V., Inc., N.Y.: 1-33, 1984.		
199	Gospodarowicz et al. "Permissive Effect of the ExtraCellular Matrix on Cell Proliferation In Vitro", Proc. Natl. Acad. Sci. USA., 77(7): 4094-4098, 1980.		
200	Li et al. "Immunohistochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer 45: 1088-1095, 1990.		
201	Graham et al. "Comparison of the Heparanase Enzymes From Mouse Melanoma Cells, Mouse Macrophages, and Human Platelets", Biochem. and Mol. Biol. Int., 39(3): 563-571, 1996.		
202	Kosir et al. Abstract 3378, Cancer Res., 37: 495, 1996.		
203	Yelton et al. "Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine", Annu. Rev. Biochem., 50: 657-680, 1981.		
204	Friedman et al. "Regulated Expression of Homeobox Genes MSX-1 and MSX-2 in Mouse Mammary Gland Development Suggests A Role in Hormone Action and Epithelial-Stromal Interactions", Devel. Biol., 177: 347-355, 1996.		
205	Soule et al. "Isolation and Characterization of A Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10", Cancer Res., 50: 6075-6086, 1990.		
206	Miller et al. "Xenograft Model of Progressive Human Proliferative Breast Disease", J. Nat. Cancer Inst., 85: 1725-1732, 1993.		
207	Nakajima et al. "Heparan Sulfate Degradation: Relation to Tumor Invasion and Metastatic Properties of Mouse B16 Melanoma Sublines", Science, 220: 611-613, 1983.		
208	Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase", Molecular Biology/Biochemistry. Proceedings of the American Association for Cancer Research, 37: 495, 1996.		
209	Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine - B- Lymphocytes", International Journal of Cancer 47(1): 92-98, Jan. 1991.		
210	Cordon-Cardo et al. "Expression of Basic Fibroblast Growth Factor in Normal Human Tissue", Laboratory Investigation, 63(6): 832-840, 1990.		
211	Hillier et al. "The WashU-Merck EST Project", No. N30824, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10.		
212	Hillier et al. "The WashU-Merck EST Project", No. N30845, Database GenBank on STN, US National Library of Medicine (Bethesda MD), 1996. Claims: 9, 10.		
213	??? "Current Protocols in Immunology". Greene Publishing Associates and Wiley-Interscience, New York: 2.1.1-2.1.2, 1991.		
214	Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis", Pediatric Pulmonology, 24: 137-142, 1997.		
215	Dasgupta et al. "Reduction in Viscoelasticity in Cystic Fibrosis Sputum In Vitro Using Combined Treatment With Nacystelyn and rhDNase", Pediatric Pulmonology, 22: 161-166, 1996.		
216	Crystal "Gene Therapy Strategies for Pulmonary Disease", Am. J. Medicine, 92 (Suppl.64): 6A-44S - 6A-52S, 1992.		
217	Lieberman "The Appropriate Use of Mucolytic Agents", Am. J. Medicine, 49(1): 1-4, 1970.		
218	Boat et al. "Biochemistry of Airway Mucus Secretions", Fed. Proc., 39(13): 3067-3074, 1980. Abstract.		
219	Mohapatra et al. "Alteration of Sulfation of Glycoconjugates, But Not Sulfate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", Pediatr. Res., 38(1): 42-48, 1995. Abstract.		
220	Cheng et al. "Increased Sulfation of Glycoconjugates NY Cultured Nasal Epithelial Cells From Patients With Cystic Fibrosis", J. Clin. Invest., 84(1): 68-72, 1989. Abstract.		
221	Boat et al. "Epithelial Cell Dysfunction in Cystic Fibrosis: Implications for Airways Disease", Acta Paediatr. Scand. Suppl., 363: 25-29, 1989.		
222	Schwartz et al. "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower Respiratory Tract", J. Clin. Invest., 100(1): 68-73, 1997. Abstract.		

223	Chase et al. "Respiratory Mucous Secretions in Patients With Cystic Fibrosis: Relationship Between Levels of Highly Sulfated Mucin Component and Severity of the Disease", <i>Clinica Chimica Acta</i> , 132: 143-155, 1983.
224	Allen "Opportunities for the Use Aerosolized $\alpha 1$ - Antitrypsin for the Treatment of Cystic Fibrosis", <i>Chest</i> , 110: 256S-260S, 1996.
225	Schwab et al. "Increased Adherence of Staphylococcus Aureus From Cystic Fibrosis Lungs to Airway Epithelial Cells", <i>Am. Rev. Respir.</i> , 148(2): 365-369, 1993. Abstract.
226	Barghouthi et al. "Nonopsonic Phagocytosis of Pseudomonas Aeruginosa Requires Facilitated Transport of D-Glucose by Macrophages", <i>J. Immunol.</i> , 154(7): 3420-3428, 1995. Abstract.
227	Moser et al. "Chronic Pseudomonas Aeruginosa Lung Infection Is More Severe in Th2 Responding BALB/c Mice Compared to Th1 Responding C3H/HeN Mice", <i>ARMIS</i> , 105(11): 838-842, 1997. Abstract.
228	Cowley et al. "Mucociliary Clearance in Cystic Fibrosis Knockout Mice Infected With Pseudomonas Aeruginosa", <i>Eur. Respir.</i> , 10(10): 2312-2318, 1997. Abstract.
229	Zahn et al. "Early Alterations in Airway Mucociliary Clearance and Inflammation of the Lamina Propria in CF mice", <i>Am. J. Physiol.</i> 272(3 Pt 1): C853-C859, 1997. [Abstract]
230	Thompson et al. "Identification of Chondroitin Sulfate E in Human Lung Mast Cells", <i>J. Immunol.</i> , 140(8): 2708-2713, 1988. Abstract.
231	Giuffre et al. "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-Selectin and Heparan Sulfate Proteoglycans", <i>J. Cell Biol.</i> , 136(4): 945-956, 1997. Abstract.
232	Shimada et al. "Involvement of Cell Surface Heparin Sulfate in the Binding of Lipoprotein Lipase to Cultured Bovine Endothelial Cells", <i>J. Clinical Invest.</i> , 68(4): 995-1002, 1981. Abstract.
233	Hayward et al. "Heparinase III Exerts Endothelial and Cardioprotective Effects in Feline Myocardial Ischemia-Reperfusion Injury", <i>J. Pharm. Exp. Ther.</i> , 283(3): 1032-1038, 1997. Abstract.
234	Yamaguchi et al. "Neutrophil Elastase Inhibitor Reduces Neutrophil Chemoattractant Production After Ischemia-Reperfusion in Rat Liver", <i>Gastroenterology</i> , 112(2): 551-560, 1997. Abstract.
235	Matgolie et al. "Identification of A Major Heparin-Precipitable Protein in Human Serum and Its Relationship to Cystic Fibrosis", <i>Pediatr. Res.</i> , 16(3): 181-186, 1982. Abstract.
236	Leong et al. "Different Classes of Proteoglycans Contribute to the Attachment of Borrelia Burgdorferi to Cultured Endothelial and Brain Cells", <i>Infect. Immun.</i> , 66(3): 994-999, 1998. Abstract.
237	Asagoe et al. "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", <i>J. Vet. Med. Sci.</i> , 59(8): 727-728, 1997. Abstract.
238	Krusat et al. "Heparin-Dependent Attachment of Respiratory Syncytial Virus (RSV) to Host Cells", <i>Arch. Virol.</i> , 142(6): 1247-1254, 1997. Abstract.
239	Alvarez-Dominguez et al. "Host Cell Heparan Sulfate Proteoglycans Mediate Attachment and Entry of Listeria Monocytogenes, and the Listeria Surface Protein ActA Is Involved in Heparan Sulfate Receptor Recognition", <i>Infection & Immun.</i> , 65(1): 78-88, 1997. Abstract.
240	Hagiwara et al. "Inhibitory Effect of Heparin on Red Blood Cell Invasion by Theileria Sergenti Merozoites", <i>Int. J. Parasitol.</i> , 27(5): 535-539, 1997. Abstract.
241	Shakibaei et al. "Dual Interaction of the Malaria Circumsporozoite Protein With the Low Density Lipoprotein Receptor-Related Protein (LRP) and Heparan Sulfate Proteoglycans", <i>J. Exp. Med.</i> , 184(5): 1699-1711, 1996. Abstract.
242	Inaba et al. "Effect of Heparin on Infection of Cells by Porcine Reproductive and Respiratory Syndrome Virus", <i>Am. J. Vet. Res.</i> , 58(5): 488-491, 1997. Abstract.
243	Chen et al. "Dengue Virus Infectivity Depends on Envelope Protein E1 to Target Cell Heparan Sulfate", <i>Nature Medicine</i> , 3(8): 866-871, 1997. Abstract.
244	Gantt et al. "Cell Adhesion to A Motif Shared by the Malaria Circumsporozoite Protein and Thrombospondin Is Mediated by Its Glycosaminoglycan-Binding Region and Not by CSVTCG", <i>J. Biol. Chem.</i> , 272(31): 19205-19213, 1997. Abstract.
245	Robert et al. "Chondroitin-4-Sulphate (Proteoglycan), A Receptor for Plasmodium Falciparum-Infected Erythrocyte Adherence on Brain Microvascular Endothelial Cells", <i>Res. Immunol.</i> , 146(6): 383-393, 1995. Abstract.

246	Herrera et al. "Mediation of Trypanosoma Cruzi Invasion by Heparan Sulfate Receptors on Host Cells and Penetrin Counter-Receptors on the Trypanosomes", <i>Mol. & Biochem. Parasit.</i> , 65: 73-83, 1994.
247	Berkow "The Merck Manual". R. Berkow, M.D., Ed-in-Chief, Merck Research Laboratories: 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601, 1997.
248	Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part II. Use of Therapies", <i>Pediatr. Pulmonol.</i> 28(4): 248-54, Oct. 1999. [Abstract]
249	Frederiksen et al. "Antibiotic Treatment of Initial Colonization with Pseudomonas Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary Function in Cystic Fibrosis", <i>Pediatr. Pulmonol.</i> 23(5): 330-335, May 1997.
250	Frederiksen et al. "Changing Epidemiology of Pseudomonas Aeruginosa Infection in Danish Cystic Fibrosis Patients (1974-1995)", <i>Pediatr. Pulmonol.</i> 28(3): 159-166, Sep. 1999. [Abstract]
251	Ramsey et al. "Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", <i>New England Journal of Medicine</i> 340(1): 23-30, Jan. 7, 1999. [Abstract]
252	Tang et al. "Contribution of Specific Pseudomonas Aeruginosa Virulence Factors to Pathogenesis of Pneumonia in a Neonatal Mouse Model of Infection", <i>Infect. Immun.</i> 64(1): 37-43, 1996. Abstract.
253	Bennett et al. "Effect of Uridine 5'-Triphosphate plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", <i>Am. J. Respir. Crit. Care Med.</i> 153(6 Pt.1): 1796-1801, June 1996. [Abstract]
254	Armstrong et al. "Lower Airway Inflammation in Infants and Young Children with Cystic Fibrosis", <i>Am. J. Respir. Crit. Care Med.</i> 156(6 Pt.1): 1197-1204, 1997. Abstract.
255	Naparstek et al. "Activated T Lymphocytes Produce a Matrix-Degrading Heparan Sulphate Endoglycosidase", <i>Nature</i> , 310(5974): 241-244, 1984. Abstract.
256	Weller "Implications of Early Inflammation and Infection in Cystic Fibrosis: A Review of New and Potential Interventions", <i>Pediatric Pulmonology</i> 24: 143-146, 1997.
257	Rubin "Emerging Therapies for Cystic Fibrosis Lung Disease", <i>Chest</i> 115: 1120-1126, 1999.
258	Ducy et al. "The Osteoblast: A Sophisticated Fibroblast under Central Surveillance", <i>Science</i> 289: 1501-1504, 2000.
259	Reddi "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and Regeneration", <i>Nature Biotechnology</i> 16: 247-252, 1998.
260	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", <i>The FASEB Journal</i> 15: 1661-1663, 2001.
261	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", <i>The FASEB Journal</i> , Published online, May 29, 2001.
262	Finkel "Potential Target Found for Antimetastasis Drugs", <i>Science</i> 285: 33-34, July 2, 1999.
263	Webster et al. "EGFR Activation in Skeletal Disorders: Too Much of a Good Thing", <i>TIG</i> 13(5): 178-182, May 1997.
264	Shimazu et al. "Syndecan-3 and the Control of Chondrocyte Proliferation During Endochondral Ossification", <i>Exp. Cell. Res.</i> 229(1): 126-136, 1998. Abstract.
265	Blanquaert et al. "CMDBS, Functional Analogs of Sulfate Heparans Used as Osseous Cicatrizing Agents", <i>Ann. Endocrinol. (Paris)</i> 55(2): 121-123, 1994. [Abstract]
266	Blanquaert et al. "Heparan-Like Molecules Induce The Repair Of Skull Defects", <i>Bone</i> , 17(6): 499-506, 1995. Abstract.
267	Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in vivo", <i>Blood</i> 88(4): 1314-1320, August 15, 1996. [Abstract]
268	Hoffman et al. "Human Bone Morphogenic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity", <i>Eur. J. Biochem.</i> 237(1): 295-302, 1996. [Abstract]
269	Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)", <i>J. Cell. Biol.</i> 143(4): 1113-1128, 1998. [Abstract]
270	Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone Morphogenetic Protein-2 in Equine Cartilage Explant Cultures", <i>Am. J. Vet. Res.</i> 57(4): 554-559, 1996.
271	Kiberstis et al. "Bone Health in the Balance", <i>Science</i> 289: 1497, 2000.

272	Service "Tissue Engineers Build New Bone", Science 289: 1498-1500, 2000.
273	Stracke et al. "Autotaxin, Tumor Motility-Stimulating Exophosphodiesterase", Advan. Enzyme Regul. 37: 135-144, 1997. Introduction.
274	Bost et al. "Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2", Immunol. Invest. 17: 577-586, 1988.
275	Bendayan "Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody", J. Histochem. Cytochem. 43: 881-886, 1995.
276	Bar-Ner et al. "Inhibition of Heparanase-Mediated Degradation of Extracellular Matrix Heparan Sulphate by Non-Anticoagulant Heparin Species", Blood, 70(2): 551-557, 1987.
277	Savitsky et al. "Ataxia-Telangiectasia: Structural Diversity of Untranslated Sequences Suggests Complex Post-Transcriptional Regulation of ATM Gene Expression", Nucleic Acids Research, 25(9): 1678-1684, 1997.
278	Ross "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", Nature, 362: 801-809, 1993.
279	Putnak et al. "A Putative Cellular Receptor for Dengue Viruses", Nature Medicine, 3(8): 828-829, 1997.
280	Shieh et al. "Cell Surface Receptors for Herpes Simplex Virus Are Heparan Sulfate Proteoglycan Proteoglycans", J. Cell. Biol., 116(5): 1273-1281, 1992.
281	Lider et al. "A Disaccharide That Inhibits Tumor Necrosis Factor α Is Formed from the Extracellular Matrix by the Enzyme Heparanase", Proc. Natl. Acad. Sci. USA, 92: 5037-5041, 1995.
282	Spivak-Kroizman et al. "Heparin-Induced Oligomerization of FGF Molecules Is Responsible For FGF Receptor Dimerization, Activation, and Cell Proliferation", Cell, 79: 1015-1024, 1994.
283	Vlodavsky et al. "Endothelial Cell-Derived Basic Fibroblast Growth Factor: Synthesis and Deposition Into Subendothelial Extra-Cellular Matrix", Proc. Natl. Acad. Sci. USA, 84: 2292-2296, 1987.
284	Vlodavsky et al. "Involvement of the Extra-Cellular Matrix, Heparin Sulfate Proteoglycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and Metastasis", Tumor Angiogenesis, P.128-140, 1997.
285	Bashkin et al. "Basic Fibroblast Growth Factor Binds to Subendothelial ExtraCellular Matrix and Is Released by Heparanase and Heparin-Like Molecules", Biochemistry, 28: 1737-1743, 1989.
286	Nicolson "Organ Specificity of Tumor Metastasis: Role of Preferential Adhesion, Invasion and Growth of Malignant Cells at Specific Secondary Sites", Cancer Met. Rev., 7: 143-188, 1988.
287	Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1996. Claims: 9, 10.
288	Adams et al. "Initial Assessment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547): 3-174, 1995. GenBank Entry AA304653, 1997. Claims: 30.
289	Yagel et al. "Normal Nonmetastatic Human Trophoblast Cells Share in vitro Invasive Properties of Malignant Cells", J. Cellular Physiology 136: 455-462, 1988.
290	Kizaki et al. "Cloning and Localization of Heparanase in Bovine Placenta", Placenta 24: 425-430, 2003.
291	Dempsey et al. "Heparanase Expression in Invasive Trophoblasts and Acute Vascular Damage", Glycobiology 10(5): 467-475, 2000. Abstract. P. 470, Col. 1 - P. 471, Col.1; P. 472, Col. 1, § 4 - Col. 2, § 2. Claims: 1-24.
292	Haimov-Kochman et al. "Localization of Heparanase in Normal and Pathological Human Placenta", Molecular Human Reproduction 8(6): 566-573, 2002.
293	Kizaki et al. "Expression of Heparanase mRNA in Bovine Placenta During Gestation", Reproduction 121: 573-580, 2001. Claims: 1-50.
294	Edwards et al. "Some Properties and Applications of Monoclonal Antibodies", Biochem. Journal 200: 1-10, 1981.
295	Zhou et al. "HFE Gene Knockout Produces Mouse Model of Hereditary Hemochromatosis", PNAS 95(5): 2492-2497, 1998.
296	Menezo et al. "Mouse and Bovine Models for Human IVF", Reproductive BioMedicine Online 2002 4(2): 170-175, 2002. Abstract.
297	Bean et al. "Fertilization in vitro Increases Non-Disjunction During Early Cleavage Divisions in a Mouse Model System", Human Reproduction 17(9): 2362-2367, 2002.

		Abstract.	
	298	Brinster et al. "Restoration of Fertility by Germ Cell Transplantation Requires Effective Recipient Preparation", <i>Biology of Reproduction</i> 69: 412-420, 2003. Abstract.	
	299	Liu et al. "Live Offspring by In Vitro Fertilization of Oocytes from Cryopreserved Primordial Mouse Follicles after Sequential In Vivo Transplantation and In Vitro Maturation", <i>Biology of Reproduction</i> 64: 171-178, 2001. Abstract.	
	300	Kawase et al. "Effect of Partial Incision of the Zona Pellicida by Piezo-Micromanipulator for In Vitro Fertilization Using Frozen-Thawed Mouse Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell Stage", <i>Biology of Reproduction</i> 66: 3810385, 2002. Abstract.	
	301	Pfaff et al. "Cryobiology of Rat Embryos I: Determination of Zygote Membrane Permeability Coefficients for Water and Cryoprotectants, Their Activation Energies, and the Development of Improved Cryopreservation Methods", <i>Biology of Reproduction</i> 63: 1294-1302, 2000. Abstract.	
	302	Yesildaglar et al. "The Mouse as a Model to Study Adhesion Formation Following Endoscopic Surgery: A Preliminary Report", <i>Human Reproduction</i> 14(1): 55-59, 1999. Abstract.	
	303	Ejima et al. "Induction of Apoptosis in Placentas of Pregnant Mice Exposed to Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System", <i>Biology of Reproduction</i> 62: 178-185, 2000. Abstract.	
	304	Prahalada et al. "Diethylstilbestrol-Induced Cervical and Vaginal Adenosis Using the Neonatal Mouse Model", <i>Biology of Reproduction</i> 38: 935-943, 1988. Abstract.	
	305	Newbold et al. "Exposure to Diethylstilbestrol During Pregnancy Permanently Alters the Ovary and Oviduct", <i>Biology of Reproduction</i> 28: 735-744, 1983. Abstract.	
	306	??? "Mouse Models for Reproductive Biology Research" - www.jax.org/jaxmice : 1-2, Summer 2002.	
	307	Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA", <i>Proceedings American Association for Cancer Research Annual Meeting 1992</i> , 33: 57, 1992. Abstract 343. Claims: X: 1-10, 15-18. / Y: 11-14.	
	308	Thuong et al. "Sequence-Specific Recognition and Modification of Double-Helical DNA by Oligonucleotides", <i>Angew. Chem. Int. Ed. Engl.</i> 32: 666-690, 1993.	
	309	Cohen "Oligonucleotide Therapeutics", <i>Trends in Biotechnology</i> 10: 87-91, 1992. Abstract.	
	310	Szczylik et al. "Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides", <i>Science</i> 253: 562-565, 1991. Abstract.	
	311	Calabretta et al. "Normal and Leukemic Hematopoietic Cell Manifest Differential Sensitivity to Inhibitory Effects of C-myc Antisense Oligodeoxynucleotides: An in vitro Study Relevant to Bone Marrow Purging", <i>Proc. Natl. Acad. Sci. USA</i> 88: 2351-2355, 1991.	
	312	Burch et al. "Oligodeoxynucleotides Antisense to the Interleukin 1 Receptor mRNA Block the Effects of Interleukin 1 in Cultured Murine and Human Fibroblasts and in Mice", <i>J. Clin. Invest.</i> 88: 1190, 1991. Abstract.	
	313	Agrawal "Antisense Oligonucleotides As Antiviral Agents", <i>Trends Biotechnol.</i> , 10(5): 152-158, 1992. Abstract.	
	314	Ngo et al. "The Protein Folding Problem and Tertiary Structure", K. Merz, Jr. and S. Le Grand, Ed Birkhauser Boston: 491-495, 1994.	
	315	Ferber et al. "Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia", <i>Nature Medicine</i> , 6(5): 568-572, 2000.	
	316	Benjamin et al. "A Plasticity Window for Blood Vessel Remodelling is Defined by Pericyte Coverage of the Preformed Endothelial Network and is Regulated by PDGF-B and VEGF", <i>Development</i> 125: 1591-1598, 1998.	
	317	Vukicevic et al. "Induction of Nephrogenic Mesenchyme by Osteogenic Protein 1 (Bone Morphogenetic Protein 7)", <i>Proc. Natl. Acad. Sci.</i> , 93: 9021-9026, 1996.	
	318	Massague "The TGF-BETA Family of Growth and Differentiation Factors", <i>Cell</i> , 49: 437-438, 1987.	
	319	Pilbeam et al. "Comparison of the Effects of Various Lengths of Synthetic Human Parathyroid Hormone-Related Peptide (hPTHrP) of Malignancy on Bone Resorption and Formation in Organ Culture", <i>Bone</i> , 14: 717-720, 1993.	
	320	Skolnick et al. "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era", <i>Trends in Biotech.</i> , 18: 34-39,	

		2000.	
321	Bork	"Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", <i>Genome Res.</i> , 10 : 398-400, 2000.	
322	Doerks et al.	"Protein Annotation: Detective Work for Function Prediction", <i>Trends in Genetics</i> , 14(6): 248-250, 1998.	
323	Smith et al.	"The Challenges of Genome Sequence Annotation or 'The Devil is in the Details'", <i>Nature Biotechnol.</i> , 15: 1222-1223, 1997.	
324	Brenner	"Errors in Genome Annotation", <i>Trends in Genetics</i> , 15(4): 132-133, 1999.	
325	Bork	"Go Hunting in Sequence Databases but Watch out for the Traps", <i>Trends in Genetics</i> , 12(10): 425-427, 1996.	
326	Bowie et al.	"Deciphering the Message in Protein Sequences: Tolerance to Amide Acid Substitutions", <i>Science</i> , 247: 1306-1310, 1990.	
327	?? A Genesq	Accession No. AA17083, 1999.	
328	Beadig et al.	"Humanization of Rodent Monoclonal Antibodies by CDR Grafting", <i>Methods</i> , 8: 83-93, 1995.	
329	Miao et al.	"Cloning, Expression and Purification of Mouse Heparanase", <i>Protein Expression and Purification</i> , 26: 425-431, 2002.	
330	Coligan et al.	"Current Protocols in Immunology", Green Publishing Assoc. 1991.	
331	Sasisekharan et al.	"Cloning and Expression of Heparinase I Gene from <i>Flavobacterium heparinum</i> ", <i>Proc. Natl. Acad. Sci.</i> , 90: 3668-3664, 1993.	
332	Gordon-Cardo et al.	"Expression of Basic Fibroblast Growth Factor in Normal Human Tissues", <i>Laboratory Investigation</i> , 63: 832-840, 1990.	
333	Harper	"Harper's Biochemistry", 24th Ed., P. 660-685.	
334	Boat et al.	"Increased Sulfation of Glycoconjugates in Cultured Nasal Epithelia Cells From Patients With Cystic Fibrosis", <i>Journal of Clinical Investmet</i> , 84(1): 68-72, 1989. Abstract.	
335	Nossuli et al.	"Heparinas III Exerts Endothelial And Cardioprotective Effects In Feline Myocardial Ischemia-Reperfusion Injury", <i>Journal of Pharmaceutical Experimental Therapy</i> , 283(3): 1082-1038, 1997. Abstract.	
336	Nakajima et al.	"Immunohistochemical Localization of Heparanase in Mouse and Human Melanomas", <i>International Journal of Cancer</i> , 45: 1088-1095, 1990.	
337	Wands	Federal Circular, 1988.	
338	Fisher	CCPA, 1970.	
339	Carson et al.	"Mucin And Proteoglycan Functions In Embryo Implantation", <i>BioEssays</i> , 20(7): 577-583, Abstract. P. 580, Col. 2, § 2; P. 582, Col. 1, Fig. 1. Claims: 1-24.	
340	Clontech Laboratories	"RT-PCR Methods and Applications Book 1", Clontech Laboratories, 1st Ed., P.1-15, 26, 40, 1991.	
341	Novagen	"PET System Manual", Novagen, 6th Ed., P.1, 1995.	
342	Ennis et al.	<i>PNAS USA</i> , 87: 2833-2837, 1990.	
343	Gilat et al.	"Molecular Behaviour Adapts to Context: Heparanase Functions As An Extracellular Matrix-Degrading Enzyme Or As A T-Cell Adhesion Molecule, Depending on the Local pH", <i>J. Exp. Med.</i> , 181: 1929-1934, 1995.	
344	Murphy et al.	"The Latent Collagenase and Gelatin of Human Polymorphonuclear Neutrophil Leucocytes", <i>Biochem. J.</i> , 192: 517-525, 1980.	
345	Morel et al.	"Human Neutrophil Gelatinase Is A Collagenase Type IV", <i>Biochem. & Biophys. Res. Comm.</i> , 191: 269-274, 1993.	
346	Kane	"High-Level Expression of Foreign Genes in Mammalian Cells", <i>Genetic Eng.</i> , 13: 167-182, 1991.	
347	Makrides	"Strategies for Achieving High-Level Expression of Genes in <i>Escherichia Coli</i> ", <i>Microbiolog. Rev.</i> , 60: 512-538, 1996.	
348	Hrlow et al.	"Antibodies, A Laboratory Manual", CSH Laboratory Press, 1988.	
349	Williams et al.	"Cytoplasmic Inclusion Bodies in <i>Escherichia Coli</i> Producing Biosynthetic Human Insulin Proteins", <i>Science</i> , 215: 687-689, 1982.	
350	Chubet et al.	"Vectors for Expression and Secretion of FLAG Epitope-Tagged Proteins in Mammalian Cells", <i>BioTechniques</i> , 20: 136-141, 1996.	
351	Sambrook et al.	"Molecular Cloning", CSH Laboratory Press, 1989.	
352	Romanos	"Advances in the Use of <i>Pichia Pasteris</i> for High-Level Gene Expression", <i>Curr. Opin. Biotech.</i> , 6: 527-533, 1995.	
353	Freshney	"Animal Cell Culture", P.48-49.	
355	Wight et al.	"Cell Biology of Arterial Proteoglycans", <i>Arteriosclerosis</i> , 9(1): 1-20,	

		1989.	
	356	Kjellen et al. "Proteoglycans: Structures and Interactions", Annu. Rev. Biochem., 60: 443-475, 1991.	
	357	Ruoslahti et al. "Proteoglycans As Modulators of Growth Factor Activities", Cell, 64: 867-869, 1991.	
	358	Vlodavsky et al. "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", Basic Membranes: Cellular and Molecular Aspects, P. 327-343, 1993.	
	359	Vlodavsky et al. "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extra Vasion", Invasion & Metastasis, 12(2): 112-127, 1992. Abstract; Claims: 1-24.	
	360	Vlodavsky et al. "Inhibition of Tumor Metastasis Inhibiting Species of Heparin" Invasion & Metastasis, 14(1-6): 290-302, 1994/95.	
	361	Liotta et al. "Tumor Invasion and the ExtraCellular Matrix", Laboratory Investigation, 49(6): 636-647, 1983.	
	362	Vlodavsky et al. "Lymphoma Cell-Mediated Degradation of Sulfated Proteoglycans in the Subendothelial ExtraCellular Matrix: Relationship to Tumor Cell Metastasis", Cancer Research, 43: 2704-2711, 1983.	
	363	Vlodavsky et al. "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", Israel J. Med. Sci., 24(9-10): 464-470, 1988.	
	364	Parish et al. "Evidence That Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanases", Int. J. Cancer, 40: 511-517, 1987.	
	365	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", Cell, 19: 607-616, 1980.	
	366	Vlodavsky et al. "Extracellular Sequestration and Release of Fibroblast Growth Factor: A Regulatory Mechanism?", Trends Biochem. Sci., 16: 268-271, 1991.	
	367	Lider et al. "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals With Low Doses of Heparin", J. Clin. Invest., 83: 752-756, 1989.	
	368	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparin", FEBS Letters, 117(1): 203-206, 1980.	
	369	Sudhalter et al. "Importance of Size, Sulfation and Anticoagulant Activity in the Potentiation of Acidic Fibroblast Growth Factor by Heparin", J. Biol. Chem., 254(12): 6892-6897, 1989.	
	371	Inoue et al. "Selective N-Desulfation of Heparin with Dimethyl Sulfoxide containing Water or Methanol", Carbohydrate Research, 40: 67-95, 1976.	
	372	Nagasawa et al. "Solvolytic Desulfation of Glycosaminoglycuronan Sulfates with Dimethyl Sulfoxide Containing Water or Methanol", Carbohydrate Research, 58: 47-55, 1977.	
	373	Matia Bar-New et al. "Inhibition of Heparanase-Mediated Degradation of Extracellular Matrix Heparin Sulfate by Non-Anticoagulant Heparin Species", Blood, 70(2): 551-557, 1987.	
	374	Gospodarowicz et al. "Stimulation of Corneal Endothelial Cell Proliferation In Vitro by Fibroblast and Epidermal Growth Factors", Exp. Eye Res., 25: 75-89, 1977.	
	375	Haimovitz-Friedman et al. "Activation of Platelet Heparitinase by Tumor Cell-Derived Factors", Blood, 78: 789-796, 1991.	
	376	Vlodavsky et al. "Extracellular Matrix-Resident Growth Factors and Enzymes: Possible Involvement in Tumor Metastasis and Angiogenesis", Cancer and Metastasis Rev., 9: 203-226, 1990.	
	377	Regan et al. "Mimicry of Biological Macromolecules by Polyaromatic Anionic Compounds", J. Bioactive and Compatible Polymers, 8:317-337, 1993.	
	378	Benezra et al. "Antiproliferative Activity to Vascular Smooth Muscle Cells and Receptor Binding of Heparain-Mimicking Polyaromatic Anionic Compounds", Arteriosclerosis and Thrombosis, 14(12): 1992-1999, 1993.	
	379	Katz et al. "Antiproliferative Activity to Glomerular Mesangial Cells and Receptor Binding of a Heparain-Mimicking Polyaromatic Anionic Compound", J. Am. Soc. Nephrology, 1688-1697, 1997.	
	380	Miao et al. "Modulation of Fibroblast Growth Factor-2 Receptor Binding Dimerization, Signaling, and Angiogenic Activity by a Synthetic Heparain-Mimicking Polyaromatic Compound", J. Clin. Invest., 99(7): 1565-1575, 1997.	
	381	Benezra et al. "Reversal of Fibroblast Growth Factor-mediated Autocrine Cell Transformation by Aromatic Anionic Compounds", Cancer Research, 52:5656-5662,	

		1992.	
382	Irimura et al. "Chemically Modified Heparins as Inhibitors of Heparan Sulfate Specific Endo- β -glucuronidase (Heparanase) of Metastatic melanoma Cells", <i>Biochemistry</i> , 25:5322-5328, 1986.		
383	Coombe et al. "Analysis of the Inhibition of Tumor Metastasis by Sulphated Polysaccharides", <i>Int. J. Cancer</i> , 39: 82-88, 1987		
384	Ornitz et al. "Heparin is Required for Cell-Free Binding of Basic Fibroblast Growth Factor to a Soluble Receptor and for Mitogenesis in Whole Cells", <i>Molecular and Cellular Biology</i> , 12:240-247, 1992.		
385	Yayon et al. "Cell Surface, Heparin-Like Molecules Are Required For Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor", <i>Cell</i> , 64: 841-848, 1991.		
386	Aviezer et al. "Differential Structural Requirements of Heparin and Heparan Sulfate Proteoglycans that Promote Binding of Basic Fibroblast Growth Factor to its Receptor", <i>J. Bio. Chem.</i> , 269(1):114-121, 1994.		
387	Bartlett et al. "Comparative Analysis of the Ability of Leucocytes, Endothelial Cells, and Platelets to Degrade the Subendothelial Basement Membrane: Evidence for Cytokine Dependence and Detection of a Novel Sulfatase", <i>Immunology and Cell Biol.</i> , 73: 113-124, 1995.		
388	Nakajima et al. "A Solid-Phase Substrate of Heparanase: Its Application to Assay of Human Melanoma for Heparan Sulfate Degradative Activity", <i>Analytical Biochemistry</i> , 157: 162-171, 1986.		
389	Oosta et al. "Purification and Properties of Human Platelets Heparitinase", <i>J. Biol. Chem.</i> , 257(19): 11249-11255, 1982.		
390	Sewell et al. "Human Mononuclear Cells Contain an Endoglycosidase Specific for Heparan Sulfate Glycosaminoglycan Demonstrable with the Use of a Specific Solid-Phase Metabolically Radiolabelled Substrate", <i>Biochem J.</i> , 264: 777-783, 1989		
391	Freeman et al. "A Rapid Quantitative Assay for the Detection of Mammalian Heparanase Activity", <i>Biochem J.</i> , 325: 229-237, 1997.		
392	Mullings et al. "New Reducing Sugar Assay for the Study of Cellulases", <i>Enzyme Microb. Technol.</i> , 6:491-496, 1984.		
393	Taylor et al. "A Colorimetric Method for the Quantitation of Uronic Acids and a Specific Assay for Galacturonic Acid", <i>Analytical Biochemistry</i> , 201: 190-196, 1992.		
394	Linhardt "Capillary Electrophoresis of Oligosaccharides", <i>Methods in Enzymology</i> , 230:265-280, 1994.		
395	Basu et al. "Analysis of Glycosphingolipids by Fluorophore-Assisted Carbohydrate Electrophoresis Using Ceramide Glycanase from <i>Mercenaria mercenaria</i> ", <i>Analytical Biochemistry</i> , 222:270-274, 1994.		
396	Jackson "The Use of Polyacrylamide-gel Electrophoresis for the High-Resolution of Separation of Reducing Saccharides Labelled with the Fluorophore 8-aminonaphthalene-1,3,6-trisulphonic Acid", <i>Biochem J.</i> , 280: 705-713, 1990.		
397	Coquet et al. "Applications of a Post-Column Fluorogenic Reaction in Liquid Chromatography for the Determination of Glucose and Fructose in Biological Matrices", <i>Analytica Chimica Acta</i> , 252: 173-179, 1991.		
398	De Vouge et al. "Immunoselection of GRP94/Endoplasmic Reticulum From A KNRK Cell-Specific cgt11 Library Using Antibodies Directed Against A Putative Heparanase Amino-Terminal Peptide", <i>Int. J. Cancer</i> , 56:286-294, 1994. Claims: 1, 3, 5-7, 15-17.		
399	Zsolnai et al. "Directional Immobilization of Heparin onto Nonporous Surface of Polystyrene Microplates", <i>Biotechniques</i> , 23(3): 382-385, 1997.		
400	Bellott et al. "Closing the Loop in Combinatorial Chemistry", <i>European Pharmaceutical Contracotr</i> , 1997.		
401	Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by Chondrocytes in Culture", <i>Live Tissue Research</i> , 24: 265-275, 1990.		
402	Yen et al. "Potentialities of a new Class of Anticlotting and Antihemorrhagic Polymers", <i>J. Macromol. Sci., Chem.</i> , 4(3), pp. 693-714 in <i>Chem. Abst. AN</i> , 1970 418456		
403	Mes et al. "Use of Triphenyltetrazolium Chloride for the Quantative Analysis of Sugars and Sugar Derivatives Reported in Glycoproteins", <i>J. Chromatogr.</i> , 43(3), pages 480-486, 1969.		
404	Mes et al. "Relative Sensitivity of Various Reagents for the Detection and Differentiation of Sugars and Sugar Derivatives in Glycoproteins", <i>J. Chromatogr.</i> , 38(1): 120-125, 1968.		

405	Vlodavsky et al. "Morphological Appearance, Growth Behaviour and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", <i>Cell</i> , 19: 607-616, 1980.
406	Burgess et al. "The Heparin-Binding (Fibroblast) Growth Factor of Proteins", <i>Annu. Rev. Biochem.</i> , 58: 575-606, 1989.
407	Campbell et al. "Heparan Sulfate-Degrading Enzymes Induce Modulation of Smooth Muscle Phenotype", <i>Experimental Cell Research</i> , 20: 156-167, 1992.
408	Eisenberg et al. "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan Sulfate on Cell Surface and Extracellular Matrix", <i>J. Clin. Invest.</i> , 90: 2013-2021, 1992.
409	Folkman et al. "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth Factor - Is Stored Within Basement Membrane", <i>Am. J. Pathology</i> , 130(2): 393-400, 1988.
410	Folkman et al. "Angiogenic Factors", <i>Science</i> , 235: 442-447, 1987.
412	Mattner et al. "Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by a Readily Released Heparanase from Human Neutrophils", <i>J. Clin. Invest.</i> 76(4): 1306-1313, Oct. 1985.
413	Mollinedo et al. "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", <i>Biochem. J.</i> , 327: 917-923, 1997.
414	Narindrasorasak et al. "High Affinity Interactions Between the Alzheimer's β -Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", <i>J. Biol. Chem.</i> , 266(20): 12878-12883, 1991.
415	Ornitz et al. "FGF Binding and FGF Receptor Activation by Synthetic Heparin-Derived Di- and Trisaccharides", <i>Science</i> , 268: 432-436, 1995.
416	Rapraeger et al. "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", <i>Science</i> , 252: 1705-1709, 1991.
417	Zhong-Sheng et al. "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", <i>J. Biol. Chem.</i> , 268(14): 10160-10167, 1993.
418	Hudson "Recombinant Antibody Fragment", <i>Curr. Opin. Biotech.</i> , 4:395-402, 1998.
419	Schoepe et al. "Neutralization of Hemolytic and Mouse Lethal Activities of <i>C. Perfringens</i> Alpha-Toxin Need Simultaneous Blockage of Two Epitopes by Monoclonal Antibodies", <i>Microbiol. Pathogenesis</i> , 23: 1-10, 1997.
420	Chiba et al. "Generation of Neutralizing Antibody to the Reserve Transcriptase of Human Immunodeficiency Virus Type 1 by Immunizing of Mice with an Infectious Vaccinia Virus Recombinant", <i>J. Immunological Methods</i> , 207:53-60, 1997.
421	Wong "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number", <i>Genetic Engineering News</i> : 23-49, 1998.
422	Sherman-Gold "Monoclonal Antibodies: The Evolution from '80s Magic Bullets to Mature, Mainstream Applications as Clinical Therapeutics", <i>Genetic Engineering News</i> : 4, 35, 1997.
423	Danheiser "Rituxin Leads Line of Hopeful Mab Therapies, yet FDA still has Bulk Manufacturing Concerns", <i>Genetic Engineering News</i> : 1,6,33,38, 1997.
424	Rader et al. "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", <i>Proc. Natl. Acad. Sci.</i> , 95: 8910-8915, 1998.
425	Mateo et al. "Humanization of a Mouse Monoclonal Antibody that Blocks the Epidermal Growth Factor Receptor: Recovery Antagonistic Activity", <i>Immunotechnology</i> , 3: 71-81, 1997.
426	Thunberg et al. "The Molecular Size of the Antithrombin-Binding Sequence in Heparin", <i>FEBS Lett.</i> , 117: 203-206, 1980.
427	Nakajima et al. "Heparanases and Tumor Metastasis", <i>J. Cell Biochemistry</i> , 36(2): 157-167, 1988.
428	Ngo et al. "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", in <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp.433 and 492-495.
429	Colman "Effects of amino Acid Sequence Changes on Antibody-antigen Interactions", in <i>Research in Immunology</i> , 1994; 145(1): 33-36.
430	Abaza et al. "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of

		Myoglobin", in Journal of Protein Chemistry, 11(5): 433-444, 1992.	
431		Lederman et al. "A Single amino Acid Substitution in a common African allele of the CD4 Molecule Ablates Binding of the Monoclonal antibody, OKT4", Molecular Immunology 28: 1171-1181, 1991)	
432		Lj et al. "β-Endorphin Omission Analogs: Dissociation of Immunoreactivity from other Biological Activities", PNAS 77: 3211-3214, 1980)	
433		Marchetti et al. "Neurotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", Cancer Research, 56: 2856-2863, 1996, also in: Advances in Enzyme Regulation, 37: 111-134, 1997.	
434		Kosir et al. "Human Prostate Carcinoma Cells Produce Extracellular Heparanase", J. Surg. Res., 67: 98-105, 1997.	
435		Kochler et al. "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", Nature 256: 495-497, 1975.	
438		Kussie et al. "Cloning and Functional Expression of a Human Heparanase Gene", Biochemical and Biophysical Research Communication 261(1): 187-187, 1999.	
439		Walch et al. "Correlation of Overexpression of the Low-Affinity 675 Neurotrophin Receptor with Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", Int. J. Cancer 82: 112-120, 1999.	
440		Freeman et al. "Evidence that Platelet and Tumour Heparanases are Similar Enzymes", Biochem J. 342: 361-368, 1999.	
441		Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. in Biochemistry and Molecular Biology, 30(5): 387-444, 1995.	
442		Zhou et al. "A 182 bp Fragment of the Mouse pro α 1(I) Collagen Gene is Sufficient to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science 108: 3677-3684, 1995.	
443		Hormuzdi et al. "A Gene-Targeting Approach Identifies A Function for the First Intron in Expression of the α 1 (I) Collagen Gene.", Mol Cell Biol., 18(6): 3368-3375, 1998. Abstract.	
444		Chow et al. "Development of an Epithelium-Specific Expression Cassette with Human DNA Regulatory Elements for Transgene Expression in Lung Airways", Proc. Natl. Acad. Sci., 94:14696-14700, 1997.	
445		Ye et al. "Targeted Gene Correction: A New Strategy for Molecular Medicine", Molecular Medicine Today: 431-437, 1998.	
446		Lai et al. "Homologous Recombination Based Gene Therapy", Exp. Nephrol, 7(1):11-14, 1999. Abstract.	
447		Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues", Biochimica et Biophysica Acta, 1172: 37-42, 1993.	
448		Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. natl. Acad. Sci., 94: 5332-5337, 1997.	
449		Gewirtz et al. "Nucleic Acid Therapeutics: State of the Art and Future Prospects", Blood 92(3): 712-736, 1998.	
450		Shetty "Gene Disruption in Mice: Models of Development and Disease", Molecular and Cellular Biochemistry, 181: 163-179, 1998.	
451		Carpentier et al. "DNA Vaccination with HuD Inhibits Growth of a Neuroblastoma in Mice", Clinical Cancer Research, 4: 2819-2824. 1998.	
452		Lai et al. "DNA Vaccines" Critical Reviews in Immunology 18: 449-484, 1998.	
453		Kurachi et al. "Role of Intron I in Expression of the Human Factor IX Gene", Journal of Biological Chemistry 270(10): 5276-5281, 1995.	
454		Shekhar et al. "Correlation of Differences in Modulation of ras Expression with Metastatic Competence of Mouse Mammary Tumour Subpopulations", Invasion Metastasis, 14: 27-37, 1994/5.	

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

Approved for use through 10/31/99 OMB 0051-0051
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Forming unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/371,218
--------------------	------------

Filing Date	02/24/2003
-------------	------------

First Named Inventor	Zcharia
----------------------	---------

Group Art Unit	1652
----------------	------

Examiner Name

Attorney Docket Number	28783
------------------------	-------

Sheet	1	Of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Foreign Patent Documents				Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
Examiners Initials	Cite No. 1	Office ²	Number ³ Kind Code ³ (if known)				
		WO	99/57244	Ben-Artzi et al	11-11-1999		
		WO	99/57153	Pecker et al	11-11-1999		
		WO	99/11798	Pecker et al	03-11-1999		
Examiner Signature					Date Considered		

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant: Is to place a check mark here if English language translation is attached.

English language translation is attached.

Bureau Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 10/371,218
Filing Date 02/24/2003
First Named Inventor Zcharia
Group Art Unit 1652
Examiner Name

Attorney Docket Number 25783

Sheet	Of	2	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Cite No. ¹		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
			AVludavsky et al, "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", <i>Nature Medicine</i> , 5(7):793-802, 1999
			Kussie et al, "Cloning And Functional Expression Of A Human Heparanase Gene", <i>Biochem Biophys Res Commun.</i> , 261(1):183-187, 1999
			Hulett et al, "Cloning Of Mammalian Heparanase, An Important Enzyme In Tumor Invasion And Metastasis", <i>Nat Med.</i> , 5(7): 803-09, 1999
			Toyoshima et al, "Human Heparanase: Purification, Characterization, Cloning, and Expression", <i>J. Biological Chemistry</i> , 274: 34:24153-24160, 1999
			Farbanks et al, "Processing Of The Human Heparanase Precursor And Evidence That The Active Enzyme Is A Heterodimer", <i>J Biol Chem.</i> , 274(42):29587-29590, 1999.
			Dempsey et al, "Heparanase, a Potential Regulator of Cell-Matrix Interactions". <i>TISS</i> , 25(8):349-351, 2000
			Niwa et al, "Efficient Selection For High Expression Transfectants With A Novel Eukaryotic Vector", <i>Gene</i> , 108(2):193-197, 1991
			Clark, AJ, "The Mammary Gland as a Bioreactor: Expression, Processing, and Production of Recombinant Proteins", <i>J. Mammary Gland Biol. And Neoplasia</i> . 3(3):337-350, 1998
			Mirault et al, "Transgenic Glutathione Peroxidase Mouse Models for Neuoprotection Studies", <i>Ann NY Acad Sci</i> , 738:104-115, 1994
			Lampard et al, "Secretion Of Foreign Proteins Mediated By Chicken Lysozyme Gene Regulatory Sequences", <i>Biochem Cell Biol.</i> , 80(6):777-788, 2002
			Harvey et al, "Expression of Exogenous Protein in the Egg White of Transgenic Chickens", <i>Nature Biotechnology</i> , 19:396-399, 2002
			Morrison et al, "Sequences In Antibody Molecules Important For Receptor-Mediated Transport Into The Chicken Egg Yolk", <i>Mol Immunol.</i> , 38(8):619-625, 2002
			Clark et al, "Pharmaceuticals from Transgenic Livestock", <i>TIBTECH</i> , 5:20-24, 1987
			Richards et al, "Construction And Preliminary Characterization Of The Rat Casein And Alpha-Lactalbumin Cdna Clones", <i>J Biol Chem.</i> , 256(1):526-32, 1981
			Campbell et al, "Comparison Of The Whey Acidic Protein Genes Of The Rat And Mouse", <i>Nucleic Acids Res.</i> 1984 Nov 26; 12(22):8685-8697.
			Gorodetsky et al, "Isolation and Characterization of the <i>Bos Taurus</i> β -Casein Gene", <i>Gene</i> , 66:87-96, 1988
			Alexander et al, "Complete Sequence of the Bovine β -Lactoglobulin cDNA", <i>Nucleic Acids Research</i> , 17(16):6739-6744, 1989
Examiner Signature			Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Substitute for form 1449A/PTO						Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						Application Number 10/456,373	
(use as many sheets as necessary)						Filing Date 06/09/2003	
						First Named Inventor Iris PECKE	
						Group Art Unit 1646	
						Examiner Name	
						Attorney Docket Number 25677	
Sheet 2		Of 2					
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²
		Vlodavsky et al., "Inhibition of tumor metastasis by heparanase inhibiting species of heparin", <i>Invasion Metastasis</i> . 1994-95;14 1-6);290-302 (abstract)					
		Parish et al., "Evidence that sulphated polyaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases". <i>Int J Cancer</i> . 1987 Oct;15:40(4):511-8.					
		Lider et al., "Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins", <i>J Clin Invest</i> . 1989 Mar;83(3):852-6.					
		Gewirtz et al., "Nucleic acid therapeutics: state of the art and future prospects", <i>Blood</i> . 1998 Aug 1;92(3):712-36.					
		Hida et al., "Antisense EGF transfection restrains oral cancer invasion by reducing matrix metalloproteinase activities", <i>Am J Pathol</i> . 1997 Jun;150(6):2125-32 (abstract)					
		Thuong et al., "Sequence-specific recognition and modification of double-helical DNA by oligonucleotides", <i>Angew Chem Int Ed Engl</i> , 32:666-690, 1993					
		Cohen, JS, "Oligonucleotide therapeutics", <i>Trends Biotechnol</i> , 10(3):87-91, 19992 (abstract)					
		Szczylk et al., "Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides", <i>Science</i> . 1991 Aug 2;253(5019):562-5. (abstract)					
		Calabretta et al., "Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myc antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging", <i>Proc Natl Acad Sci USA</i> . 1991 Mar 15;88(6):2351-5.					
		Burch et al., "Oligonucleotides antisense to the interleukin-1 receptor mRNA block the effects of interleukin 1 in cultured murine and hum fibroblasts and in mice", <i>J Clin Invest</i> . 88(4):1190-1196. 1991 (abstract)					
		Agrawal S., "Antisense oligonucleotides: antiviral agents", <i>Trends Biotechnol</i> , 10(5):152-158. 19992, (abstract)					
		Uno et al. "Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells". <i>Cancer Res</i> . 2001 Nov 16;61(21):7855-60.					
Examiner Signature							Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTX/5B/08A (10-96)

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/645,659
				Filing Date	08/22/2003
				First Named Inventor	YACOBY ZEEVI
				Group Art Unit	1635
				Examiner Name	
				Attorney Docket Number	26128
Sheet	1	Of	1		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", <i>J. Biol. Chem.</i> , vol. 274, No. 42, pp. 29517-29590, 15 Oct. 1999.			
		Hulett et al. "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis", <i>Nature Medicine</i> , 5(7):803-809, 1999			
		Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression", <i>J. of Biolog. Chemistry</i> , vol. 274, No. 34, pp. 24153-24160, 20 Aug. 1999.			
		Miao et al. "Cloning, Expression, and Purification of Mouse Heparanase", <i>Protein Expression and Purification</i> , 26:425-431, 2002			
		Freeman et al. "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", <i>Biochem J.</i> , 350(3): 1341-1350, 1998.			
Examiner Signature		Date Considered			

* XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Estimated Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC :0231.



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/722,502
Filing Date	August 22, 2003
First Named Inventor	YACOBY-ZEEVI Oron et al
Art Unit	1644
Examiner Name	
Attorney Docket Number	26872

Sheet		of		Attorney Docket Number		26872	
U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number, Kind Code ² or Letters					
	1	US-5,362,641	08-8-1994	Fuks et al.			
	2	US-5,399,351	01-1-1995	Leshchiner et al			
	3	US-5,550,116	01-1-1996	Lormeau et al.			
	4	US-5,667,501	01-1-1997	Fowler et al			
	5	US-5,739,115	01-1-1998	Fugedi et al			
	6	US-6,177,545	01-13-2001	Pecker et al.			
	7	US-6,348,344	02-19-2002	Ayal-Hershkovitz et al			
	8	US-4,946,778	08-8-1990	Ladner et al.			
	9	US-5,997,863	07-7-1999	Zimmermann et al.			
	10	US-6,242,238	05-5-2001	Freeman et al			
	11	US-5,688,679	11-18-1997	Powell			
	12	US-6,387,643	05-14-2002	Heinrikson et al.			
	13	US-6,423,312	07-23-2002	Yacoby-Zeevi			
	14	US-6,531,129	01-1-2003	Pecker et al.			
	15	US-4,455,296	06-19-1984	Hansen et al.			
	16	US-5,571,506	01-1-1996	Regan et al.			
	17	US-5,917,830	06-29-1999	Chen et al.			
	18	US-5,859,660	01-12-1999	Perkins et al.			
	19	US-5,600,366	04-4-1997	Schulman			
	20	US-6,020,931	01-1-2000	Bilbrey et al.			
	21	US-5,968,822	10-19-1999	Pecker et al.			
	22	US-6,153,187	11-28-2000	Yacoby-Zeevi			
	23	US-6,664,105	12-16-2003	Pecker et al.			
	24	US-5,145,679	08-8-1992	Hinson			
	25	US-5,736,137	07-7-1998	Anderson et al.			
	26	US-5,194,596	03-16-1993	Tischer et al.			
	27	US-5,350,876	09-27-1994	Kopchick et al.			
	28	US-6,562,950	05-13-2003	Peretz et al.			
	29	US-6,699,672	02-2-2004	Pecker et al.			
	30	US-5,580,862	03-3-1996	Rosen et al.			
	31	US-5,474,983	12-12-1995	Kuna et al.			
	32	US-2002/0102560	01-1-2002	Pecker et al.			
	33	US-4,859,581	01-1-1989	Nicholson et al.			
	34	US-4,882,318	01-1-1989	Vlodavsky et al.			
	35	US-5,129,877	01-1-1992	Gallo et al.			
	36	US-5,206,223	04-27-1993	Vlodavsky et al			
	37	US-5,332,812	07-26-1994	Nicolson et al.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/72,502	
				Filing Date	August 22, 2003	
				First Named Inventor	YACOBY-ZEEVI Oron et al	
				Art Unit	1644	
				Examiner Name		
Sheet	2	of	11	Attorney Docket Number	26872	
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	38	PCT WO 99/57244	11-11-1999	Ben-Artzi et al.		
	39	PCT WO 99/57153	11-11-1999	Pecker et al.		
	40	PCT WO 99/11708	03-11-1999	Pecker et al.		
	41	PCT WO 88/01280	01-1-1988	Nicolson et al.		
	42	PCT WO 95/04158	09-9-1995	Hoogewerf et al.		
	43	PCT WO 99/21975	06-6-1999	Freeman et al.		
	44	PCT WO 91/19197	12-12-1991	Nicolson et al.		
	45	PCT WO 95/04518	02-16-1995	Migita et al.		
	46	PCT WO 03/006645 A2	01-23-2003	Bohlen et al.		
	47	PCT WO 97/11684	04-4-1997	Bennett et al.		
	48	PCT WO 91/02977	07-7-1991	Fuks et al.		
	49	PCT WO 97/27327	07-31-1997	Van Ness et al.		
	50	PCT WO 00/52149	08-8-2000	Yacobi-Zeevi		
	51	PCT WO 00/52178	08-8-2000	Pecker et al.		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁵
	52	"Mouse Models for Reproductive Biology Research" - www.jax.org/jaxmie: 1-2, Summer 2002.				
	53	Abaza et al. "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site...) of Myoglobin", in Journal of Protein Chemistry, 11(5): 433-444, 1992.				
	54	Adams et al. "Initial Assessment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA Sequence", Nature, 377(6547): 3-174, 1995. GenBank Entry AA304653, 1997.				
	55	Agrawal "Antisense Oligonucleotides as Antiviral Agents", Trends Biotechnol., 10(5): 152-158, 1992. Abstract.				
	56	Agrawal "Antisense Oligonucleotides: Towards Clinical Trials", Reviews: 376-387.				
	57	Albus et al. "Staphylococcus Aureus Capsular Types and Antibody Response to Lung Infection in Patients with Cystic Fibrosis", J. Clin. Microbiol. 26(12): 2505-2509, 1988. Abstract.				
	58	Allison et al. "Polysaccharide Production in Pseudomonas Cepacia", J. Bacteriol. 156(1): 3-10, 1994. Abstract.				
Examiner Signature					Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (A/ISO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual cases. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/7: 2,502		
		Filing Date	August 22, 2003		
		First Named Inventor	YAC JBY-ZEEVI Oron et al		
		Art Unit	1644		
		Examiner Name			
Sheet	3	of	11	Attorney Docket Number	2687
59	Anatolii "Hyaluronic Capsule as one of the Factors of Hemolytic Streptococcus Pathogenicity", Chem. Abstracts 86(17): 339. Abstr. 118714 citing Zh. Mikrobiol. Epidemiol. Immunobiol. 2: 22-27, 1977.				
60	Armstrong et al. "Lower Airway Inflammation in Infants and Young Children with Cystic Fibrosis". Am. J. Respir. Crit. Care Med. 156(4 Pt. 1): 1197-1204, 1997. Abstract.				
61	Bean et al. "Fertilization in vitro Increases Non-Disjunction During Early Cleavage Divisions in a Mouse Model System", Human Reproduction 17(9): 2362-2367, 2002. Abstract.				
62	Bendayan "Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-Proinsulin Antibody", J. Histochem. Cytochem. 43: 881-886, 1995.				
63	Bendig et al. "Humanization of Rodent Monoclonal Antibodies by CDR Grafting", Methods, 8: 83-93, 1993.				
64	Benezra et al. "Thrombin Enhances the Degradation of Heparan Sulfate in the Extracellular Matrix by Tumor Cell Heparanase." Exptl. Cell. Res. (1992) vol. 201:208-215				
65	Benjamin et al. "A Plasticity Window for Blood Vessel Remodelling is Defined by Pericyte Coverage of the Preformed Endothelial Network and is Regulated by PDGF-B and VEGF", Development 125: 1591-1598, 1998.				
66	Bennett et al. "Effect of Uridine 5' Triphosphate plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis". Am. J. Respir. Crit. Care Med. 153(6 Pt. 1): 1796-1801, June 1996. [Abstract]				
67	Berkow "The Merck Manual". R. Berkow, M.D., Ed-in-Chief, Merck Research Laboratories: 201, 204, 1998. 177-179, 1016-1017, 194-197, 885, 601, 1997.				
68	Beuth et al. "Lectin-Mediated Bacterial Adhesion to Human Tissue". Eur. J. Clin. Microbiol. 6(5): 591-593, 1987. Abstract.				
69	Bhaskar et al. "Dysregulation of Proteoglycan Production by Intrahepatic Biliary Epithelial Cells Bearing Defective (delta-1508) Cystic Fibrosis Transmembrane Conductance Regulator", Hepatology 27(1): 7-14, Jan. 1998. [Abstract]				
70	Blanquart et al. "CMDBS, Functional Analogs of Sulfate Heparanes, Used as Osseous Cicatrizing Agents". Ann. Endocrinol. (Paris) 55(2): 121-123, 1994. [Abstract]				
71	Blanquart et al. "Heparan-Like Molecules Induce The Repair Of Skull Defects". Bone, 17(6): 499-506, 1995. Abstract.				
72	Bork "Go Hunting in Sequence Databases but Watch out for the Traps", Trends in Genetics, 12(10): 425-427, 1996.				
73	Bork "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome Res., 10: 398-400, 2000.				
74	Bost et al. "Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2", Immunol. Invest. 17: 577-586, 1981.				
75	Bowie et al. "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions". Science, 247: 1306-1310, 1990.				
Examiner Signature					Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (A/PO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/7: 2,502
				Filing Date	August 22, 2003
				First Named Inventor	YACIOBY-ZEEVI Oron et al
				Art Unit	1644
				Examiner Name	
Sheet	4	of	11	Attorney Docket Number	2687
76	Brenner "Errors in Genome Annotation". Trends in Genetics. 15(4): 132-133, 1999.				
77	Brinster et al. "Restoration of Fertility by Germ Cell Transplantation Requires Effective Recipient Preparation". Biology of Reproduction 69: 412-420, 2013. Abstract.				
78	Burns et al. "Oligodeoxynucleotides Antisense to the Interleukin 1 Receptor mRNA Block the Effects of Interleukin 1 in Cultured Murine and Human Fibroblasts and in Mice". J. Clin. Invest. 88: 1190, 1991. Abstract.				
79	Calabretta et al. "Normal and Leukemic Hematopoietic Cell Manifest Differential Sensitivity to Inhibitory Effects of C-myc Antisense Oligodeoxynucleotide: An in vitro Study Relevant to Bone Marrow Purging". Proc. Natl. Acad. Sci. USA 88: 2351-2355, 1991.				
80	Carpentier et al. "DNA Vaccination with HuD Inhibits Growth of a Neuroblastoma in Mice". Clinical Cancer Research. 4: 2819-2824, 1998.				
81	Carson et al. Mucin And Mucoglycan Functions in Embryo Implantation". BioEssays. 20(7): 577-583. Abstract.				
82	Chow et al. "Development of an Epithelium-Specific Expression Cassette with Human DNA Regulatory Elements for Transgene Expression in Lung Airways". Proc. Natl. Acad. Sci.. 94:14695-14700, 1997.				
83	Cohen "Oligonucleotide Therapeutics". Trends in Biotechnology 10: 87-91, 1992. Abstract.				
84	Coligan et al. "Current Protocols in Immunology". Green Publishing Assoc. 1991.				
85	Colman "Effects of amino Acid Sequence Changes on Antibody-antigen Interactions". in Research in Immunology. 1994: 145(1): 33-36.				
86	De Vouge et al. "Immunoselection of GRP94/Endoplasmic Reticulum Cell-Specific IgT11 Library Using Antibodies Directed Against A Putative Hepatocellular Amino-Terminal Peptide". Int. J. Cancer. 56:286-294, 1994.				
87	Dempsey et al. "Heparanase Expression in Invasive Trophoblasts and Acute Vascular Damage". Glycobiology 10(5): 467-475, 2000. Abstract.				
88	Dempsey et al. "Heparanase, A Potential Regulator of Cell-Matrix Interactions". TIBS. 25(5):349-351, 2000.				
89	Doerks et al. "Protein Annotation: Detective Work for Function Prediction" Trends in Genetics. 14(6): 248-250, 1998.				
90	Drigues et al. "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of Pseudomonas Solanacearum and From Three Avirulent Mutants". Journal of Bacteriology 162(2): 504-509, 1985. Abstract.				
91	Ducy et al. "The Osteoblast: A Sophisticated Fibroblast under Central Surveillance". Science 289: 1501-1504, 2000.				
92	Durand et al. "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Clan GH-A Glycosyl Hydrolases Deduced from Hydrophobic Cluster Analysis". Glycobiology 7(2): 277-284, 1997.				
93	Edwards et al. "Some Properties and Applications of Monoclonal Antibodies", Biochem. Journal 200: 1-10, 1981.				
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (see WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/7: 2,502
				Filing Date	August 22, 2003
				First Named Inventor	YACOBY-ZEEVI Oron et al
				Art Unit	1644
				Examiner Name	
Sheet	3	of	11	Attorney Docket Number	26872
94	Ejima et al. "Induction of Apoptosis in Placentas of Pregnant Mice Exposed to Lipopolysaccharides: Possible Involvement of Fas/Fas Ligand System". Biology of Reproduction 62: 178-185, 2000. Abstract.				
95	Erkin et al. "Heparanase as Mediator of Angiogenesis.: Mode of Action", The FASEB Journal 15: 1661-1663, 2001.				
96	Ennis et al. PNAS USA. 87: 2833-2837, 1990.				
97	Ernst et al. "Enzymatic Degradation of Glycosaminoglycans", Crit. Rev. in Biochemistry and Molecular Biology. 30(5): 387-444, 1995.				
98	Faber-Elman et al. "Involvement of Wound-Associated Factors in Rat Brain Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", J. Clin. Invest.. 97(1): 162-171, 1996.				
99	Fairbanks et al. "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", Journal of Biol. Chem..274.(42): 29537-29590, 1999.				
100	Famdale et al. "A Direct Spectrophotometric Microassay for Sulfated Glycosaminoglycans in Cartilage Cultures", Connective Tissue Research 9: 247-248, 1982.				
101	Ferber et al. "Pancreatic and Duodenal Homobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia", Nature Medicine. 6(5): 568-572, 2000.				
102	Finkel "Potential Target Found for Antimetastasis Drugs", Science 285: 33-34, July 2, 1999.				
103	Fisher CCPA. 1970.				
104	Flanagan et al. "Potent and Selective Gene Inhibition Using Antisense Oligodeoxynucleotides", Molecular and Cellular Biochemistry, 172: 213-225, 1997.				
105	Freeman et al. "Evidence that Platelet and Tumour Heparanases are Similar Enzymes", Biochem. J. 342: 361-368, 1999.				
106	Freeman et al. "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", Biochem. J.. 330: 1341-1350, 1998.				
107	Gewirtz et al. "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on its Promise", Proc. Natl. Acad. Sci. USA, vol. 93: 3161-3163, April 1996.				
108	Gewirtz et al. "Nucleic Acid Therapeutics: State of the Art and Future Prospects", Blood 92(3): 712-736, 1998.				
109	Gosder et al. "Heparanase Activity in Cultured Endothelial Cells", Journal of Cellular Physiology, 148: 274-280, 1991.				
110	Goldberg et al. "An Improved Method for Determining Proteoglycans Synthesized by Chondrocytes in Culture", Live Tissue Research, 24: 265-275, 1990.				
111	Goshen et al. "Purification and Characterization of Placental Heparanase and Its Expression by Cultured Cytotrophoblasts", Molecular Human Reproduction 2(9): 679-684, 1996.				
112	Green et al. "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease", Journal of American Coll Surgery. 191(1): 93-105, 2000.				
Examiner Signature				Date Considered	

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual cases. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/72,502
		Filing Date	August 22, 2003
		First Named Inventor	YACOBY-ZEEVI Ori et al
		Art Unit	1644
		Examiner Name	
Sheet	5 of 11	Attorney Docket Number	26872
113	Haimov-Kochman et al. "Localization of Heparinase in Normal and Pathological Human Placenta". Molecular Human Reproduction 8(6): 566-573, 2002.		
114	Harlow et al. "Antibodies" A Laboratory Manual, eds. Harlow et al.: 471-500, 1996.		
115	Hatch et al. "Alginate Lyase Promotes Diffusion of Aminoglycosides Through the Extracellular polysaccharide of Mucoid Pseudomonas Aeruginosa". Antimicrob. Agents Chemother. 42(4): 974-977, 1998. [Abstract]		
116	Hayward et al. "Cellular Mechanisms of Heparinase III Protection in Rat Traumatic Shock". American Journal of Physiology 275:H23-H30, 1998.		
117	Hida et al. "Antisense E1AF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities". Am. J. Pathol., 50(6): 2125-2132, 1997. Abstract.		
118	Hill et al. "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in a Mouse Model of Cystic Fibrosis". Biochem. Mol. Med., 62(1): 113-122, 1997. Abstract.		
119	Hillier et al. "The WashU-Merck EST Project" GenBank Entry N32056, 1996.		
120	Hillier et al. "The WashU-Merck EST Project". No. N30824. Database GenBank on STN. US National Library of Medicine (Bethesda MD). 1996.		
121	Hillier et al. "The WashU-Merck EST Project". No. N30845. Database GenBank on STN. US National Library of Medicine (Bethesda MD). 1996.		
122	Hoffman et al. "Human Bone Morphogenetic Protein 2 Contains a Heparin-Binding Site Which Modifies its Biological Activity". Eur. J. Biochem. 237(1): 295-302, 1996. [Abstract]		
123	Hoogwerf et al. "CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 Are Heparin/Heparan Sulfate-Degrading Enzymes". J. Biol. Chem., 270(7): 3268-3277, 1995.		
124	Hormuzdi et al. "A Gene-Targeting Approach Identifies A Function for the First Intron in Expression of the $\alpha 1(I)$ Collagen Gene". Mol Cell Biol., 18(6): 3368-3375, 1998. Abstract.		
125	Hulett et al. "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis". Nature Medicine: 5(7): 803-809, 1999.		
126	Imai et al. "Osteoblast Recruitment and Bone Formation Enhanced by Cell Matrix-Associated Heparin-Binding Growth-Associated Molecule (HB-GAM)". J. Cell. Biol. 143(4): 1113-1128, 1998. [Abstract]		
127	Ishai-Michaeli et al. "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells Releases Active Fibroblast Growth Factor From Extracellular Matrix". Cell Regulation, 1: 833-842, 1990.		
128	Jayaraman et al. "Rational Selection and Quantitative Evaluation of Antisense Oligonucleotides". Biochimica et Biophysica Acta 1520: 105-114, 2001.		
129	Jin et al. "Immunohistochemical Localization of Heparanase in Mouse and Human Melanomas". Int. J. Cancer. 45: 1088-1095, 1990.		
130	Jin et al. "Molecular Cloning and Expression of Human Heparanase cDNA". Proceedings American Association for Cancer Research Annual Meeting 1992, 33: 57, 1992. Abstract		
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/APTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/712,502
				Filing Date	August 22, 2003
				First Named Inventor	YACOBY-ZEEVI Oron et al
				Art Unit	1644
				Examiner Name	
Sheet	7	of	11	Attorney Docket Number	26872
131	Jorba et al. ["Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars"] (author's translation). Rev. Esp. Fisiol. 36(2): 155-161, 1980. Abstract.				
132	Kato et al. "Physiological Degradation Converts the Soluble Syndecan-1 Extracellular Domain from an Inhibitor to a Potent Activator of FGF-2". Nature Medicine, 4(6): 611-697, 1998.				
133	Kawase et al. "Effect of Partial Incision of the Zona Pellucida by Piezo-Micromanipulator for In Vitro Fertilization Using Frozen-Thawed Mouse Spermatozoa on the Developmental Rate of Embryos Transferred at the 2-Cell Stage". Biology of Reproduction 66: 3810385, 2002. Abstract.				
134	Kiberstis et al. "Bone Health in the Balance". Science 289: 1497, 2000.				
135	Kizaki et al. "Cloning and Localization of Heparanase in Bovine Placenta". Placenta 24: 424-430, 2003.				
136	Kizaki et al. "Expression of Heparanase mRNA in Bovine Placenta During Gestation". Reproduction 121: 573-580, 2001.				
137	Kuehler et al. "Continuous Cultures of Fused Cells Secreting Antibody of F redefined Specificity". Nature 256: 495-497, 1975.				
138	Konstan et al. "Current Understanding of the Inflammatory Process in Cystic Fibrosis". Pediatric Pulmonology, 24: 137-142, 1997.				
139	Konstan et al. "Patterns of Medical Practice in Cystic Fibrosis: Part II. Use of Therapies". Pediatr. Pulmonol. 28(4): 248-254, Oct. 1999. [Abstract]				
140	Korb et al. "Stimulation of Gene Expression by Introns: Conversion of an Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Donor Sequence". Nucleic Acids Research 21(25): 5901-5908, 1993.				
141	Kosir et al. "Early Human Breast Carcinoma Cells Produce Extra Cellular Heparanase". Molecular Biology/Biochemistry. Proceedings of the American Association for Cancer Research, 37: 495, 1996.				
142	Kosir et al. "Human Prostate Carcinoma Cells Produce Extracellular Heparanase". J. Surg. Res., 67: 98-105, 1997.				
143	Kosir et al. Abstract 3378. Cancer Res., 37: 495, 1996.				
144	Kronenberg et al. "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset". Blood, 91(3): 852-862, 1998.				
145	Kurachi et al. "Role of Intron 1 in Expression of the Human Factor IX Gene". Journal of Biological Chemistry 270(10): 5276-5281, 1995.				
146	Kussie et al. "Cloning and Functional Expression of a Human Heparanase Gene". Biochemical and Biophysical Research Communication 261(1): 183-187, 1999.				
147	Lai et al. "DNA Vaccines" Critical Reviews in Immunology 18: 449-484, 1998.				
148	Lai et al. "Homologous Recombination Based Gene Therapy". Exp. Nephro., 7(1): 11-14, 1999. Abstract.				
149	Laskov et al. "Production of Heparanase by Normal and Neoplastic Murine B-Lymphocytes". International Journal of Cancer 47(1): 92-98, Jan. 1991.				
Examiner Signature				Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (A/IPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

(Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.)

Substitute for form 1449A/PTO		Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/712,502
		Filing Date	August 22, 2003
		First Named Inventor	YACOBY-ZEEVI Oron et al
		Art Unit	164
		Examiner Name	
Sheet 8 of 11	Attorney Docket Number	268'2	
150	Le Fur et al. "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", Proc. natl. Acad. Sci., 94: 5332-5337, 1997.		
151	Lederman et al. "A Single amino Acid Substitution in a common African allele of the CD4 Molecule Ablates Binding of the Monoclonal antibody, OKT4", Molecular Immunology 28: 1171-1181, 1991)		
152	Li et al. "Immunochemical Localization of Heparanase in Mouse and Human Melanomas", Int. J. Cancer 45: 1088-1095, 1990.		
153	Li et al. "β-Endorphin Omission Analogs: Dissociation of Immunoreactivity from other Biological Activities", PNAS 77: 3211-3214, 1980)		
154	Lider et al. "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals With Low Doses of Heparin", J. Clin. Invest., 83: 752-756, 1989.		
155	Linhardt et al. "Polysaccharide Lyases", Applied Biochemistry and Biotechnology 12: 135-176, 1986.		
156	Liu et al. "Live Offspring by In Vitro Fertilization of Oocytes from Cryopreserved Primordial Mouse Follicles after Sequential In Vivo Transplantation and In Vitro Maturation", Biology of Reproduction 64: 171-178, 2001. Abstract.		
157	Loredo et al. "Regulation of Glycosaminoglycan Metabolism by Bone Morphogenetic Protein-2 in Equine Cartilage Explant Cultures", Am. J. Vet. Res. 57(4): 554-559, 1996.		
158	Luft "Making sense out of Antisense Oligodeoxynucleotide Delivery: Getting there is Half the Fun", J. Mol. Med. 75:76, 1998.		
159	Macone et al. "Mucoid Escherichia coli in Cystic Fibrosis", The New England Journal of Medicine 304(24): 1445-1449, June 11, 1981. Abstract.		
160	Marchetti et al. "Neurotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", Cancer Research, 56: 2856-2863, 1996. also in: Advances in Enzyme Regulation, 37: 111-134, 1997.		
161	Marty et al. "Influence of Nutrient Media on the Chemical Composition of the Exopolysaccharide from Mucoid and non-Mucoid Pseudomonas aeruginosa", FEMS Microbiol. Letters, 77(1-3): 35-44, Nov. 1992. Abstract.		
162	Massague "The TGF-BETA Family of Growth and Differentiation Factors", Cell, 49: 437-438, 1987.		
163	Menezo et al. "Mouse and Bovine Models for Human IVF", Reproductive BioMedicine Online 2002 4(2): 170-175, 2002. Abstract.		
164	Miao et al. "Cloning, Expression and Purification of Mouse Heparanase", Protein Expression and Purification, 26: 425-431, 2002.		
165	Mollinedo et al. "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", Biochem J., 327: 917-923, 1997.		
166	Motokuni et al. "In Vivo Transfer Efficiency of Antisense Oligonucleotides into the Myocardium Using HVJ-Liposome Method", Biochemical and Biophysical Research Communications 231: 540-545, 1997.		
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation - not in conformance and not considered. Include copy of copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/722,502
		Filing Date	August 22, 2003
		First Named Inventor	YACOBY-ZEEVI Oron et al
		Art Unit	164
		Examiner Name	
Sheet	of	Attorney Docket Number	268'2
167		Muir et al. "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone in vivo". Blood 88(4): 1314-1320, August 15, 1996. [Abstract]	
168		Mullings et al. "New Reducing Sugar Assay for the Study of Cellulases". Enzyme Microb. Technol., 6:491-496, 1984.	
169		Nakajima et al. "Heparanases and Tumor Metastasis". J. Cell Biochemistry, 6(2): 157-167, 1988.	
170		Naparsten et al. "Activated T Lymphocytes Produce a Matrix-Degrading Heparan Sulphate Endoglycosidase". Nature, 310(5974): 241-244, 1984. Abstract.	
171		Newbold et al. "Exposure to Diethylstilbestrol During Pregnancy Permanently Alters the Ovary and Oviduct". Biology of Reproduction 28: 735-744, 1983. Abstract.	
172		Ofek et al. "Bacterial Adhesion to Cells and Tissues". Chapman and Hall, New York, 1994, pp. 114-118, 148-153, 418-423, 420-423.	
173		Oldberg et al. "Characterization of a Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides". Biochemistry 19: 5755-5762, 1980.	
174		Parish et al. "Evidence That Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor-Cell-Derived Heparanases". Int. J. Cancer, 40: 511-517, 1987.	
175		Pasquier et al. "Implication of Neutral Polysaccharides Associated to Alginate in Inhibition of Murine Macrophage Response to Pseudomonas Aeruginosa". EMS Microbiol. Lett. 147(2): 195-202, Feb. 1997. Abstract.	
176		Pfaff et al. "Cryobiology of Rat Embryos I: Determination of Zygote Membrane Permeability Coefficients for Water and Cryoprotectants. Their Activation Energies, and the Development of Improved Cryopreservation Methods". Biology of Reproduction 63: 1294-1302, 2000. Abstract.	
177		Pilbeam et al. "Comparison of the Effects of Various Lengths of Synthetic Human Parathyroid Hormone-Related Peptide (hPTHrP) of Malignancy on Bone Resorption and Formation in Organ Culture". Bone, 14: 717-720, 1993.	
178		Prahallada et al. "Diethylstilbestrol-Induced Cervical and Vaginal Adenosis Using the Neonatal Mouse Model". Biology of Reproduction 38: 935-943, 1988. Abstract.	
179		Prockop "Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues". Science 276: 71-74, 1997.	
180		Rahmouni et al. "Chondroitin Sulfate in Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis". Am. J. Resp. Cell & Mol. Biol., 5(4): 315-320, 1991. Abstract.	
181		Rajur et al. "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules". Bioconjugate Chem., 8, 935-940, 1997.	
182		Ramos et al. "Relationship Between Glycolysis and Exopolysaccharide Biosynthesis in Lactococcus Lactis". Appl. Environ. Microbiol. 67(1): 33-41, 2001. [Abstract]	
182		Reddi "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and Regeneration". Nature Biotechnology 16: 247-252, 1998.	
184		Richardson et al. "Regulation of Basic Fibroblast Growth Factor Binding and Activity by Cell Density and Heparan Sulfate", J. Biological Chemistry, 274(19): 13534-13540, 1999).	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (AIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/7. 2,502
				Filing Date	August 22, 2003
				First Named Inventor	YACOBY-ZEEVI Oron et al
				Art Unit	1644
				Examiner Name	
Sheet	10	of	11	Attorney Docket Number	2687
	185	Sasisekharan et al. "Heparinase Inhibits Neovascularization". Proc. Natl. Acad. Sci. 91:1524-1528, 1994.			
	186	Selvan et al. "Heparan Sulfate in Immune Responses". An. NY Acad. Sci., 97: 127-139, 1996.			
	187	Service "Tissue Engineers Build New Bone". Science 289: 1498-1500, 2001.			
	188	Shastri "Gene Disruption in Mice: Models of Development and Disease". Molecular and Cellular Biochemistry, 181: 163-179, 1998.			
	189	Shekhar et al. "Correlation of Differences in Modulation of ras Expression with Metastatic Competence of Mouse Mammary Tumour Subpopulations". Invasion Metastasis, 14: 27-37, 1994/5.			
	190	Shimazu et al. "Syndecan-3 and the Control of Chondrocyte Proliferation During Endochondral Ossification". Exp. Cell. Res. 229(1): 126-136, 1996. Abstract.			
	191	Skolnick et al. "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era". Trends in Biotech., 18: 34-39, 2000.			
	192	Smith et al. "The Challenges of Genome Sequence Annotation or "The Devil is in the Details"". Nature Biotechnol., 15: 1222-1223, 1997.			
	193	Sutherland "Structure-Function Relationships in Microbial Exopolysaccharides". Biotech. Adv. 12: 393-448, 1994.			
	194	Szczylik et al. "Selective Inhibition of Leukemia Cell Proliferation by BCR ABL Antisense Oligodeoxynucleotides". Science 253: 562-565, 1991. Abstract.			
	195	Tang et al. "Contribution of Specific Pseudomonas Aeruginosa Virulence Factors to Pathogenesis of Pneumonia in a Neonatal Mouse Model of Infection". Infect. Immun. 64(1): 37-43, 1996. Abstract.			
	196	Tatnell et al. "Characterisation of Alginates from Mucoid Strains of Pseudomonas Aeruginosa". Biochemical Society Transactions 24: 404S, 1996.			
	197	Tatnell et al. "Chemical Analysis of Alginates from Mucoid Strains of Pseudomonas Aeruginosa". Biochemical Society Transactions 22: 310S, 1994.			
	198	Tatnell et al. "Colonisation of Cystic Fibrosis Patients by non-Mucoid Pseudomonas Aeruginosa - Characterisation of the Alginate from Mucoid Variants". Biochemical Society Transactions 24: 406S, 1996.			
	199	Thuong et al. "Sequence-Specific Recognition and Modification of Double-Helical DNA by Oligonucleotides". Angew. Chem., Int. Ed. Engl. 32: 666-690, 1993.			
	200	Toyoshima et al. "Human Heparanase: Purification, Characterization, Cloning, and Expression". J. of Biol. Chemistry, 274(34): 24153-24160, 1999.			
	201	Uno et al. "Antisense-Mediated Suppression of Human Heparanase Gene Expression Inhibits Pleural Dissemination of Human Cancer Cells". Cancer Research 6 (21), 7855-7860, 2001.			
	202	Vlodavsky et al. "Inhibition of Tumor Metastasis Inhibiting Species of Heparin", Inv. Metast., 14(1-6): 290-302, 1994/95.			
	203	Vlodavsky et al. "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", Nature Medicine, 5(7): 793-802, 1999.			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a checkmark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid (OMB) control number.

Substitute for form 1449A/PTO		Complete if known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/712,502		
		Filing Date	August 22, 2003		
		First Named Inventor	YACOBY-ZEEVI Oron et al		
		Art Unit	164		
		Examiner Name			
Sheet	11	of	11	Attorney Docket Number	268.2
204	Vogel et al. "Production of Proteoglycans by Human Lung Fibroblasts (IMR-90) maintained in a Low Concentration of Serum". Biochem J. 207(3): 369-379. Abstract.				
205	Vukicevic et al. "Induction of Nephrogenic Mesenchyme by Osteogenic Protein 1 (Bone Morphogenetic Protein 7)". Proc. Natl. Acad. Sci., 93: 9021-9026, 1996.				
206	Walch et al. "Correlation of Overexpression of the Low-Affinity p75 Neurotrophin Receptor with Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells". Int. J. Cancer 82: 112-120, 1999.				
207	Walton et al. "Prediction of Antisense Oligonucleotide Binding Affinity to a Structured RNA Target". Biotechnology and Bioengineering, 65(1): 1-9, 1999.				
208	Wang "Basic Fibroblast Growth Factor for Stimulation of Bone Formation in Osteoinductive or Conductive Implants". Acta Orthop Scand Suppl. 269: 1-33, 1006 (abstract)				
209	Webster et al. "FGFR Activation in Skeletal Disorders: Too Much of a Good Thing", TIG 13(5): 178-182, May 1997.				
210	Welch et al. "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts". Pediatr. Research, 9(9): 698-702, 1975.				
211	Weller "Implications of Early Inflammation and Infection in Cystic Fibrosis: A Review of New and Potential Interventions". Pediatric Pulmonology 24: 143-146, 1997.				
212	Wessels et al. "Effects on Virulence of Mutations in a Locus Essential for Hyaluronic Acid Capsule Expression in Group A Streptococci". Infect. Immun. 62(2) 433-441, 1994. [Abstract]				
213	Whitelock et al. "The Degradation of Human Endothelial Cell-Derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases". Journal of Biological Chemistry, 271(17):10079-10086, 1996.				
214	Yagel et al. "Normal Nonmetastatic Human Trophoblast Cells Share in vivo Invasive Properties of Malignant Cells". J. Cellular Physiology 136: 455-462, 1988.				
215	Yazaki et al. "The Structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissues". Biochimica et Biophysica Acta, 1172: 37-42, 1993.				
216	Ye et al. "Targeted Gene Correction: A New Strategy for Molecular Medicine". Molecular Medicine Today: 431-437, 1998.				
217	Yesildaglar et al. "The Mouse as a Model to Study Adhesion Formation Following Endoscopic Surgery: A Preliminary Report", Human Reproduction 14(1): 55-59, 1999. Abstract.				
218	Zhou et al. "A 182 bp Fragment of the Mouse pro α 1(1) Collagen Gene is Sufficient to Direct Chondrocyte Expression in Transgenic Mice", J. Cell Science 108: 3677-3684, 1995.				
219	Zhou et al. "HFE Gene Knockout Produces Mouse Model of Hereditary Hemochromatosis", PNAS 95(5): 2492-2497, 1998.				
Signature		Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/341,582
--------------------	------------

Filing Date	01/14/2003
-------------	------------

First Named Inventor	Ilan et al
----------------------	------------

Group Art Unit	1652
----------------	------

Examiner Name

Attorney Docket Number	25449
------------------------	-------

Sheet

1

of

4

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiners Initials	Cite No. 1	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ²	Kind Code ³ (if known)				
		WO	95/04158		Hoogwerf et al	02-09-1995		
Examiner Signature						Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 10 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/341,582
Filing Date	01/14/2003
First Named Inventor	Ilan et al
Group Art Unit	1652
Examiner Name	
Attorney Docket Number	25449

Sheet	2	Of	4
-------	---	----	---

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Richardson et al, "Regulation of Basic Fibroblast Growth factor Binding and Activity by Cell Density and Heparan Sulfate", <i>J. Biological Chemistry</i> , 274(19):13534-13540	
		Hayward et al, "Cellular Mechanisms of Heparinase III Protection in Rat Traumatic Shock", <i>American Journal of Physiology</i> 275:H23-H30, 1998.	
		Sasisekharan et al, "Heparinase Inhibits Neovascularization", <i>Proc.Natl. Acad. USA</i> , 91:1524-1528, 1994	
		Whitelock et al, "The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanase", <i>J. Biological Chemistry</i> 271(17):10079-10086, 1996	
		Vlodavsky et al, "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", <i>Invasion Metastasis</i> , 12:112-127, 1992	
		Ishai-Michaeli et al, "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells Releases Active Fibroblast Growth Factor from Extracellular Matrix", <i>Cell Regulation</i> , 1:833-842, 1990	
		Godder et al, "Heparanase Activity in Cultured Endothelial Cells", <i>J. Cellular Physiology</i> , 148:274-280, 1991	
		Kato et al, "Physiological Degradation Converts the Soluble Syndecan-1 Ectodomain from an Inhibitor to a Potent Activator of FGF-2", <i>Nature Medicine</i> , 4(6):691-697, 1998	
		Ernst et al, "Enzymatic Degradation of Glycosaminoglycans", <i>Critical Rev. in Biochemistry and Mol. Biology</i> , 30(5):387-444, 1995	
		Linhardt et al, "Polysaccharide Lyases", <i>Applied Biochemistry and Biotechnology</i> , 12:135-176, 1986	
		Kosir et al, "Human Prostate Carcinoma Cells Produce Extracellular Heparanase", <i>J. Surgical Res.</i> , 67:98-105, 1997	
		Jin et al, "Immunohistochemical Localization of Heparanase in Mouse and Human Melanomas", <i>Int. J. Cancer</i> , 45:1088-1095, 1990	
		Fairbanks et al, "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", <i>J. Biol. Chem.</i> , 274(42):29587-29590, 1999	
		Hoogewerf et al, "CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparan/Heparan Sulfate-degrading Enzymes", <i>J. Biol. Chem.</i> , 270(7):3268-3277, 1995	
		Ngo et al, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", Chap. 14 from "The Protein Folding Problem and Tertiary Structure Prediction", Merz and LeGrand, Eds., Birkhäuser, Boston, 1994	
		Oldberg et al, "Characterization of a Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides", <i>Biochemistry</i> , 19:5755-5762, 1980	
Examiner Signature	S. Sasisekharan et al	on of heparanase I gene from heparinase from the	Date 10/30/99 1660-2660 Considered April 93

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/341,582		
		Filing Date	01/14/2003		
		First Named Inventor	Ilan et al		
		Group Art Unit	1652		
		Examiner Name			
Sheet	5	Of	4	Attorney Docket Number	25479
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country, where published.			T ²
		Kussie et al, "Cloning and Functional Expression of a Human Heparanase Gene", <i>Biochem. And Biophysical Res. Comm.</i> , 261:183-187, 1999			
		Walch et al, Correlation of Overexpression of the Low-Affinity p75 Neurotrophin Receptor with Augmented Invasion and Heparanase Production in Human Malignant Melanoma Cells", <i>Int. J. Cancer</i> , 82:112-120, 1999			
		Okamoto et al, "Highly Specific and Sensitive Detection of Malignancy in Urine Samples from Patients with Urothelial Cancer by CD44v8-V/CD44v10 Competitive RT-PCR", <i>Int. J. Cancer</i> , 79(6):560-564, 1998 (abstract only)			
		Zhou et al, "A 182 bp Fragment of the Mouse pro α 1(I) Collagen Gene is Sufficient to Direct Chondrocyte Expression in Transgenic Mice", <i>J. Cell Science</i> , 108:3677-3684, 1995			
		Hormuzdi et al, "A Gene-Targeting Approach Identifies a Function for the First Intron in Expression of the Alpha 1(I) Collagen Gene", <i>Mol. Cell Biol.</i> , 18(6):3368-3375, 1998 (abstract only)			
		Kang et al, "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine Beta-Casein Gene". <i>Mol Cells</i> , 8(3):254-265, 1998 (abstract only)			
		Chow et al, "Development of an Epithelium-Specific Expression Cassette with Human DNA Regulatory Elements for Transgene Expression in Lung Airways", <i>Proc. Nat. Acad. Sci. USA</i> , 94:14695-14700, 1997			
		Gottschalk et al, "Somatic Gene Therapy: Present Situation and Future Perspective", <i>Arzneimittelforschung</i> , 48(11):1111-1120, 1998 (Abstract only)			
		Ye et al, "Targeted Gene Correction: A New Strategy for Molecular Medicine", <i>Molecular Medicine Today</i> , Oct. 1998, pp 431-437			
		Lai et al, "Homologous Recombination Based Gene Therapy", <i>Exp Nephrol</i> , 7(1):11-14, 1999 (abstract only)			
		Yazaki et al, "The structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissue", <i>Biochemica et Biophysica Acta</i> , 1172:37-42, 1993			
		Le Fur et al, "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", <i>Proc. Natl. Acad. Sci. USA</i> , 94:5332-5337, 1997			
		Gahiec et al, "CD44 Isoforms with Exon v6 and Metastasis of Primary N0M0 Breast Carcinomas", <i>Breast Cancer Res Treat</i> , 44(3):261-268, 1997 (abstract only)			
		Gewirtz et al, "Nucleic Acid Therapeutics: State of the Art and Future Prospects", <i>Blood</i> , 92(3):712-736, 1998			
		Hida et al, "Antisense E1AF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities", <i>Am J Pathol</i> , 50(6):2125-2132, 1997 (abstract only)			
		Shastry, BS, "Gene Disruption in Mice: Models of Development and Disease", <i>Molecular and Cellular Biochemistry</i> , 181:163-179, 1998			
Examiner Signature				Date Considered	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/341,582
		Filing Date	01/14/2003
		First Named Inventor	Ilan et al
		Group Art Unit	1652
		Examiner Name	
Sheet	1	OF	4
		Attorney Docket Number	25449
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Carpentier et al, "DNA Vaccination with HuD Inhibits Growth of a Neuroblastoma in Mice", <i>Clinical Cancer Research</i> , 4:2819-2824, 1998	
		Lai, et al, "DNA Vaccines", <i>Critical Reviews in Immunology</i> , 18:449-484, 1998	
		Marchetti et al, "Neurotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", <i>Cancer Research</i> , 56:2856-2863, 1996	
		DeVouge et al, Immunoselection of GRP94/Endoplasmic Reticulum from a KNRK Cell-Specific λ gt10 Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", <i>Int. J. Cancer</i> , 56:286-294, 1994	
		Marchetti et al, "Neurotrophin Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", <i>Advances in Enzyme Regulation</i> , 37:111-134, 1997	
		Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", <i>Biochem.</i> , 327:917-923, 1997	
		Freeman et al, "Evidence that Platelet and Tumour Heparanases are Similar Enzymes", <i>Biochem. J.</i> , 342:361-368, 1999	
		Hulett et al, "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis", <i>Nature Medicine</i> , 5(7):803-809, 1999	
		Vlodavsky et al, "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", <i>Nature Medicine</i> , 5(7):793-802, 1999	
		Toyoshima et al, "Human Heparanase", <i>J. Biol. Chem.</i> , 274(34):24153-24160, 1999	
		Korb et al, "Stimulation of Gene Expression by Introns: Conversion of an Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Donor Sequence", <i>Nucleic Acids Research</i> , 21(25):5901-5908, 1993	
		Faber-Elman et al, "Involvement of Wound-associated Factors in Rat Brain Astrocyte Migratory Response to Axonal Injury: In Vitro Simulation", <i>J. Clin. Invest.</i> , 97(1):162-171, 1996	
		Durand et al, "Active-Site Motifs of Lysosomal Acid Hydrolases: Invariant Features of Class GH-A Glycosyl Hydrolases Deduced from Hydrophobic Cluster Analysis", <i>Glycobiology</i> , 7(2):277-284, 1997	
		Shekhar et al, "Correlation of Differences in Modulation of <i>ras</i> Expression with Metastatic Competence of Mouse Mammary Tumor Subpopulations", <i>Invasion Metastasis</i> , 14:27-37, 1994-5	
		Kurachi et al, "Role of Intron 1 in Expression of the Human Factor IX Gene", <i>J. Biological Chemistry</i> , 270(10):5276-5281, 1995	
		Zheng et al, "Increment of hFIX Expression with Endogenous Intron 1 <i>in vitro</i> ", <i>Cell Res.</i> , 7(1):21-9, 1997 (Abstract)	
		Welch et al, "Expression of Ribozymes in Gene Transfer Systems to Modulate Target RNA Levels", <i>Curr Opin Biotechnol</i> , 9(5):486-496, 1998 (Abstract)	
Examiner Signature			Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
This collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/163,997
Filing Date	June 7, 2002
First Named Inventor	Yacobi-Zeevi
Group Art Unit	1652
Examiner Name	
Attorney Docket Number	02/23884

Sheet 2 of 6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume/issue number(s) publisher, city and/or country where published.	P ²
	AD	"The Merck Manual", R. Berkow, M.D. Ed-in-Chief, Merck Research Laboratories, 1997, pp 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 661.	
	AE	Konstan et al, "Patterns of Medical Practice in Cystic Fibrosis: Part III. Use of Therapies", <i>Pediatr Pulmonol</i> , 1999, Oct; 28(4):248-54 (Abstract)	
	AF	Frederiksen et al, "Antibiotic Treatment of Initial Colonization with Pseudomonas Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary Function in Cystic Fibrosis", <i>Pediatr Pulmonol</i> , 1997 May; 23(5):330-335 (Abstract)	
	AG	Frederiksen et al, "Changing Epidemiology of Pseudomonas Aeruginosa Infection in Danish Cystic Fibrosis Patients (1974-1995)", <i>Pediatr Pulmonol</i> , 1999 Sep; 28(3):159-166 (Abstract)	
	AH	Ramsey et al, "Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", <i>N. Eng. J. Med.</i> , 1999 Jan 7; 340(1):23-30 (Abstract)	
	AI	Matzner et al, "Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by a Readily Released Heparanase from Human Neutrophils. Possible Role in Invasion Through Basement Membranes", <i>J. Clin. Invest.</i> , 1985 Oct; 76(4):1306-1313 (Abstract)	
	AJ	Bennett et al, "Effect of Uridine 5'-Triphosphate plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", <i>Am J Respir Crit Care Med</i> , 1996 Jun; 153(6 Pt 1):1796-1801 (Abstract)	
	AK	Vlodavsky et al, "Expression Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", <i>Invasion Metastasis</i> , 1992; 12(2):112-127 (Abstract)	
	AL	Naparstek et al, "Activated T Lymphocytes Produce a Matrix-Degrading Heparan Sulphate Endoglycosidase", <i>Nature</i> , 1984 July 19-25; 310(5974):241-244 (Abstract)	
	AM	Armstrong et al, "Lower Airway Inflammation in Infants and Young Children with Cystic Fibrosis", <i>Am J Respir Crit Care Med</i> , 1997 Oct; 156(4 Pt 1):1197-1204 (Abstract)	
	AN	Tang et al, "Contribution of Specific Pseudomonas Aeruginosa Virulence Factors to Pathogenesis of Pneumonia in a Neonatal Mouse Model of Infection", <i>Infect Immun</i> , 1996 Jan; 64(1):37-43 (Abstract)	
	AO	Murray et al, "The Extracellular Matrix", found in Harper's Biochemistry, 24 th Ed., McGraw-Hill Professional 1998, Chap. 57, pp 667-679	
	AP	Selvan et al, "Heparan Sulfate in Immune Responses", <i>Annals New York Academy of Sciences</i> , 797:127-139, 1996	

Examiner
Signature

Date
Considered

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/165,993
Filing Date	June 7, 2002
First Named Inventor	Yacobi Zeevi
Group An Unit	1657
Examiner Name	
Attorney Docket Number	02/23884

Sheet 3 of 6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume, issue number(s), publisher, city and/or country where published.	T ²
	AQ	Weller, Peter H., "Implications of Early Inflammation and Infection in Cystic Fibrosis: A Review of New and Potential Interventions", <i>Pediatric Pulmonology</i> , 24:143-146, 1997	
	AR	Konstan, Michael W., "Current Understanding of the Inflammatory Process in Cystic Fibrosis", <i>Pediatric Pulmonology</i> , 24:137-142, 1997	
	AS	Rubin, Bruce K., "Emerging Therapies for Cystic Fibrosis Lung Disease", <i>Chest</i> , 115:1126-1126, 1999	
	AT	Marty et al, "Influence of Nutrient Media on the Chemical Composition of Exopolysaccharide from Mucoid and Non-Mucoid Pseudomonas Aeruginosa", <i>FEMS Microbiol Lett</i> , 1992 Nov 1; 77(1-3):35-44 (Abstract)	
	AU	Pasquier et al, "Implication of Neutral Polysaccharides Associated to Alginate Inhibition of Murine Macrophage Response to Pseudomonas Aeruginosa", <i>FEMS Microbiol Lett</i> , 1997 Feb 15; 147(2):195-202 (Abstract)	
	AV	Drigues et al, "Comparative Studies of Lipopolysaccharide and Exopolysaccharide From a Virulent Strain of Pseudomonas Solanacearum and for Three Avirulent Mutants", <i>J Bacteriol</i> , 1985 May; 162(2):504-509 (Abstract)	
	AW	Jorba et al, "Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars (author's transl)", <i>Rev Esp Fisiol</i> , 1980 Jun; 36(2):155-161 (Abstract)	
	AX	Ramos et al, "Relationship Between Glycosis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", <i>Appl Environ Microbiol</i> , 2001 Jan; 67(1):33-41 (Abstract)	
	AY	Bhaskar et al, "Dysregulation of Proteoglycan Production by Intrahepatic Epithelial Cells Bearing Defective (delta-f508) Cystic Fibrosis Transmembrane Conductance Regulator", <i>Hepatology</i> , 1998 Jan; 27(1):7-14 (Abstract)	
	AZ	Vogel et al, "Production Of Proteoglycans By Human Lung Fibroblasts (IMR-90) Maintained In A Low Concentration Of Serum", <i>Biochem J</i> 1982 Dec 1; 207(3):369-379. (Abstract)	
	BA	Hill et al, "Organ-Specific Over-Sulfation Of Glycosaminoglycans And Altered Extracellular Matrix In A Mouse Model Of Cystic Fibrosis", <i>Biochem Mol Med</i> , 1997 Oct; 62(1):113-22. (Abstract)	
	BB	Welch et al, "Complex Saccharide Metabolism In Cystic Fibrosis Fibroblasts", <i>Pediatr Res</i> , 1975 Sep; 9(9):698-702. (Abstract)	
	BC	Rahmoune et al, "Chondroitin Sulfate In Sputum From Patients With Cystic Fibrosis and Chronic Bronchitis", <i>Am J Respir Cell Mol Biol</i> , 1991 Oct; 5(4):315-20. (Abstract)	

Examiner
Signature

Date
Considered

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/163,993
Filing Date	June 7, 2002
First Named Inventor	Yacoby Zeevi
Group Art Unit	1652
Examiner Name	
Attorney Docket Number	02/23884

Sheet 1 of 5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume/issue number(s), publisher, city and/or country where published.
	BD	Beuth et al, "Lectin-Mediated Bacterial Adhesion To Human Tissue", <i>Eur J Clin Microbiol</i> , 1987 Oct;6(5):591-3. (Abstract)
	BE	Allison et al, "Polysaccharide Production in <i>Pseudomonas Cepacia</i> ", <i>J Basic Microbiol</i> , 1994; 34(1):3-10 (Abstract)
	BF	Albus et al, "Staphylococcus Aureus Capsular Types And Antibody Response To Lung Infection In Patients With Cystic Fibrosis", <i>J Clin Microbiol</i> , 1988 Dec; 26(12):2505-9. (Abstract)
	BG	Macone et al, "Mucoïd <i>Escherichia Coli</i> In Cystic Fibrosis". <i>N Engl J Med</i> , 1981 Jun 11;304(24):1445-9. (Abstract)
	BH	Golberg et al, "An Improved Method For Determining Proteoglycans Synthesized by Chondrocytes in Culture", <i>Connective Tissue Research</i> , 24:265-275, 1990
	BI	Farnside et al, "A Direct Spectrophotometric Microassay for Sulfated Glycosaminoglycans in Cartilage Cultures", <i>Connective Tissue Research</i> , 9:247-248, 1982
	BJ	Sutherland, Ian W., "Structure-Function Relationships in Microbial Exopolysaccharides", <i>Biotech Adv.</i> , 12:393-448, 1994
	BK	Tatnell et al, "Characterisation of Alginate from Mucoïd Strains of <i>Pseudomonas Aeruginosa</i> ", <i>Biochem. Soc. Trans.</i> , 24:404S, 1996
	BL	Tatnell et al, "Chemical Analysis of Alginate from Mucoïd Strains of <i>Pseudomonas Aeruginosa</i> ", <i>Biochem. Soc. Trans.</i> , 22:310S, 1994
	BM	Tatnell et al, "Colonisation of Cystic Fibrosis Patients by Non-Mucoïd <i>Pseudomonas Aeruginosa</i> - Characterisation of the Alginate from Mucoïd Variants", <i>Biochem. Soc. Trans.</i> , 24:406S, 1996
	BN	P. Dury et al., "The Osteoblast: A Sophisticated Fibroblast under Central Surveillance", <i>Science</i> , Vol. 289, September 1, 2000, pp. 1501 - 1504
	BO	Figues et al, "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of <i>Pseudomonas Solanacearum</i> and from Three Avirulent Mutants", <i>J Bacteriology</i> , May, 1985, pp 504-509
	BP	Macone et al, "Mucoïd <i>Escherichia Coli</i> in Cystic Fibrosis". <i>New England J Medicine</i> , 304(24):1445-1449
	BQ	Ofek et al, "Bacterial Adhesion to Cells and Tissue", Chapman & Hall, N.Y., Pub. 1994, pp 114-118, 148-153, 418-418, 420-423

Examiner Signature:		Date Considered	
---------------------	--	-----------------	--

Please type a plus sign (+) inside this box → ☐

PT(USB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/163,993
Filing Date	June 7, 2002
First Named Inventor	Yacoby-Zeevi
Group Art Unit	1552
Examiner Name	
Attorney Docket Number	G2/23884

Sheet 5 of 6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BR	Reddi, A. Hari, "Role of Morphogenetic Proteins in Skeletal Tissue Engineering and Regeneration", <i>Nature Biotechnology</i> , Vol. 16, March 1998, pp. 247 - 252
	BS	L.A. Dempsey et al., "Heparanase, A Potential Regulator of Cell-Matrix Interactions", <i>Trends in Biochem Sci</i> , 25:349-351, 2000
	BT	Elkin et al., "Heparanase as Mediator of Angiogenesis; mode of action", <i>The FASEB Journal</i> , 15: 1661-1663, 2001
	BU	Elkin et al., "Heparanase as Mediator of Angiogenesis; mode of action", <i>The FASEB Journal</i> , Published online May 29, 2001
	BV	E. Finkel, "Potential Target Found for Antimetastasis Drugs", <i>Science</i> , Vol. 285, July 2, 1999, pp. 33 - 34
	BW	I. Vlodavsky, et al., "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", <i>Nature Medicine</i> , Vol. 5, No. 7, July 1999, pp. 793 - 802
	BX	Webster et al., "FGFR Activation in Skeletal Disorders: too much of a good thing", <i>TIG</i> , May 1997, Vol. 13, No. 5, pp. 178 - 182
	BY	Prockop, D.J., "Marow Stromal Cells as Stem Cells for Nonhematopoietic Tissues", <i>Science</i> , Vol. 276, 4 April 1997, pp. 71 - 74
	BZ	Shmazu, et al., "Syndecan-3 and the control of chondrocyte proliferation during endochondral ossification", <i>Exp. Cell. Res.</i> 1996 Nov. 25:229:1, pp. 126 - 136 (Abstract)
	CA	F. Blanquaert et al., "CMDBS, functional analogs of sulfate heparanes, used as osseous cicatrizing agents", <i>Ann. Endocrinol (Paris)</i> 1994 56:2 pp. 121 - 123 Abstract
	CB	F. Blanquaert et al., "Heparan-like molecules induce the repair of skull defects", <i>Bone</i> 1995, December 17:6 pp. 499 - 506 (Abstract)
	CC	Muir et al., "Histomorphometric Analysis of the Effects of Standard Heparin on Trabecular Bone <i>in vivo</i> ", <i>Endocr.</i> August 15, 1996:88(4):1314 - 1320 (Abstract)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

File Copy

• Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14-19A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/988,113
--------------------	------------

Filing Date	March 1, 1999
-------------	---------------

First Named Inventor	Pecker et al
----------------------	--------------

Group Art Unit	1652
----------------	------

Examiner Name	Holson, Richard
---------------	-----------------

Attorney Docket Number 01/22781

Sheet	1
-------	---

of 3

3

Attorney Docket Number 01/22781

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiners Initials	Cite No.	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	76
		Office	Number	Kind Code (if known)				
		WO	95/04158		Hoogwerf et al	02-09-1995		
Examiner Signature						Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/988,113
		Filing Date	March 1, 1999
		First Named Inventor	Pecker et al
		Group Art Unit	1652
		Examiner Name	Hutson, Richard G.
Sheet 2 of 3	Attorney Docket Number		01/22781
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Ernst et al, "Enzymatic Degradation of Glycosaminoglycans", <i>Critical Rev. in Biochemistry and Mol. Biology</i> , 30(5):387-444, 1995	
		Linhardt et al, "Polysaccharide Lyases", <i>Applied Biochemistry and Biotechnology</i> , 12:135-136, 1986	
		Kosir et al, "Human Prostate Carcinoma Cells Produce Extracellular Heparanase", <i>J. Surgical Res.</i> , 67:98-105, 1997	
		Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", <i>Biochem.</i> , 327:917-923, 1997	
		DeVouge et al, "Immunoselection of GRP94/Endoplasmic Reticulum from a KNRK Cell-Specific λ gt11 Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", <i>Int. J. Cancer</i> , 56:286-294, 1994	
		Marchetti et al, "Neutrophil Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", <i>Cancer Research</i> , 56:2856-2863, 1996	
		Marchetti et al, "Neutrophil Stimulation of Human Melanoma Cell Invasion: Selected Enhancement of Heparanase Activity and Heparanase Degradation of Specific Heparan Sulfate Subpopulations", <i>Advances in Enzyme Regulation</i> , 37:111-134, 1997	
		Jin et al, "Immunohistochemical Localization of Heparanase in Mouse and Human Melanomas", <i>Int. J. Cancer</i> , 45:1088-1095, 1990	
		Fairbanks et al, "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", <i>J. Biol. Chem.</i> , 274(42):29587-29590, 1999	
		Toyoshima et al, "Human Heparanase", <i>J. Biol. Chem.</i> , 274(34):24153-24160, 1999	
		Hoogewerf et al, "CXCL Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparan/Heparan Sulfate-Degrading Enzymes", <i>J. Biol. Chem.</i> , 270(7):3268-3277, 1995	
		Freeman et al, "Evidence that Platelet and Tumor Heparanases are Similar Enzymes", <i>Biochem. J.</i> , 342:361-368, 1999	
		Vlodavsky et al, "Mammalian Heparanase: Gene Cloning, Expression and Function in Tumor Progression and Metastasis", <i>Nature Medicine</i> , 5(7):793-802, 1999	
		Hallett et al, "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis", <i>Nature Medicine</i> , 5(7):803-809, 1999	
		Ngo et al, "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", Chap. 14 from <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz and LeGrand, Eds., Birkhäuser, Boston, 1994	
		Oldberg et al, "Characterization of a Platelet Endoglycosidase Degrading Heparin-Like Polysaccharides", <i>Biochemistry</i> , 19:5755-5762, 1980	
		Kussie et al, "Cloning and Functional Expression of a Human Heparanase Gene", <i>Biochem. And Biophysical Res. Comm.</i> , 261:183-187, 1999	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form: 1449A PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/988,113
Filing Date	March 1, 1999
First Named Inventor	Pecker et al
Group Art Unit	1652
Examiner Name	Hutson, Richard G.
Attorney Docket Number	01/22781

Sheet 3 of 3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Walch et al, Correlation of Overexpression of the Low-Affinity p75 Neurotrophin Receptor with Augmented Invasion and H-paranase Production in Human Malignant Melanoma Cells", <i>Int. J. Cancer</i> , 82:112-120, 1999	
		Okamoto et al, "Highly Specific and Sensitive Detection of Malignancy in Urine Samples from Patients with Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", <i>Int. J. Cancer</i> , 79(6):560-564, 1998 (abstract only)	
		Zhou et al, "A 182 bp Fragment of the Mouse pro α 1(11) Collagen Gene is Sufficient to Direct Chondrocyte Expression in Transgenic Mice", <i>J. Cell Science</i> , 108:3677-3684, 1993	
		Horrouzdi et al, "A Gene-Targeting Approach Identifies a Function for the First Intron in Expression of the Alpha 1(I) Collagen Gene", <i>Mol. Cell Biol.</i> , 18(6):3368-3375, 1998 (abstract Only)	
		Kang et al, "Prolactin-Inducible Enhancer Activity of the First Intron of the Bovine Beta-Casein Gene", <i>Mol Cells</i> , 8(3):259-265, 1998 (abstract only)	
		Chow et al, "Development of an Epithelium-Specific Expression Cassette with Human DNA Regulatory Elements for Transgene Expression in Lung Airways", <i>Proc. Nat. Acad. Sci. USA</i> , 94:14695-14700, 1997	
		Gottschalk et al, "Somatic Gene Therapy: Present Situation and Future Perspective", <i>Arzneimittelforschung</i> , 48(11):1111-1120, 1998 (Abstract only)	
		Ye et al, "Targeted Gene Correction: A New Strategy for Molecular Medicine", <i>Molecular Medicine Today</i> , Oct. 1998, pp 431-432	
		Lai et al, "Homologous Recombination Based Gene Therapy", <i>Exp Nephrol</i> , 7(1):11-14, 1999 (abstract only)	
		Yazaki et al, "The structure and Expression of the FGF Receptor-1 mRNA Isoforms in Rat Tissue", <i>Biochemica et Biophysica Acta</i> , 1172:37-42, 1993	
		Le Fur et al, "Selective Increase in Specific Alternative Splice Variants of Tyrosinase in Murine Melanomas: A Projected Basis for Immunotherapy", <i>Proc. Natl. Acad. Sci. USA</i> , 94:5332-5337, 1997	
		Guriec et al, "CD44 Isoforms with Exon v6 and Metastasis of Primary NOMO Breast Carcinomas", <i>Breast Cancer Res Treat</i> , 44(3):261-268, 1997	
		Gewirtz et al, "Nucleic Acid Therapeutics: State of the Art and Future Prospects", <i>Blood</i> , 92(3):712-736, 1998	
		Hida et al, "Antisense E1AF Transfection Restrains Oral Cancer Invasion by Reducing Matrix Metalloproteinase Activities", <i>Am J Pathol</i> , 50(6):2125-2132, 1997 (abstract only)	
		Shastry, BS, "Gene Disruption in Mice: Models of Development and Disease", <i>Molecular and Cellular Biochemistry</i> , 181:163-179, 1998	
		Carpentier et al, "DNA Vaccination with HuD Inhibits Growth of a Neuroblastoma in Mice", <i>Clinical Cancer Research</i> , 4:2819-2824, 1998	
		Lai, et al, "DNA Vaccines", <i>Critical Reviews in Immunology</i> , 18:449-484, 1998	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.
Burden Hour Statement: This form is estimated to take 2.3 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

(10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

Sheet	1	Of	4
-------	---	----	---

Application Number	09/978,297
Filing Date	10/17/2001
First Named Inventor	Yacobi-Zeevi
Group Art Unit	1633
Examiner Name	
Attorney Docket Number	04/22716

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. In this form with next communication to applicant

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3

Origine creation designateur number. See attached kind of U.S. Patent documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/978,297
		Filing Date	10/17/2001
		First Named Inventor	Yacobi-Zeevi
		Group Art Unit	1633
		Examiner Name	
Sheet 1	Of 4	Attorney Docket Number	01/22716
OTHER PRIOR ART - NON PATENT ¹ LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	T ²	
	BA	"The Merck Manual", R. Berkow, M.D. Ed-in-Chief, Merck Research Laboratories, 1991, pp 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601.	
	BB	Konstan et al, "Patterns of Medical Practice in Cystic Fibrosis: Part III. Use of Therapies", <i>Pediatr Pulmonol</i> , 1999, Oct; 28(4):248-54 (Abstract)	
	BC	Frederiksen et al, "Antibiotic Treatment of Initial Colonization with Pseudomonas Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary Function in Cystic Fibrosis", <i>Pediatr Pulmonol</i> , 1997 May; 23(5):330-335 (Abstract)	
	BD	Frederiksen et al, "Changing Epidemiology of Pseudomonas Aeruginosa infection in Danish Cystic Fibrosis Patients (1974-1995)", <i>Pediatr Pulmonol</i> , 1999 Sep; 28(3):159-166 (Abstract)	
	BE	Ramsey et al, "Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", <i>N. Eng. J. Med.</i> , 1999 Jan 7; 340(1):23-30 (Abstract)	
	BF	Matzner et al, "Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by a Readily Released Heparanase from Human Neutrophils. Possible Role in Invasion Through Basement Membranes", <i>J. Clin. Invest.</i> , 1985 Oct; 76(4):1306-1313 (Abstract)	
	BG	Bennett et al, "Effect of Uridine 5'-Triphosphate plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", <i>Am J Respir Crit Care Med</i> , 1996 Jun; 153(6 Pt 1):1796-1801 (Abstract)	
	BH	Vlodavsky et al, "Expression Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", <i>Invasion Metastasis</i> , 1992; 12(2):112-127 (Abstract)	
	BI	Naparstek et al, "Activated T Lymphocytes Produce a Matrix Degrading Heparan Sulphate Endoglycosidase", <i>Nature</i> , 1984 July 19-25; 310(5974):241-244 (Abstract)	
	BJ	Armstrong et al, "Lower Airway? Inflammation in Infants and Young Children with Cystic Fibrosis", <i>Am J Respir Crit Care Med</i> , 1997 Oct; 156(4 Pt 1):1197-1204 (Abstract)	
	BK	Tang et al, "Contribution of Specific Pseudomonas Aeruginosa Virulence Factors to Pathogenesis of Pneumonia in a Neonatal Mouse Model of Infection", <i>Infect Immun</i> , 1996 Jan; 64(1):37-43 (Abstract)	
	BL	Murray et al, "The Extracellular Matrix", found in Harper's Biochemistry, 24 th Ed., McGraw-Hill Professional 1998, Chap. 57, pp 667-679	
	BM	Selvan et al, "Heparan Sulfate in Immune Responses", <i>Annals New York Academy of Sciences</i> , 797:127-139, 1996	
	BN	Weller, Peter H., "Implications of Early Inflammation and Infection in Cystic Fibrosis: A Review of New and Potential Interventions", <i>Pediatric Pulmonology</i> , 24:143-146, 1997	
Examiner Signature	Date Considered		

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered in this form with next communication to applicant.

²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3

⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/978,297		
		Filing Date	10/17/2001		
		First Named Inventor	Yacobi Zeevi		
		Group Art Unit	1623		
		Examiner Name			
Sheet	3	Of	4	Attorney Docket Number	01/22716
✓	DA	Golberg et al, "An Improved Method For Determining Proteoglycans Synthesized by Chondrocytes in Culture", <i>Connective Tissue Research</i> , 24:265-273, 1990			
✓	DB	Farnsdale et al, "A Direct Spectrophotometric Microassay for Sulfated Glycosaminoglycans in Cartilage Cultures", <i>Connective Tissue Research</i> , 9:247-248, 1982			
✓	DC	Sutherland, Ian W., "Structure-Function Relationships in Microbial Exopolysaccharides", <i>Biotech Adv.</i> , 12:393-408, 1994			
✓	DD	Tatnell et al, "Characterisation of Alginates from Mucoid Strains of <i>Pseudomonas Aeruginosa</i> ", <i>Biochem. Soc. Trans.</i> , 24:404S, 1996			
✓	DE	Tatnell et al, "Chemical Analysis of Alginates from Mucoid Strains of <i>Pseudomonas Aeruginosa</i> ", <i>Biochem. Soc. Trans.</i> , 22:310S, 1994			
✓	DF	Tatnell et al, "Colonisation of Cystic Fibrosis Patients by Non-Mucoid <i>Pseudomonas Aeruginosa</i> - Characterisation of the Alginate from Mucoid Variants", <i>Biochem. Soc. Trans.</i> , 24:406S, 1996			
✓	DG	Drigues et al, "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of <i>Pseudomonas Soiznacearum</i> and from Three Avirulent Mutants", <i>J Bacteriology</i> , May, 1985, pp 504-509			
✓	DH	Maccone et al, "Mucoid <i>Escherichia Coli</i> in Cystic Fibrosis", <i>New England J Medicine</i> , 304(24):1444S-1449			
✓	DI	Ofek et al, "Bacterial Adhesion to Cells and Tissue", Chapman & Hall, N.Y., Pub. 1994, pp 114-118, 148-153, 418-418, 420-423			
	DJ				
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. In this form with next communication to applicant.

1. Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

Worden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/978,297
(use as many sheets as necessary)				Filing Date	10/17/2001
				First Named Inventor	Yacobi-Zeeh
				Group Art Unit	1633
				Examiner Name	
Sheet	1	Of	4	Attorney Docket Number	01/22716
	CA	Konstan, Michael W., "Current Understanding of the Inflammatory Process in Cystic Fibrosis", <i>Pediatric Pulmonology</i> , 24:137-142, 1997			
	CB	Robin, Bruce K., "Emerging Therapies for Cystic Fibrosis Lung Disease", <i>Chest</i> , 115:1120-1126, 1999			
✓	CD	Pasquier et al, "Implication of Neutral Polysaccharides Associated to Alginate Inhibition of Murine Macrophage Response to <i>Pseudomonas Aeruginosa</i> ", <i>FEMS Microbiol Lett</i> , 1997 Feb 15; 147(2):195-201 (Abstract)			
✓	CE	Marty et al, "Influence of Nutrient Media on the Chemical Composition of Exopolysaccharide from Mucoid and Non-Mucoid <i>Pseudomonas Aeruginosa</i> ", <i>FEMS Microbiol Lett</i> , 1992 Nov 1; 77(1-3):35-44 (Abstract)			
✓	CF	Drigues et al, "Comparative Studies of Lipopolysaccharide and Exopolysaccharide From a Virulent Strain of <i>Pseudomonas Solanacearum</i> and for Three Avirulent Mutants", <i>J Bacteriol</i> , 1985 May; 162(2):504-509 (Abstract)			
✓	CG	Jorba et al, "Variations in the <i>P. Aeruginosa</i> Polysaccharide Synthesis Conditioned by Aminosugars (author's transl)", <i>Rev Esp Fisiol</i> , 1980 Jun; 36(2):155-161 (Abstract)			
✓	CH	Ramos et al, "Relationship Between Glycosyls and Exopolysaccharide Biosynthesis in <i>Lactococcus Lactis</i> ", <i>Appl Environ Microbiol</i> , 2001 Jan; 67(1):33-41 (Abstract)			
✓	CI	Bhaskar et al, "Dysregulation of Proteoglycan Production by Intrahepatic Epithelial Cells Bearing Defective (delta-f508) Cystic Fibrosis Transmembrane Conductance Regulator", <i>Hepatology</i> , 1998 Jan; 27(1):7-14 (Abstract)			
✓	CJ	Vogel et al, "Production Of Proteoglycans By Human Lung Fibroblasts (IMR-90) Maintained In A Low Concentration Of Serum", <i>Biochem J</i> 1982 Dec 1; 207(3):369-379. (Abstract)			
✓	CK	Hill et al, "Organ-Specific Over-Sulfation Of Glycosaminoglycans And Altered Extracellular Matrix In A Mouse Model Of Cystic Fibrosis", <i>Biochem Mol Med</i> , 1997 Oct; 62(1):173-22. (Abstract)			
✓	CL	Welch et al, "Complex Saccharide Metabolism In Cystic Fibrosis Fibroblasts", <i>Pediatr Res</i> , 1975 Sep; 9(9):698-702. (Abstract)			
✓	CM	Rahmouni et al, "Chondroitin Sulfate In Sputum From Patients With Cystic Fibrosis And Chronic Bronchitis", <i>Am J Respir Cell Mol Biol</i> , 1991 Oct; 5(4):315-20. (Abstract)			
✓	CN	Bauth et al, "Lectin-Mediated Bacterial Adhesion To Human Tissue", <i>Eur J Clin Microbiol</i> , 1987 Oct; 6(5):591-3. (Abstract)			
✓	CO	Allison et al, "Polysaccharide Production in <i>Pseudomonas Cepacia</i> ", <i>J Basic Microbiol</i> , 1994; 34(1):3-10 (Abstract)			
✓	CP	Albus et al, "Staphylococcus Aureus Capsular Types And Antibody Response To Lung Infection In Patients With Cystic Fibrosis", <i>J Clin Microbiol</i> , 1988 Dec; 26(12):2505-9. (Abstract)			
✓	CQ	Maccone et al, "Mucoid <i>Escherichia Coli</i> In Cystic Fibrosis", <i>N Engl J Med</i> , 1981 Jun 11; 304(24):1445-9. (Abstract)			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. In this form with next communication to applicant

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3)

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Form PTO-1449 (Modified)				Atty. Docket No. 910/16		Application No. 09/260,038	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)				Applicant: Maty AYAL-HERSHKOVITZ et al			
				Filing Date: March 2, 1999		Group Art Unit: 1652	
U.S. PATENT DOCUMENTS							
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AA							
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO
AB							
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
AC	mmr	Burgess et al, "The Heparin Binding (Fibroblast) Growth Factor Family of Proteins", <i>Annu Rev Biochem</i> , 58:575-606, 1989					
AD		Campbell et al, "Heparan Sulfate Degrading Enzymes Induce Modulation of Smooth Muscle Phenotype". <i>Experimental Cell Research</i> , 20:156-167, 1992					
AE		Gordon-Cardo et al, "Expression of Basic Fibroblast Growth Factor in Normal Human Tissues", <i>Laboratory Investigation</i> , 63:832-840, 1990					
AF		Eisenberg et al, "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan Sulfate on Cell Surface and Extracellular Matrix" <i>J. Clin. Invest.</i> , 90:2013-2021, 1992					
AG		Folkman et al, "A Heparin-Binding Angiogenic Protein-Basic Fibroblast Growth Factor-Is Stored Within Basement Membrane", <i>Am. J. Pathol.</i> , 130(2):393-400, 1988					
AH		Folkman et al, "Angiogenic Factors", <i>Science</i> , 235:442-447, 1987					
AI		Gitay-Goren et al, "The Binding of Vascular Endothelial Growth Factor to its Receptors is Dependent on Cell Surface-Associated Heparin-Like Molecules", <i>J. Biol. Chem.</i> , 267(8):6093-6098, 1992					
AJ		Ishai-Michaeli et al, "Importance of Size and Sulfation of Heparin in Release of Basic Fibroblast Growth Factor from the Vascular Endothelium and Extracellular Matrix", <i>Biochemistry</i> , 31:2080-2088, 1992					
AK		Jackson et al, "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", <i>Physiological Rev</i> , 71(2):481-539, 1991					
AL		Kjell��n et al, "Proteoglycans: Structures and Interactions", <i>Annu Rev Biochem</i> , 60:443-475, 1991					
AM		Liotta et al, "Tumor Invasion and the Extracellular Matrix", <i>Laboratory Investigation</i> , 49(6):636-647, 1983					
AN		Matzner et al, "Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by a Readily Released Heparanase from Human Neutrophils", <i>J. Clin Invest</i> , 76:1306-1313					
AO	mmr	Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes: Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", <i>Biochem J.</i> , 327:917-923, 1997					
EXAMINER				DATE CONSIDERED			
mmr				11/20/00			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Atty. Docket No.
910/26Application No.
09/487,716INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)Applicant:
Maty AYAL-HERSHKOVITZ et alFiling Date:
January 19, 2000

Group Art Unit

MAY 25 2000

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AA							

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
AB							

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	<i>mmr</i>	Burgess et al, "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins", <i>Annu Rev Biochem</i> , 58:575-606, 1989
AD		Campbell et al, "Heparan Sulfate-Degrading Enzymes Induce Modulation of Smooth Muscle Phenotype", <i>Experimental Cell Research</i> , 204:156-167, 1992
AE		Gordon-Cardo et al, "Expression of Basic Fibroblast Growth Factor in Normal Human Tissues", <i>Laboratory Investigation</i> , 63:832-840, 1990
AF		Eisenberg et al, "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan Sulfate on Cell Surface and Extracellular Matrix" <i>J. Clin. Invest.</i> 90:2013-2021, 1992
AG		Folkman et al, "A Heparin-Binding Angiogenic Protein-Basic Fibroblast Growth Factor-Is Stored Within Basement Membrane", <i>Am. J. Path.</i> , 130(2):393-400, 1988
AH		Folkman et al, "Angiogenic Factors", <i>Science</i> , 235:442-447, 1987
AI		Gitay-Goren et al, "The Binding of Vascular Endothelial Growth Factor to its Receptors is Dependent on Cell Surface-Associated Heparin-Like Molecules", <i>J. Biol. Chem.</i> , 267(8):6093-6098, 1992
AJ		Ishai-Michaeli et al, "Importance of Size and Sulfation of Heparin in Release of Basic Fibroblast Growth Factor from the Vascular Endothelium and Extracellular Matrix", <i>Biochemistry</i> , 31:2080-2088, 1992
AK		Jackson et al, "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", <i>Physiological Rev</i> , 71(2):481-539, 1991
AL		Kjellen et al, "Proteoglycans: Structures and Interactions", <i>Annu Rev Biochem</i> , 60:443-475, 1991
AM		Motta et al, "Tumor Invasion and the Extracellular Matrix", <i>Laboratory Investigation</i> , 49(6):636-647, 1983
AN		Matzner et al, "Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by a Readily Released Heparanase from Human Neutrophils", <i>J. Clin Invest</i> , 76:1306-1313
AO	<i>mmr</i>	Mollinedo et al, "Major Co-Localization of the Extracellular-Matrix Degradative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", <i>Biochem J.</i> , 327:917-923, 1997

EXAMINER

mmr

DATE CONSIDERED

4/29/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation

Form PTO-1449 (Modified)

Atty. Docket No.
910/26Application No.
09/487,716

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)

Applicant
Maty AYAL-HERSHKOVITZ et alFiling Date:
January 19, 2000

Group Art Unit

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
BA							

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
BB							

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BCC	Narindrasorasak et al, "High Affinity Interactions between the Alzheimer's β -Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", <i>J Biolog Chem</i> , 266(20):12878-12883, 1991
BD	Nakajima et al, "Heparanases and Tumor Metastasis", <i>J Cellular Biochem</i> , 36:157-167, 1988
BE	Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparan-Derived Di- and Trisaccharides", <i>Science</i> , 268:432-436, 1995
BF	Rapraeger et al, "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", <i>Science</i> , 252:1705-1709, 1991
BG	Vlodasky et al, "Lymphoma Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", <i>Cancer Res.</i> , 43: 2704-2711, 1983
BH	Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", <i>Israel J. Med Sci</i> , 24:464-470, 1988
BI	Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-Enriched Remnant Lipoproteins by Cultured Cells", <i>J Biolog Chem</i> , 268(4):10160-10167, 1993
BJ	Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", <i>Molecular and Cellular Aspects of Basement Membranes</i> , Academic Press, Inc. 1993, pp 327-342
BK	Wight, TN, "Cell Biology of Arterial Proteoglycans", <i>Arteriosclerosis</i> , 9:1-20, 1989
BL	
BM	
BN	
BO	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

-1449 (Modified)

Atty. Docket No.

Application No.

09/160,037

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)

Applicant:


Oron YACOBY-ZEEVI et al

Filing Date:

March 2, 1999

Group Art Unit:

1643



U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AA							

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
AB							

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AC		Murry et al, "The Extracellular Matrix", found in "Biochemistry", Chap. 57, pp 667-685
AD	✓	Selvan et al, "Heparan Sulfate in Immune Responses", <i>Ann. NY Acad. Sci.</i> , 777: 127-139, 1996
AE	✓	Wight, TN, "Cell Biology of Arterial Proteoglycans", <i>Arteriosclerosis</i> , 9: 1-20, 1989
AF	✓	Vlodavsky et al, "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", <i>Invasion Metastasis</i> , 12:112-127, 1992
AG	✓	Nakajima et al, "Heparanases and Tumor Metastasis", <i>J. Cell Biochem.</i> , 36(2): 157-167, 1988
AH	✓	Vlodavsky et al, "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species of Heparin", <i>Invasion Metastasis</i> , 14:290-302, 1994-5
AI	✓	Vlodavsky et al, "Extracellular Sequestration and Release of Fibroblast Growth Factor: A Regulatory Mechanism?", <i>Trends Biochem. Sci.</i> , 16: 268-271, 1991
✓	✓	Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", <i>Cell. Molec. Aspects</i> , 1993, Academic Press, Inc. Pp 327-343
AK	✓	Thunberg et al, "The Molecular Size of the Antithrombin-Binding Sequence in Heparin", <i>FEBS Lett.</i> , 117(1): 203-206, 1980
AL		Prockop, DJ, "Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues", <i>Science</i> , 276: 71-74, 1997; Kriegl et al, "Microglia: The Effector cell for reconstitution of the Central Nervous System Following Bone Marrow Transplantation for Lysosomal and Peroxisomal Storage Diseases", <i>Cell Transplant.</i> , 4(4): 385-392, 1995 (Abstract)
AM		Lazarus et al, "Ex Vivo Expansion and Subsequent Infusion of Human Bone Marrow-Derived Stromal Progenitor Cells (Mesenchymal Progenitor cells): Implications for Therapeutic Use", <i>Bone Marrow Transplantation</i> , 16: 557-564, 1995
AN		Robey et al, "Biochemical Characterization of Marrow Stromal Fibroblasts", <i>6th Int'l. Conf. On Molec. Biol. And Pathology of Matrix, Session IV</i> ,
AO		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)Applicant:
Oron YACOBY-ZEEVI et alFiling Date:
March 2, 1999Group Art Unit:
1643

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
BA							

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
BB							

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	Pomahac et al, "Tissue Engineering of Skin", <i>Crit Rev Oral Biol Med</i> , 9(3): 313-344, 1998 (abstract)
BD	Benathan et al, "Living Epidermal and Dermal Substitutes for Treatment of Severely Burned Patients", <i>Rev Med Suisse Romande</i> , 118(2): 149-153, 1998 (Abstract- art in French)
BE	Wang et al, Basic Fibroblast Growth Factor Enhances Bone-Graft Incorporation: Dose and Time Dependence in Rats", <i>J. Orthop Res</i> , 14(2): 316-23, 1996 (abstract)
BF	Duffy et al, "Maximizing Flap Survival in a Prefabrication Model Using Exogenous and Endogenous bFGF: A New Approach", <i>Microsurgery</i> , 17(4): 176-179, 1996 (abstract)
EG	Gamer WL, "Epidermal Regulation of Dermal Fibroblast Activity", <i>Plast Reconstr Surg</i> , 102(1): 135-139, 1998 (abstract)
EH	Raghunath et al, Cultured Epithelial Autografts: Diving from Surgery into Matrix Biology", <i>Pediatr Surg Int</i> , 12(7): 478-483, 1997 (abstract)
BI	Myers et al, "Transplantation of Keratinocytes in the Treatment of Wounds", <i>Am J Surg</i> , 170(1): 75-83, 1995 (abstract)
ES	Kawaja et al, "Employment of Fibroblasts for Gene Transfer: Applications for Grafting into the Central Nervous System", <i>Genet Eng (NY)</i> , 13: 205-220, 1991 (abstract)
EK	Maillard et al, Pre-Treatment with Elastase Improves the Efficiency of Percutaneous Adenovirus-Mediated Gene Transfer to the Arterial Media", <i>Gene Therapy</i> , 5: 1023-1030, 1998
EL	Wang, JS, "Basic Fibroblast Growth Factor for Stimulation of Bone Formation in Osteoinductive or Conductive Implants", <i>Acta Orthop Scand Suppl</i> , 269: 1-33, 1996 (abstract)
BM	Wang, JS, "Basic Fibroblast Growth Factor Infused at Different Times During Bone Graft Incorporation. Titanium Chamber Study in Rats", <i>Acta Orthop Scand</i> , 67(3): 229-236, 1996 (abstract)
BN	Inui et al, "Local Application of Basic Fibroblast Growth Factor Minipellet Induces the Healing of Segmental Bony Defects in Rabbits",
BO	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)

Applicant:
Oron YACOBY-ZEEVI et al

Filing Date:
March 2, 1999

Group Art Unit:
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
CA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
					YES NO
CB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CD	Tabata et al, "Bone Regeneration by Basic Fibroblast Growth Factor Complexed with Biodegradable Hydrogels", <i>Biomaterials</i> , 19(7-9): 807-815, 1998 (abstract)
CE	Aspenberg et al, "Stimulates Bone Formation. Bone Induction Studied in Rats", <i>Acta Orthop Scand</i> , 60(4): 473-476, 1989 (abstract)
CF	Aspenberg et al, "Dose-Dependent Stimulation of Bone Induction by Basic Fibroblast Growth Factor in Rats", <i>Acta Orthop Scand</i> , 62(5): 481-484, 1991 (abstract)
CG	Matoba et al, "Evaluation Of Omental Implantation for Perforated Gastric Ulcer Therapy: Findings in a Rat Model", <i>J Gastroenterol</i> , 31(6): 777-784, 1996 (abstract)
CH	Chleboun et al, "The Development and Enhancement of the Collateral Circulation in an Animal Model of Lower Limb Ischaemia", <i>Aust NZ Surg</i> , 64(3): 202-207, 1994 (abstract)
CI	Aplin, JD, "Adhesion Molecules in Implantation", <i>Rev Reprod</i> , 2(2): 84-93, 1997
CJ	Lessey et al, "Paracrine Signaling in the Endometrium: Integrins and the Establishment of Uterine Receptivity", <i>J Reprod Immunol</i> , 39(1-2): 105-116, 1998 (abstract)
CK	Burrows et al, "Trophoblast Migration During Human Placental Implantation" <i>Hum Reprod Update</i> , 2(4): 307-321, 1996
CL	Bischof et al, "The Regulation of Endometrial and Trophoblastic Metalloproteinases During Blastocyst Implantation", <i>Contracept Fertil Sex</i> , (art in French) 22(1): 48-54, 1994 (abstract)
CM	Smith et al, "Expression of Heparan Sulfate Protoglycan (perlecan) in the Mouse Blastocyst is Regulated During Normal and Delayed Implantation", <i>Dev Biol</i> , 184(1): 38-47, 1997 (abstract)
CN	Abrahamsohn et al, "Implantation and Decidualization in Rodents", <i>J Exp Zoo</i> , 266(6): 603-628, 1993 (abstract)
CO	Goshen et al, "Purification and Characterization of Placental Heparanase and its Expression by Cultured Cytotrophoblasts", <i>Mol. Hum. Repro.</i> , 2(9): 679-684, 1996
CP	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Atty. Docket No.

Application No.

09/250,037

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)

Applicant:
Oron YACOBY-ZEEVI et al

Filing Date:
March 2, 1999

Group Art Unit:
1642

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
DA							

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
DB							

OTHER ART (Including Author, Title, Date, Permanent Pages, Etc.)

	Yoshida, S., "Effects of Basic Fibroblast Growth Factor on the Development of Mouse Preimplantation Embryos", <i>Nippon Sanka Fujinka Gakkai Zasshi</i> , 48(3): 170-176, 1996 (abstract)
DE	Watson et al, "A Growth Factor Phenotype Map for Ovine Preimplantation Development", <i>Biol Reprod</i> , 50(4): 725-733, 1994 (abstract)
DF	Carlone et al, "Embryonic Modulation of Basic Fibroblast Growth Factor in the Rat Uterus", <i>Biol Reprod</i> , 49(4): 653-665, 1993 (abstract)
DG	Wordinger et al, "The Immunolocalization of Basic Fibroblast Growth Factor in the Mouse Uterus During the Initial Stages of Embryo Implantation", <i>Growth Factors</i> , 11(3): 171-186, 1994 (abstract)
DH	Schultz et al, "Growth Factors in Preimplantation Mammalian Embryos", <i>Oxf Rev Reprod Biol</i> , 15: 43-81, 1993 (abstract)
DI	Freeman et al, "Human Platelet Heparanase: Purification, characterization and Catalytic Activity", <i>Biochem J.</i> , 330: 1341-1350, 1998
DJ	Esko et al, "Tumor Formation Dependent on Proeoglycans Biosynthesis", <i>Science</i> , 241(4869): 1092-1096, 1988 (abstract)
DK	
DL	
DM	
DN	
DO	
DP	
DQ	
DR	
DS	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified)		Atty. Docket No. 910/12		Application No. 09/186,200	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Tuvia PERETZ et al			
		Filing Date		Group Art Unit	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS SUB- CLASS
AA					
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS
					TRANSLATION YES NO
AB					
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
AC	Wight et al, "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation", <i>Curr. Opin. Cell Biol.</i> , 4:793-801, 1992 20437				
AD	Jackson et al, "Glycosaminoglycans: Molecular Properties, Protein Interactions and Role in Physiological Processes", <i>Physiol. Rev.</i> , 71:481-539, 1991 20437				
AE	Wight et al, "Cell Biology Of Arterial Proteoglycans", <i>Arteriosclerosis</i> , 9:1-20, 1989 20437				
AF	Kjellen et al, "Proteoglycans: Structures and Interactions", <i>Annu. Rev. Biochem.</i> , 60: 443-475, 1991 20437				
AG	Ruoslahti et al, "Proteoglycans as Modulators of Growth Factor Activities", <i>Cell</i> , 64: 867-869, 1991 20437				
AH	Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes and Plasma Proteins" In <i>Basement Membranes: Cellular and Molecular Aspects</i> (eds. Rahrback and Tirup), Academic Press, Inc., Orlando, Fla., 327-343, 1993 20437				
AI	Vlodavsky et al, "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", <i>Invasion & Metastasis</i> , 12: 112-127, 1992 20437				
AJ	Vlodavsky et al, "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species of Heparin", <i>Invasion & Metastasis</i> , 14: 290-302, 1995 20437				
AK	Nakajima et al, "Heparanase and Tumor Metastasis", <i>J. Cell Biochem.</i> , 36: 157-167, 1988 20437				
AL	Liotta et al, "Tumor Invasion and the Extracellular Matrix", <i>Lab. Invest.</i> , 49: 639-649, 1983 20437				
AM	Vlodavsky et al, "Lymphoma Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix", <i>Cancer Res.</i> , 43: 2704-2711, 1983 20437				
AN	Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis", <i>Is. J. Med.</i> , 24: 464-470, 1988 20437				
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.					

Form FTO-1449 (Modified)				Atty. Docket No. 910/12		Application No. 05/186,200	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)				APPLICANT Tuvia PERETZ et al			
				Filing Date		Group Art Unit	
U.S. PATENT DOCUMENTS							
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
BA							
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO
BB							
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
BC		✓ Parish et al, "Evidence that Sulfated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell-Derived Heparanase", <i>Int. J. Cancer</i> , 40: 511-517, 1987 20432					
BD		✓ Vlodavsky et al, "Morphological Appearance, Growth Behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", <i>Cell</i> , 19: 607-616, 1980 20434					
BE		✓ Vlodavsky et al, "Extracellular Sequestration and Release of Fibroblast Growth Factor: A Regulatory Mechanism?", <i>Trends Biochem. Sci.</i> , 16: 268-271, 1991 20435					
BF		✓ Campbell et al, "Heparin Sulfate-Degrading Enzymes Induce Modulation of Smooth Muscle Phenotype", <i>Exp. Cell Res.</i> , 200: 156-167, 1992 20437					
BG		✓ Lider et al, "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals with Heparinoid Inhibitors of T Lymphocyte Heparanase", <i>J. Clin. Invest.</i> , 83: 752-756, 1989 20439					
BH		✓ Thunberg et al, "The Molecular Size of the Antithrombin-Binding Sequence in Heparin", <i>FEBS Lett.</i> , 117: 203-206, 1980 20440					
BI		✓ Goldberg et al, "An Improved Method for Determining Proteoglycans synthesized by Chondrocytes in Culture", <i>Connective Tissue Res.</i> , 24: 265-275, 1990 20441					
BJ		✓ Hudson, PJ, "Recombinant Antibody Fragment", <i>Curr. Opin. Biotech.</i> , 4: 395-400, 1998 20442					
BK		✓ Schoepe et al, "Neutralization of Hemolytic and Mouse Lethal Activities of Clostridium Alpha-Toxin Need Simultaneous Blockage of Two Epitopes by Monoclonal Antibodies", <i>Microbiol. Pathogenesis</i> , 23: 1-10, 1997 20443					
BL		✓ Chiba et al, "Generation of Neutralizing Antibody to the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 by Immunizing of Mice with an Infectious Vaccinia Virus Recombinant", <i>J. Immunological Methods</i> , 207: 53-60, 1997 20444					
BM		✓ Wong, JF, "Monoclonal Antibodies: Therapeutic Applications Grow in Promise and Number", <i>Genetic Engineering News</i> , July, 1998, pp 23, 49 20445					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

Form PTO-1449 (Modified)

Atty. Docket No.
910/12Application No.
01/186,200
**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(USE SEVERAL SHEETS IF NECESSARY)
APPLICANT
Tuvia PERETZ et al

Filing Date

Group Art Unit

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
CA							
CB							
CD							
CE							
CF							
CG							
CH							
CI							
CJ							

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
CH							

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CI	✓	Sherman-Gold, R., "Monoclonal Antibodies: The Evolution from '80s Magic bullets to Mature, Mainstream Applications as Clinical Therapeutics", <i>Genetic Engineering News</i> , August, 1997, pp 4, 35
CJ	✓	Danheiser, SL, "Rituxin Leads Line Of Hopeful Mab Therapies, yet FDA still has Bulk Manufacture Concerns", <i>Genetic Engineering News</i> , October, 1997, pp 1,6,33,38
CK	✓	Rader et al, A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", <i>Proc. Natl. Acad. Sci.</i> , 95: 8910-8915, 1998
CL	✓	Mateo et al, "Humanization of a Mouse Monoclonal Antibody that Blocks the Epidermal Growth Factor Receptor: Recovery Antagonistic Activity", <i>Immunotechnology</i> , 3: 71-81, 1997
CM		
CN		
CO		
CP		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include a copy of this form with next communication to applicant.

Modified)

Atty. Docket No
910/10

Application No.
09/141,888

DISCLOSURE CITATION
ON APPLICATION
(SEVERAL SHEETS IF NECESSARY)

Applicant:
Oron YACOBY-ZEEVI

Filing Date:
August 27, 1998

Group Art Unit:
1633

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AA							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
AB		09009962 A	14/1/97	JP				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AC		"Handbook of Microbiology", Vol. 1, 1974, pp 239-242, article by Clancy, C.I.						
AD		"Pseudomonas: biotransformations, pathogenesis, and evolving biotechnology", Eds. Silver et al. American Society for Microbiology, 1990, Chps 2,7.						
AE		Wang et al, "Isolation and Characterization of <i>Pseudomonas Aeruginosa</i> Gene: Inducible by Respiratory Mucus Derived from Cystic Fibrosis Patients", <i>Mol. Microbiol.</i> , 22(5): 1005-1012, 1996 (Abstract)						
AF		Moss et al, "Reduced IL-10 Secretion by CD4+ T Lymphocytes Expressing Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)", <i>Clin. Exp. Immunol.</i> , 106(2):374-388, 1996 (Abstract)						
AG		Davies et al, "Regulation of the Alginate Biosynthesis Gene algC in <i>Pseudomonas Aeruginosa</i> During Biofilm Development in Continuous Culture", <i>Appl. Environ. Microbiol.</i> , 61(3): 860-867, 1995 (Abstract)						
AH		Azghani et al, "A Beta-linked Mannan Inhibits Adherence of <i>Pseudomonas Aeruginosa</i> to Human Lung Epithelial Cells", <i>Glycobiology</i> , 5(1): 39-44, 1995, (Abstract)						
AI		Ofek et al, "Bacterial Adhesion to Cells and Tissues", Chapman & Hall, New York, 1994, pp 114-118, 148-153, 418-423.						
AJ		Davies et al, "The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm", <i>Science</i> , 280: 295-298, 1998.						
AK		Ghani et al, "Ceftazidime, Gentamicin, and Rifampicin, in Combination, Kill Biofilms of Mucoid <i>Pseudomonas Aeruginosa</i> ", <i>Can. J. Microbiol.</i> , 43(11): 999-1004, 1997 (Abstract)						
AL		Stickler et al, "An Assessment of the Ability of a Silver-Releasing Device to Prevent Bacterial Contamination of Urethral Catheter Drainage Systems", <i>British J. Urology</i> , 73: 579-588, 1996						
AM		Pinner, C., "Bacteria in Biofilms Exchange Developmental Signals", <i>ASM News</i> , 64(6): 321-322						
AN		Gabriel et al, "In Vitro Adherence of <i>Pseudomonas Aeruginosa</i> to Four Intracocular Lenses", <i>J. Cataract Refract. Surg</i> 24:124-129, 1998.						
AO								
AP								

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)		Atty. Docket No. 910/10		Application No. 09/14,888			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)		Applicant: Oron YACOBY-ZEEVI					
		Filing Date: August 27, 1998		Group Art Unit: 1633			
U.S. PATENT DOCUMENTS							
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
BA							
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO
CC		06197760	7/19/94	JP			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
BD		Pier, G.B., "Rationale for Development of Immunotherapies that Target Mucoid <i>Pseudomonas Aeruginosa</i> Infection in Cystic Fibrosis Patients", <i>Behring Inst Mitt</i> , 98:350-360, 1997 (Abstract)					
BE		Goldberg et al, "Biologic Activities of Antibodies to the Neutral-Polysaccharide Component of the <i>Pseudomonas Aeruginosa</i> lipopolysaccharide are Blocked by O Side Chains and Mucoid Exopolysaccharide (Alginate)", <i>Infect Immun</i> , 65(1):21-26 (Abstract)					
BF		Meluleni et al, "Mucoid <i>Pseudomonas Aeruginosa</i> Growing in a Biofilm in vitro are Killed by Opsonic Antibodies to the Mucoid Exopolysaccharide Capsule but not by Antibodies Produced During Chronic Lung Infection in Cystic Fibrosis Patients", <i>J. Immun</i> , 155(4):2029-2038, 1995 (Abstract)					
BG		Philippon et al, "Virulence Factors (acrobactin and mucoid phenotype) in <i>Klebsiella Pneumoniae</i> and <i>Escherichia coli</i> Blood Culture Isolates", <i>FEMS Microbiol Lett</i> , 130(1): 51-57, 1995 (Abstract)					
BH		Pier et al, "How Mutant CFTR May Contribute to <i>Pseudomonas Aeruginosa</i> Infection in Cystic Fibrosis", <i>Am J Respir Crit Care Med</i> , 154(4): S175-S182, 1996 (Abstract)					
BI		Pier et al, "Cystic Fibrosis Transmembrane Conductance Regulator is an Epithelial Cell Receptor for Clearance of <i>Pseudomonas Aeruginosa</i> from the Lung", <i>Proc Natl Acad Sci USA</i> 94(22): 12088-93, 1997 (Abstract)					
BJ		Boucher et al, "Mucoid <i>Pseudomonas Aeruginosa</i> in Cystic Fibrosis: Characterization of Muc Mutations in Clinical Isolates and Analysis of Clearance in a Mouse Model of Respiratory Infection", (Abstract) no further information given. <i>Infect. Immun.</i> 1997 Sep., 65(9):3938-3946.					
BK		Boucher et al, "Two Distinct Loci Affecting Conversion to Mucoid <i>Pseudomonas Aeruginosa</i> in Cystic Fibrosis Encode Homologs of the Serine Protease HtrA", <i>J. Bacteriol</i> , 178(2):511-523, 1996 (Abstract)					
BL		Yu et al, "Microbial Pathogenesis in Cystic Fibrosis: Pulmonary Clearance of Mucoid <i>Pseudomonas Aeruginosa</i> and Inflammation in a Mouse Model of Repeated Respiratory Challenge", <i>Infection and Immunity</i> , 66(1): 280-288, 1998					
BM		Van Heeckeren et al, "Excessive Inflammatory Response of Cystic Fibrosis Mice to Bronchopulmonary Infection with <i>Pseudomonas Aeruginosa</i> ", <i>J. Clin Invest</i> , 100(11): 2810-2815, 1997					
BN							
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 605: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 (Modified)

Atty. Docket No.
910/10Application No.
09,140,888INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)Applicant:
Oron YACOBY-ZEEVIFiling Date:
August 27, 1998Group Art Unit:
16:3

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Mrsny et al, "Addition of a Bacterial Alginate Lyase to Purulent CF Sputum in vitro can Result in the Disruption of Alginate and Modification of Sputum Viscoclasticity", <i>Pul Pharmacol</i> , 7(6): 357-366, 1994 (Abstract)
CB	Wills et al, "Short-Term Recombinant Human Dnase in Bronchiectasis. Effect on Clinical State and in vitro Sputum Transportability", (Abstract) no further information.
CC	Cai et al, "Comparison of Sputum Processing Techniques in Cystic Fibrosis", <i>Pediatr Pulmonol</i> , 22(6): 402-407, 1996 (Abstract)
CD	Randall et al, "Distribution of DNA and Alginate in Purulent Cystic Fibrosis Sputum: Implications to Pulmonary Targeting Strategies", <i>J Drug Therapy</i> , 4(4): 233-243, 1996
CE	Hatch et al, "Alginate Lyase Promotes Diffusion of Aminoglycosides Through the Extracellular polysaccharide of Mucoid <i>Pseudomonas Aeruginosa</i> ", <i>Antimicrob Agents Chemother</i> , 42(4): 974-977, 1998 (Abstract)
CF	Speert et al, "Modulation of Macrophage Function for Defense of the Lung against <i>Pseudomonas Aeruginosa</i> ", <i>Behring Inst Mitt</i> , 98: 274-282, 1997 (Abstract)
CG	Ying et al, "Alginate, the slime Exopolysaccharide of <i>Pseudomonas Aeruginosa</i> , Binds Human Leukocyte Elastase, Retards Inhibition by Alpha 1-proteinase Inhibitor, and Accelerates Inhibition by Secretory Leukoprotease Inhibitor", <i>Am J Cell Moll Biol</i> , 15(2): 283-291, 1996 (Abstract)
CH	Johansen et al, Chronic <i>Pseudomonas Aeruginosa</i> Pneumonia. A New Prophylactic Principle", <i>Behring Inst Mitt</i> , 90: 269-273, 1997 (Abstract)
CI	Pina et al, "The Role of Fluoroquinolones in the Promotion of Alginate Synthesis and Antibiotic Resistance in <i>Pseudomonas Aeruginosa</i> ", <i>Curr Microbiol</i> , 35(2): 103-108, 1997 (Abstract)
CJ	Spencer, RC, "Invasive Streptococci", <i>Eur J Clin Microbiol Infect Dis</i> , 14 Suppl :S26-S32, 1995 (Abstract)
CK	Mengistu et al, "Continuous Culture Studies on the Synthesis of Capsular Polysaccharide by <i>Klebsiella Pneumoniae</i> K1", <i>J Appl Bacteriol</i> , 76(5): 424-430, 1994 (Abstract)
CL	Hsueh et al, "Invasive <i>Streptococci Pneumoniae</i> Infection Associated with Rapidly Fatal Outcome in Taiwan", <i>J Formos Med Assoc</i> , 95(5):364-371, 1996 (Abstract)
CM	Moses et al. "Relative Contributions of Hyaluronic Capsule and M Protein to Virulence in a Mucoid Strain of the Group A Streptococcus", <i>Infect Immun</i> , 65(1):64-71, 1997 (Abstract)
CN	Scott et al. Visualization of an Extracellular Mucoid Layer of <i>Treponema Denticola</i> ATCC 35405 and Surface Sugar Lectin Analysis of Some <i>Treponema</i> Species", <i>Oral Microbiol Immunol</i> , 12(2): 121-125, 1997 (Abstract)
CO	Nilsson et al. "The Role of Staphylococcal Polysaccharide Microcapsule Expression in Septicemia and Septic Arthritis", <i>Infect Immun</i> , 65(10): 4216-21, 1997 (Abstract)
CP	Vessels et al. "Effects on Virulence of Mutations in a Locus Essential for Hyaluronic Acid Capsule Expression in Group A Streptococci", <i>Infect Immun</i> , 62(2): 433-441, 1994 (Abstract)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

49 (Modified)

Atty. Docket No.
910/8Application No.
09/113,168CITATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)Applicant
Hanna BEN ARTZI et alFiling Date:
July 10, 1998Group or Unit
+652-155

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
					YES	NO
AB						

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AC		Wight et al, "The Role of Proteoglycans in Cell Adhesion, Migration and Proliferation", <i>Cell Biology</i> , 4: 93-801, 1992
AD		Jackson et al, "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological processes", <i>Physiological Review</i> , 71(2):481-539, 1981
AE		Wight, T.N., "Cell Biology of Arterial Proteoglycans", <i>Arteriosclerosis</i> , 9(1):1-20, 1989
AF		Kjellen et al, "Proteoglycans: Structures and Interactions", <i>Annu. Rev. Biochem.</i> , 60: 443-475, 1991
AG		Ruoslahti et al, "Proteoglycans as Modulators of Growth Factor Activities", <i>Cell</i> , 64: 867-869, 1991
AH		Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasma Proteins", <i>In Basement Membranes: Cellular and Molecular Aspects</i> , (eds. Rohrbach & Timpl), p 327-343, Academic Press Inc., Orlando, Fla., 1993.
AI		Vlodavsky et al, "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", <i>Invasion Metastasis</i> , 12:112-127, 1992
AJ		Vlodavsky et al, "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species of Heparin", <i>Invasion Metastasis</i> , 14:290-302, 1994-95.
		Nakajima et al, "Heparanase and Tumor Metastasis", <i>J. Cellular Biochem.</i> , 36:157-167, 1988.
AL		Liotta et al, "Tumor Invasion and the Extracellular Matrix", <i>Laboratory Investigation</i> , 49(6):636-647, 1983.
AM		Vlodavsky et al, "Lymphocyte Cell-Mediated Degradation of Sulfated Proteoglycan in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", <i>Cancer Research</i> , 43: 2704-2711, 1983
AN		Vlodavsky et al, "Involvement of Heparanase in Tumor Metastasis and Angiogenesis" <i>Isr. Med. Sci.</i> , 24: 464-470, 1983
AO		Parish et al, "Evidence That Sulphated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumour-Cell-Derived Heparanases", <i>Int. J. Cancer</i> , 40: 511-518, 1987.
AP		Vlodavsky et al, "Morphological Appearance, Growth Behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix Versus Plastic", <i>Cell</i> , 19: 607-616 1980

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)

Atty. Docket No.
910/8

Application No.
09/113,168

Applicant:
Hanna BEN ARTZI et al

Filing Date:
July 10, 1998

Group A Unit:
1652/4:57

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
BA							

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
BB							

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BC	<input checked="" type="checkbox"/>	Vlodavsky et al, "Extracellular Sequestration and Release of Fibroblast Growth Factor: A Regulatory Mechanism?", <i>Trends Biochem. Sci.</i> , 16: 268-271, 1991
BD	<input checked="" type="checkbox"/>	Campbell et al, "Heparin Sulfate-Degrading Enzymes Induce Modulation of Smooth Muscle Phenotype", <i>Exp. Cell Res.</i> , 200: 156-167, 1992
BE	<input checked="" type="checkbox"/>	Lider et al, "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals with Low Doses of Heparin", <i>J. Clin. Invest.</i> , 83: 752-756, 1989
BF	<input checked="" type="checkbox"/>	Thunberg et al, "The Molecular Size of the Antithrombin-Binding Sequence in Heparin", <i>FEBS Letters</i> , 117(1): 203-206, 1980
BG	<input checked="" type="checkbox"/>	Sudhalter et al, "Importance of Size, Sulfation and Anticoagulant Activity in the Potentiation of Acidic Fibroblast Growth Factor by Heparin", <i>J. Biol. Chem.</i> , 254(12): 6892-6897, 1989
BH	<input checked="" type="checkbox"/>	Ishai-Michaeli et al, "Importance of Size and Sulfation of Heparin in Release of Basic Fibroblast Growth Factor from the Vascular Endothelium and Extracellular Matrix", <i>Biochemistry</i> , 31: 2080-2088, 1992
BI	<input checked="" type="checkbox"/>	Inoue et al, "Selective β -Desulfation of Heparin with Dimethyl Sulfoxide Containing Water or Methanol", <i>Carbohydrate Research</i> , 46:67-95, 1976
BJ	<input checked="" type="checkbox"/>	Nagasawa et al, "Solvolytic Desulfation of Glycosaminoglycuronan Sulfates With Dimethyl Sulfoxide Containing Water or Methanol", <i>Carbohydrate Research</i> , 58: 47-55, 1977
BK	<input checked="" type="checkbox"/>	Matia Bar-New et al, "Inhibition of Heparanase-Mediated Degradation of Extracellular Matrix Heparin Sulfate by Non-Anticoagulant Heparin Species", <i>Blood</i> , 70(2): 551-557, 1987
BL	<input checked="" type="checkbox"/>	Gospodrowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation <i>in vitro</i> by Fibroblast and Epidermal Growth Factors", <i>Exp. Eye Res.</i> , 25: 75-89, 1977
BM	<input checked="" type="checkbox"/>	Haimovits-Friedman et al, "Activation of Platelet Heparitinase by Tumor Cell-Derived Factors", <i>Blood</i> , 78: 789-796, 1991.
BN	<input checked="" type="checkbox"/>	Vlodavsky et al, "Extracellular Matrix-Resident Growth Factors and Enzymes: Possible Involvement in Tumor Metastasis and Angiogenesis", <i>Cancer and Metastasis Rev.</i> , 9: 203-226, 1990

EXAMINER Jon P. WalkerDATE CONSIDERED 30 Sep 99

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)		Atty. Docket No. 910/8		Application No. 09/113,158	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)		Applicant Hanna BEN ARTZI et al			
		Filing Date: July 10, 1998		Group Art Unit 1652/69	
U.S. PATENT DOCUMENTS					
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS
CA					
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
CC		Regan et al, "Mimicry of Biological Macromolecules by Polyaromatic Anionic Compounds", <i>J. Bioactive and Compatible Polymers</i> , 8: 317-337, 1993			
CD		Benezra et al, "Antiproliferative Activity to Vascular Smooth Muscle Cells and Receptor Binding of Heparin-Mimicking Polyaromatic Anionic Compounds", <i>Arteriosclerosis and Thrombosis</i> , 14(12): 1992-1999, 1993			
CE		Katz et al, "Antiproliferative Activity to Glomerular Mesangial Cells and Receptor Binding of a Heparin-Mimicking Polyaromatic Anionic Compound", <i>J. Amer. Soc. Nephrology</i> , 1638-1697, 1997			
CF		Miao et al, "Modulation of Fibroblast Growth Factor-2 Receptor Binding, Dimerization, Signaling, and Angiogenic Activity by a Synthetic Heparin-Mimicking Polyaromatic Compound", <i>J. Clin. Invest.</i> , 99(7): 1565-1575, 1997			
CG		Benezra et al, "Reversal of Fibroblast Growth Factor-mediated Autocrine Cell Transformation by Aromatic Anionic Compounds" <i>Cancer Research</i> , 52:5656-5662, 1992.			
CH		Irimura et al, "Chemically Modified Heparins as Inhibitors of Heparan Sulfate Specific Endo- β -glucuronidase (Heparanase) of Metastatic melanoma Cells", <i>Biochemistry</i> , 25: 5322-5328, 1986			
CI		Coombe et al, "Analysis of the Inhibition of Tumour Metastasis by Sulphated Polysaccharides", <i>Int. J. Cancer</i> , 39: 82-88, 1987.			
CJ		Ornitz et al, "Heparin is Required for Cell-Free Binding of Basic Fibroblast Growth Factor to a Soluble Receptor and for Mitogenesis in Whole Cells", <i>Molecular and Cellular Biology</i> , 12: 240-247, 1992			
CK		Yayon et al, "Cell Surface, Heparin-like Molecules are Required for Binding of Basic Fibroblast Growth Factor to its High Affinity Receptor", <i>Cell</i> , 64: 841-848, 1991.			
CL		Aviezer et al, "Differential Structural Requirements of Heparin and Heparan Sulfate Proteoglycans That Promote Binding of Basic Fibroblast Growth Factor to its Receptor", <i>J. Biol. Chem.</i> , 269(1):114-121, 1994.			
CM		Bartlett et al, "Comparative Analysis of the Ability of Leucocytes, Endothelial Cells, and Platelets to Degrade the Subendothelial Basement Membrane: Evidence for Cytokine Dependence and Detection of a Novel Sulfatase", <i>Immunology and Cell Biol.</i> , 73: 113-124, 1995.			
CN					
EXAMINER		DATE CONSIDERED			
J. P. Weber		30 Sep 99			
EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Form PTO-1449 (Modified)		Atty. Docket No. 910/8		Application No. 09/113,158			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)		Applicant: Hanna BEN ARTZI et al					
		Filing Date: July 10, 1998		Group Art Unit 1652-1675			
U.S. PATENT DOCUMENTS							
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
DA							
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
DB				Nakajima et al, "A Solid-Phase Substrate of Heparanase: Its Application to Assay of Human Melanoma for Heparan Sulfate Degradative Activity", <i>Analytical Biochemistry</i> , 157: 162-171, 1986.			
DC				Oosta et al, "Purification and Properties of Human Platelet Heparanase", <i>J. Biol. Chem.</i> , 257(19): 11249-11255, 1982.			
DD				Sewell et al, "Human Mononuclear Cells Contain an Endoglycosidase Specific for Heparan Sulfate Glycosaminoglycan Demonstrable with the Use of a Specific Solid-Phase Metabolically Radiolabelled Substrate", <i>Biochem J.</i> , 264: 777-783, 1989.			
DE				Freeman et al, "A Rapid Quantitative Assay for the Detection of Mammalian Heparanase Activity", <i>Biochem J.</i> , 325: 229-237, 1997.			
DF				Mullings et al, "New Reducing Sugar Assay for the Study of Cellulases", <i>Enzyme Microb. Technol.</i> , 6:491-496, 1984.			
DG				Taylor et al, "A colorimetric Method for the Quantitation of Uronic Acids and a Specific Assay for Galacturonic Acid", <i>Analytical Biochemistry</i> , 201: 190-196, 1992.			
DH				Linhardt, R.J., "Large Electrophoresis of Oligosaccharides", <i>Methods in Enzymology</i> , 230: 265-280, 1994.			
DI				Basu et al, "Analysis of Glycosphingolipids by Fluorophore-Assisted Carbohydrate Electrophoresis Using Ceramide Glycanase from <i>Morone nereis</i> ", <i>Analytical Biochemistry</i> , 222: 271-274, 1994.			
DJ				Jackson, P., "The Use of Polyacrylamide-gel Electrophoresis for the High-Resolution of Separation of Reducing Saccharides Labelled with the Fluorophore 8-aminonaphthalene-1,3,6-trisulphonic Acid", <i>Biochem J.</i> , 270: 705-713, 1990.			
DK				Coquet et al, "Applications of a Post-column Fluorogenic Reaction in Liquid Chromatography for the Determination of Glucose and Fructose in Biological Matrices", <i>Analytica Chimica Acta</i> , 252: 173-179, 1991.			
DL				DeVouge et al, "Immunoselection of GRP94/Endoplasmic Reticulum Protein From a KNRK Cell-Specific λ gt11 Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", <i>Int. J. Cancer</i> , 56: 286-294, 1994.			
DM				Zsolnai et al, "Directional Immobilization of Heparin onto the Nonporous Surface of Polystyrene Microplates", <i>Biotechniques</i> , 23(3): 382-385, 1997.			
DN				Bellott et al, "Closing the Loop in Combinatorial Chemistry", <i>European Pharmaceutical Contractor</i> , Aug., 1997.			
DO				Goldberg et al, "An Improved Method for Determining Proteoglycans Synthesized by Chondrocytes in Culture", <i>Live Tissue Research</i> , 24: 265-275, 1990.			
EXAMINER		DATE CONSIDERED					
Don P. Weber		30 Sep 98					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



Form PTO-1449 (Modified)

AUG 07 1998

Atty. Docket No.
910/4Application No.
09/046,475INFORMATION DISCLOSURE
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)Applicant:
Oron Yacoby ZEEVIFiling Date:
March 25, 1998Group Art Unit:
1652

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AA							
AB							
AC							
AD							AUG 10 1998

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
AE								

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	RP	Allen, E.D., "Opportunities for the Use Aerosolized α_1 - Antitrypsin for the Treatment of Cystic Fibrosis", <i>Chest</i> , 110: 256S - 260S, 1996						
AG	RP	Konstan et al, "Current Understanding of the Inflammatory Process in Cystic Fibrosis", <i>Pediatric Pulmonology</i> , 24:137-142, 1997						
AH	RP	Dasgupta et al, "Reduction in Viscoelasticity in Cystic Fibrosis Sputum <i>In Vitro</i> Using Combined Treatment with Nacystelyn and mDNase", <i>Pediatric Pulmonology</i> , 22:161-166, 1996						
AI	RP	Crystal, R.G., Gene Therapy Strategies for Pulmonary Disease", <i>Am. J. Medicine</i> , 92(supp 64): 6A-44S - 6A-52S (June 1992)						
AJ	RP	Lieberman, J., "The Appropriate Use of Mucolytic Agents", <i>Am. J. Medicine</i> , 49(1): 1-4, 1970						
AK	RP	Boat et al, "Biochemistry of Airway Mucus Secretions", <i>Fed Proc</i> , 39:13: 3067-3074, 1980 (Abstract)						
AL	RP	Mohapatra et al, "Alteration of Sulfation of Glycoconjugates, but not Sulfate Transport and Intracellular Inorganic Sulfate Content in Cystic Fibrosis Airway Epithelial Cells", <i>Pediatr Res</i> , 38(1): 42-45, 1995 (Abstract)						
AM	RP	Boat et al, "Increased Sulfation of Glycoconjugates by Cultured Nasal Epithelial Cells from Patients with Cystic Fibrosis", <i>J. Clin Invest.</i> , 84(1):68-72, 1989 (Abstract)						
AN	RP	Boat et al, "Epithelial Cell Dysfunction in Cystic Fibrosis: Implications for Airways Disease", <i>Acta Paediatr Scand Suppl</i> , 363:25-29, 1989						
AO	RP	Welch et al, "Complex Saccharide Metabolism in Cystic Fibrosis Fibroblasts", <i>Pediatr Res</i> , 9:698-702, 1975						
AP	RP	Schwartz et al "CpG Motifs in Bacterial DNA Cause Inflammation in the Lower Respiratory Tract", <i>J. Clin. Invest.</i> , 100(1): 68-73, 1997 (Abstract)						

EXAMINER

Rebecca Prouty

DATE CONSIDERED

7-21-99

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)				Atty. Docket No. 910/4		Application No. 09/046,475	
INFORMATION DISCLOSURE CITATION TO AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY) AUG 07 1998 PATENT & TRADEMARK OFFICE				Applicant Oron Yacoby ZEEVI			
				Filing Date: March 25, 1998		Group Art Unit 1652	
U.S. PATENT DOCUMENTS							
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
BA							
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
BC							AUG 10 1998 YES <input type="checkbox"/> NO <input type="checkbox"/>
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
BD	RP	Hill et al, "Organ-Specific Over-Sulfation of Glycosaminoglycans and Altered Extracellular Matrix in a Mouse Model of Cystic Fibrosis", <i>Biochem Mol Med</i> , 62(1): 113-122, 1997 (Abstract)					
BE	RP	"Harper's Biochemistry", 24th Ed. Pp 660-685					
BF	RP	Chase et al, "Respiratory Mucous Secretions in Patients with Cystic Fibrosis: Relationship Between Levels of Highly Sulfated Mucin Component and Severity of the Disease", <i>Clinica Chimica Acta</i> , 132: 143-155, 1983					
BG	RP	Schwab et al, "Increased Adherence of <i>Staphylococcus Aureus</i> From Cystic Fibrosis Lungs to Airway Epithelial Cells", <i>Am Rev Respir</i> , 148(7): 365-369, 1993 (Abstract)					
BH	RP	Barghouthi et al, "Nonopsonic Phagocytosis of <i>Pseudomonas Aeruginosa</i> Requires Facilitated Transport of D-Glucose by Macrophages", <i>J. Immunol.</i> , 154(7): 3420-3428, 1995 (Abstract)					
BI	RP	Moser et al, "Chronic <i>Pseudomonas Aeruginosa</i> Lung Infection is more Severe in Th2 Responding BALB/c Mice compared to Th1 Responding C3H/HeN Mice", <i>APMIS</i> , 105(11): 838-842, 1997 (Abstract)					
BJ	RP	Cowley et al, "Mucociliary Clearance in Cystic Fibrosis Knockout Mice Infected with <i>Pseudomonas Aeruginosa</i> ", <i>Eur Respir</i> , 10(10): 2312-2318, 1997 (Abstract)					
BK	RP	Zahn et al, "Early Alterations in Airway Mucociliary Clearance and Inflammation of the Lamina Propria in CF Mice", <i>Am J Physiol</i> , 272(3 Pt 1): C853-C859, 1997 (Abstract)					
BL	RP	Pier et al, "Cystic Fibrosis Transmembrane Conductance Regulator is an Epithelial Cell Receptor for Clearance of <i>Pseudomonas Aeruginosa</i> From the Lung", <i>Proc Natl Acad Sci USA</i> , 94(22): 12088-12093, 1997					
BM	RP	Selvan et al, "Heparan Sulfate in Immune Responses", <i>An. NY Acad. Sci.</i> , 797: 127-139, 1996					
BN	RP	Vlodavsky et al, "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", <i>Invasion Metastasis</i> , 12:112-127, 1992					
BO	RP	Nakajima et al, "Heparanases and Tumor Metastasis", <i>J. Cell Biochem.</i> , 36(2): 157-167, 1988					
EXAMINER				DATE CONSIDERED			
Rebecca Prouty				7-21-99			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 (Modified)				Atty. Docket No. 910/4		Application No. 09/046,475	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)				Applicant Oron Yacoby ZEEVI			
				Filing Date: March 25, 1998		Group Art Unit: 1652	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUB- CLASS	FILING DATE
CA							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
CB						AUG 10	1998
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
CC	RP	Thompson et al, "Identification of Chondroitin Sulfate E in Human Lung Mast Cells", <i>J. Immunol.</i> , 140(8): 2708-2713, 1988 (Abstract)					
CD	RP	Giuffre et al, "Monocyte Adhesion to Activated Aortic Endothelium: Role of L-Selectin and Heparan Sulfate Proteoglycans", <i>J Cell Biol</i> , 136(4): 945-956, 1997 (Abstract)					
CE	RP	Shimada et al, "Involvement of Cell Surface Heparin Sulfate in the Binding of Lipoprotein Lipase to Cultured Bovine Endothelial Cells", <i>J Clinical Invest</i> , 68(4): 995-1002, 1981 (Abstract)					
CF	RP	Rahmouni et al, "Chondroitin Sulfate in Sputum from Patients with Cystic Fibrosis and Chronic Bronchitis", <i>Am J Resp Cell & Mol Biol</i> , 5(4): 313-320, 1991					
CG	RP	Hayward et al, "Heparinase III Exerts Endothelial and Cardioprotective Effects in Feline Myocardial Ischemia-Reperfusion Injury", <i>J. Pharm Exp Ther</i> , 283(3): 1032-1038, 1997 (Abstract)					
CH	RP	Yamaguchi et al, "Neutrophil Elastase Inhibitor Reduces Neutrophil Chemoattractant Production After Ischemia-Reperfusion in Rat Liver", <i>Gastroenterology</i> , 112(2): 551-560, 1997 (Abstract)					
CI	RP	Matgolie et al, "Identification of a Major Heparin-Precipitable Protein in Human Serum and its Relationship to Cystic Fibrosis", <i>Pediatr Res</i> , 16(3): 181-186, 1982 (Abstract)					
CJ	RP	Leong et al, "Different Classes of Proteoglycans Contribute to the Attachment of <i>Borrelia burgdorferi</i> to Cultured Endothelial and Brain Cells", <i>Infect Immun</i> , 66(3): 994-999, 1998 (Abstract)					
CK	RP	Asagoe et al, "Effect of Heparin on Infection of Cells by Equine Arteritis Virus", <i>J Vet Med Sci</i> , 59(8): 727-728, 1997 (Abstract)					
CL	RP	Krusat et al, "Heparin-Dependent Attachment of Respiratory Syncytial Virus (RSV) to Host Cells", <i>Arch Virol</i> , 142(6): 1247-1254, 1997 (Abstract)					
CM	RP	Alvarez-Dominguez et al, "Host Cell Heparan Sulfate Proteoglycans Mediate Attachment and Entry of <i>Listeria monocytogenes</i> , and the Listerial Surface Protein ActA is Involved in Heparan Sulfate Receptor Recognition", <i>Infection & Immunity</i> , 65(1): 78-88, 1997, (ABSTRACT)					
CN	RP	Hagwara et al, "Inhibitory Effect of Heparin on Red Blood Cell Invasion by <i>Theileria Sargenti</i> Microzoites", <i>Int J Parasitol</i> , 27(5): 535-539 (Abstract) 1997					
CO							
CP							
EXAMINER		Rebecca Parity			DATE CONSIDERED 7-21-99		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 (Modified)		Atty. Docket No. 910/4		Application No. 09/046,475	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)		Applicant Oron Yacoby ZEEVI			
		Filing Date: March 25, 1998		Group Art Unit: 1652	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS
DA					
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS
					TRANSLATION
					YES NO
DB					
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
DC	RP	Shakibaei et al, "Dual Interaction of the Malaria Circumsporozoite Protein with the Low Density Lipoprotein Receptor-Related Protein (LRP) and Heparan Sulfate Proteoglycans", <i>J Exp Med</i> , 184(5): 1699-1711, 1996 (Abstract)			
DD	RP	Inaba et al, "Effect of Heparinon Infection of Cells by Porcine Reproductive and Respiratory Syndrome Virus", <i>Am J Vet Res</i> , 58(5):488-491, 1997 (Abstract)			
DE	RP	Chen et al, "Dengue Virus Infectivity Depends on Envelope Protein Bin to Target Cell Heparan Sulfate", <i>Nature Medicine</i> , 3(8): 866-871, 1997			
DF	RP	Gantt et al, "Cell Adhesion to a Motif Shared by the Malaria Circumsporozoite Protein and Thrombospondin is Mediated by its Glycosaminoglycan-Binding Region and not by CSVTCG", <i>J Biol Chem</i> , 272(31): 19205-19213, 1997 (Abstract)			
DG	RP	Robert et al, "Chondroitin-4-Sulphate (Proteoglycan), a receptor for Plasmodium falciparum-Infected Erythrocyte Adherence on Brain Microvascular Endothelial Cells", <i>Res Immunol</i> , 146(6): 383-93, 1995. (Abstract)			
DH	RP	Herrera et al, "Mediation of <i>Trypanosoma Cruzi</i> Invasion by Heparan Sulfate Receptors on Host Cells and Penetrin Counter-Receptors on the Trypanosomes", <i>Mol & Biochem Parasit</i> , 65: 73-83, 1994			
DI					
DJ					
DK					
DL					
DM					
CN					
CO					
CP					
EXAMINER		DATE CONSIDERED			
Rebecca Pouty		7-2-199			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Form PTO-1449 (Modified)

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)

Atty. Docket No.
910/1

Application No.
08/922,170

Applicant:
Iris PECKER et al

Filing Date:
September 2, 1997

Class A 1 (U.S.)

RECEIVED 1652 1644
GROUP 1998

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DATE
AA	RP MD	5,362,641	Nov 94	Fuks et al	435 209	—
AB	RP MD	5,571,506	Nov 96	Regan et al	424 78.17	—
AC						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
AD	RP MD WO 9504518	Jul 94	PCT	—	—		
AE							

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	MD RP	Goshen et al, "Purification and Characterization of Placental Heparanase and its Expression by Cultured Cytotrophoblasts", <i>Molecular Human Reproduction</i> , 2(9): 679-684, 1996
AG	RP MD	Bar-Ner et al, "Inhibition of Heparanase-Mediated Degradation of Extracellular Matrix Heparan Sulphate by Non-anticoagulant Heparin Species", <i>Blood</i> , 70(2): 551-557, 1987
AH	RP MD	Savitsky et al, "Ataxia-Telangiectasia: Structural Diversity of Untranslated Sequences Suggests Complex Post-Transcriptional Regulation of ATM Gene Expression", <i>Nucleic Acids Research</i> , 25(9): 1678-1684 (1997)
AI	RP MD	Haimovitz-Friedman et al, "Activation of Platelet Heparitanase by Tumor Cell Derived Factors", <i>Blood</i> , 78: 789-796, 1991
AJ	RP MD	Gospodarowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation <i>in vitro</i> by Fibroblast and Epidermal Growth Factors", <i>Exp. Eye Res.</i> , 25: 75-89, 1977
AK	RP MD	Ernst et al, "Enzymatic degradation of Glycosaminoglycans", <i>Crit. Rev. In Biochem. & Molec. Biology</i> , 30(5): 387-444, 1995
AL	MD RP	Zhong-Sheng et al, "Role of Heparan Sulfate Proteoglycans in the Binding and Uptake of Apolipoprotein E-enriched Remnant Lipoproteins by Cultured Cells", <i>J. Biol. Chem.</i> , 268(14): 10160-10167, 1993
AM	RP MD	R. Ross, "The Pathogenesis of Atherosclerosis: A Perspective for the 1990s", <i>Nature</i> , 362: 801-809, (1993)
AN	RP MD	1993 Putnak et al, "A Putative Cellular Receptor for Dengue Viruses", <i>Nature Medicine</i> , 3(8): 828-829, 1997
AO	RP MD	Cordon-Cardo et al, "Expression of Basic Fibroblast Growth Factor in Normal Human Tissues", <i>Laboratory Investigation</i> , 63(6): 832-840, 1990

EXAMINER Marianne DiBriano/Rebecca Frisby DATE CONSIDERED 7-24-11/03/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)		Atty. Docket No. 910/1		Application No. 08/922 170			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)		Applicant: Iris PECKER et al		REC FEB GROUP 4 1652-70084-1800			
		Filing Date: September 2, 1997					
U.S. PATENT DOCUMENTS							
	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
BA							
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO
BB							
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
BC	MD RP	Narindrasorasak et al, "High Affinity Interactions between the Alzheimer's β -Amyloid Precursor Proteins and the Basement Membrane Form of Heparan Sulfate Proteoglycan", <i>J. Biol. Chem.</i> , 266(20): 12878-12883, 1991					
BD	MD RP	Chen et al, "Dengue Virus Infectivity Depends on Envelope Protein Binding to Target Cell Heparan Sulfate", <i>Nature Medicine</i> , 3(8): 866-871, 1997					
BE	MD RP	Shieh et al, "Cell Surface Receptors for Herpes Simplex Virus are Heparan Sulfate Proteoglycan Proteoglycans", <i>J. Cell Biol.</i> , 116(5): 1273-1281, 1992					
BF	MD RP	Eisenberg et al, "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan Sulfate on Cell Surfaces and Extracellular Matrix", <i>J. Clin. Invest.</i> , 90: 2013-2021, 1992					
BG	MD RP	Rapraeger et al, "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", <i>Science</i> , 252: 1705-1708, 1991					
BH	MD RP	Lider et al, "A Disaccharide that Inhibits Tumor Necrosis Factor α is Formed from the Extracellular Matrix by the Enzyme Heparanase", <i>Proc. Natl. Acad. Sci. USA</i> , 92:5037-5041, 1995					
BI	MD RP	Lider et al, "Suppression of Experimental Autoimmune Diseases and Prolongation of Allograft Survival by Treatment of Animals with Low Doses of Heparins", <i>J. Clin. Invest.</i> , 83: 752-756, 1989					
BJ	MD RP	Gitay-Goren et al, "The Binding of Vascular Endothelial Growth Factor to its Receptors is Dependent on Cell Surface-associated Heparin-like Molecules", <i>J. Biol. Chem.</i> , 267(9): 6093-6098, 1992					
BK	MD RP	Ornitz et al, "FGF Binding and FGF Receptor Activation by Synthetic Heparin Derived Di- and Trisaccharides", <i>Science</i> , 268: 432-436, 1995.					
BL	MD RP	Spivak-Kroizman et al, "Heparin-Induced Oligomerization of FGF Molecules is Responsible for FGF Receptor Dimerization, Activation, and Cell Proliferation", <i>Cell</i> , 79: 1015-1024, 1994					
BM	MD RP	Yayon et al, "Cell Surface Heparin-Like Molecules are required for Binding of Basic Fibroblast Growth Factor to its High Affinity Receptor", <i>Cell</i> , 64: 841-848, 1991					
BN							
EXAMINER		Marianne DiBrino/ Rebecca Pinsky			DATE CONSIDERED 7-21-18 11/03/2006		
EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 (Modified)

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)

Atty. Docket No.
910/1

Applicant
08/922, 70

Applicant:
Iris PECKER et al

Filing Date:
September 2, 1997

Group / Unit

16.52 / 115904

RECEIVED
FEB 1998
GROUP 18904

U.S. PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
CA							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
CB								

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CC		Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes, and Plasm a Proteins", Basic Membranes: Cellular and Molecular Aspects (eds. Rohrbach & Timpl) pp 327-343, Academic Press, Orlando, Fla., 1993						
CD	RP MD	Vlodavsky et al, "Extracellular Sequestration and release of Fibroblast Growth Factor: A Regulatory Mechanism?", <i>Trends Biochem. Sci.</i> , 16: 268-271, 1991						
CE	RP MD	Ishai-Michaeli et al, "Heparanase Activity Expressed by Platelets, Neutrophils, and Lymphoma Cells releases Active Fibroblast Growth Factor from ExtraCellular Matrix", <i>Cell Regulation</i> , 1: 833-842, 1990						
CF	MD RP	Ishai-Michaeli et al, "Importance of Size and Sulfatation of Heparin in Release of Basic Fibroblast Growth Factor from the Vascular Endothelium and ExtraCellular Matrix", <i>Biochemistry</i> , 31(7): 2080-2088, 1992						
CG	MD RP	Folkman et al, "A Heparin-Binding Angiogenic Protein - Basic Fibroblast Growth Factor - is Stored Within Basement Membrane", <i>Am. J. Pathology</i> , 130(2): 393-400, 1988						
CH	MD RP	Vlodavsky et al, "Endothelial Cell-Derived Basic Fibroblast Growth Factor: Synthesis and Deposition into Subendothelial ExtraCellular Matrix", <i>Proc. Natl. Acad. Sci. USA</i> , 84: 2292-2296, 1987						
CI	MD RP	Folkman et al, "Angiogenic Factors", <i>Science</i> , 235: 442-447, 1987						
CJ	MD RP	Burgess et al, "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins", <i>Annu. Rev. Biochem.</i> , 58:575-606, 1989						
CK	MD RP	Vlodavsky et al, "Involvement of the ExtraCellular Matrix, Heparin Sulfate Proteoglycans, and Heparin Sulfate Degrading Enzymes in Angiogenesis and Metastasis", In: <i>Tumor Angiogenesis</i> , Eds. Lewis et al, Oxford Univ. Press, pp 125-140, 1997						
CL	MD RP	Parish et al, "Evidence that Sulfated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor Cell Derived Heparanases", <i>Int. J. Cancer</i> , 40: 511-518, 1987						
CM	MD RP	Bashkin et al, "Basic Fibroblast Growth Factor Binds to Subendothelial ExtraCellular Matrix and is Released by Heparitanase and Heparin-Like Molecules", <i>Biochemistry</i> , 28:1737-1743, 1989						
CN		Marianne DiBrino/						

EXAMINER

Rebecca Party

DATE CONSIDERED

7-21-98 11/03/2006


EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

Atty Docket No.
910/5Application No.
09/071,739INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)Applicant:
Iris PECKER et al

RECEIVED

JUL 15 1998

Filing Date:
May 1, 1998GROUP 1804
1644

PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
AA							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
AB								

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	MD MD	Wight et al, "The Role of Proteoglycans in Cell Adhesion, migration and Proliferation", <i>Current Opinion in Cell Biology</i> , 1992, 4:793-801
AD	MD MD	Jackson et al, "Glycosaminoglycans: Molecular Properties, Protein Interactions, and Role in Physiological Processes", <i>Physiological Reviews</i> , 71(2):481-539, 1991
AE	MD MD	Wight, T.N., "Cell Biology of Arterial Proteoglycans", <i>Arteriosclerosis</i> , 9:1-20, 1989
AF	MD MD	Kjellen et al, "Proteoglycans: Structures and Interactions", <i>Annu. Rev. Biochem.</i> , 60: 443-475, 1991
AG	MD MD	Ruoslahti et al, "Proteoglycans as Modulators of Growth Factor Activities", <i>Cell</i> , 64:867-869, 1991
AH	MD MD	Vlodavsky et al, "Extracellular Matrix-Bound Growth Factors, Enzymes and Plasma Protein", in <i>Basement Membranes: Cellular and Molecular Aspects</i> (eds. Rohrbach et al) pp 327-343, Academic Press Inc., Orlando, Fla.
AI	MD MD	Vlodavsky et al, "Expression of Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", <i>Invasion & Metastasis</i> , 12: 112-127, 1992
AJ	MD MD	Vlodavsky et al, "Inhibition of Tumor Metastasis by Heparanase Inhibiting Species of Heparin", <i>Invasion & Metastasis</i> , 14: 290-302, 1995
AK	MD MD	Nakajima et al, "Heparanase and Tumor Metastasis", <i>J. Cell. Biochem.</i> , 36: 157-167, 1988
AL	MD MD	Liotta et al, "Tumor Invasion and the Extracellular Matrix", <i>Lab. Invest.</i> , 49: 636-646, 1983
AM	MD MD	Vlodavsky et al, "Lymphoma Cell Mediated Degradation of Sulfated Proteoglycans in the Subendothelial Extracellular Matrix: Relationship to Tumor Cell Metastasis", <i>Cancer Res.</i> , 43: 2704-2711, 1983
AN	MD MD	Parish et al, "Evidence that Sulfated Polysaccharides Inhibit Tumor Metastasis by Blocking Tumor cell-Derived Heparanase", <i>Int. J. Cancer</i> , 40: 511-518, 1987
AO	MD MD	Vlodavsky et al, "Morphological Appearance, Growth behavior and Migratory Activity of Human Tumor Cells Maintained on Extracellular Matrix vs. Plastic", <i>Cell</i> , 19: 607-616, 1980
AP		

EXAMINER *Marianne DiBrino*


DATE CONSIDERED 7/2/97 11/02/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

Atty. Docket No.
910/5Application No.
09/071,739INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)Applicant:
Dr. PECKER et alFiling Date:
May 1, 1998

Group Art Unit:

RECEIVED 1644
JUL 15 1998
GROUP CLASS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
BA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
					YES NO

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BCC	MD	Gospodarowicz et al, "Permissive Effect of the Extracellular Matrix on Cell Proliferation <i>in-vitro</i> ", <i>Proc. Natl. Acad. Sci. USA</i> , 77:4094-4098, 1980
BD	MD	Burgess et al, "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins", <i>Annu. Rev. Biochem.</i> , 58: 575-606, 1989
BE	MD	Folkman et al, "Angiogenic Factors", <i>Science</i> , 233: 442-447, 1987
BF	MD	Vlodavsky et al, "Extracellular Sequestration and Release of Fibroblast Growth Factor: a Regulatory Mechanism?", <i>Trends Biochem. Sci.</i> , 16: 842-846, 1990
BG	MD	Ishai-Michaeli et al, "Heparanase Activity Expressed by Platelets, Neutrophils and Lymphoma Cells Releases Active Fibroblast Growth Factor from Extracellular Matrix", <i>Cell Reg.</i> , 1: 833-842, 1990
BH	MD	Campbell et al, "Heparin Sulphate-Degrading Enzymes Induce Modulation of Smooth Muscle Phenotype", <i>Exp. Cell Res.</i> , 200: 156-167 (1992)
BI	MD	Oosta et al, "Purification and Properties of Human Platelet Heparitinase", <i>J. Biol. Chem.</i> , 257: 11,249 - 11,255, 1982
BJ	MD	Hoogewerf et al, "CXC Chemokines Connective Tissue Activating peptide-III and neutrophil Activating peptide -2 are Heparin/Heparan Sulfate-Degrading Enzymes", <i>J. Biol. Chem.</i> , 270: 3268-3277, 1995
BK	MD	Gordon-Cardo et al, "Expression of Basic Fibroblast Growth Factor in Normal Human Tissue", <i>Lab. Invest.</i> , 63(6): 832-840, 1990
BL	MD	Freeman et al, "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", <i>Biochem. J.</i> , 330: 1341-1350, 1988
BM	MD	Goshen et al, Purification and Characterization of Placental Heparanase and its Expression by Cultured Cytotrophoblasts", <i>Mol. Human Reprod.</i> , 2: 679-684, 1996
BN	MD	Nakajima et al, Immunochemical Localization of Heparanase in Mouse and Human Melanomas", <i>Int. J. Cancer</i> , 45: 1088-1095, 1990
BO	MD	Mollinendo et al, "Major Colocalization of the Extracellular-Matrix Degradative Enzymes Heparanase and Gelatinase in Tertiary Granules of Human Neutrophils", <i>Biochem. J.</i> , 327: 917-923, 1997

EXAMINER: Marianne DiBrino

DATE CONSIDERED 7/13/99 11/02/2006

AMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation

Form PTO-1449 (Modified)

Atty. Doc. et No.
910/5

Application No.

09/07/739

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION
(USE SEVERAL SHEETS IF NECESSARY)

Applicant
Marianne DiBrino ARTZI et al

JUL 15 1998

GROUP 1800

Filing Date:
May 1, 1998

Group Art Unit:

1544

PATENT DOCUMENTS

	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
CA							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
H								

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CM	MD	De Vouge et al, "Immunoselection of GRP94/Endoplasmic Reticulum Protein From a KNRK Cell-Specific λ gt11 Library Using Antibodies Directed Against a Putative Heparanase Amino-Terminal Peptide", <i>Int. J. Cancer</i> , 56: 286-294, 1994
CN	MD	Graham et al, "Comparison of the Heparanase Enzymes From Mouse Melanoma Cells, Mouse Macrophages, and Human Platelets", <i>Biochem. And Mol. Biol. Int.</i> , 39(3): 563-571, 1996
CO	MD	Kosir et al, "Human Prostate Carcinoma Cells Produce Extracellular Heparanase", <i>J. Surg. Res.</i> , 67: 98-105, 1997
CP	MD	Kosir et al, Abstract 3378, <i>Cancer Res.</i> , 37: 495 1996
CQ	MD	Ernst et al, "Enzymatic Degradation of Glycosaminoglycans", <i>Crit. Rev. In Biochem. And Mol. Biol.</i> , 30(5): 387-444 1995
	MD	Gospodarowicz et al, "Stimulation of Corneal Endothelial Cell Proliferation <i>in vitro</i> by Fibroblast and Epidermal Growth Factors", <i>Exp. Eye Res.</i> , 25: 15-89, 1977
	MD	Haimovitz-Friedman et al, "Activation of Platelet Heparitinase by Tumor Cell-Derived Factors", <i>Blood</i> , 78: 789-796, 1991
	MD	Yelton et al, "Monoclonal Antibodies: a Powerful New Tool in Biology and Medicine", <i>Annu. Rev. Biochem.</i> , 50: 657-680, 1981
	MD	Friedman et al, "Regulated Expression of Homeobox Genes <i>Msx-1</i> and <i>Msx-2</i> in Mouse Mammary Gland Development Suggests a Role in Hormone Action and Epithelial-Stromal Interactions", <i>Devel. Biol.</i> , 177: 347-355, 1996
	MD	Soule et al, "Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10 ¹ ", <i>Cancer Res.</i> , 50: 6075-6086, 1990
	MD	Miller et al, "Xenograft Model of Progressive Human Proliferative Breast Disease", <i>J. Nat. Cancer Inst.</i> , 85: 1725-1732, 1993
	MD	Nakajima et al, Heparan Sulfate Degradation: Relation to Tumor Invasion and Metastatic Properties of Mouse B16 melanoma Sublines", <i>Science</i> , 220 611-613, 1983
CR		/Marianne DiBrino/

EXAMINER

Marianne DiBrino

DATE CONSIDERED

7/13/99

11/02/2006

This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox